NZ720856B2 - Condensed imidazolylimidazoles as antiviral compounds - Google Patents

Abstract

Disclosed are specific velpatasvir analogues as antiviral compounds, optionally in combination with sofosbuvir for the treatment of Hepatitis C Virus. Representative compounds of the present application include methyl {(2S)-1-[(2S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate. -4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate.

Description

CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS This application is a divisional application of New Zealand patent application no. , the entire disclosure of which is incorporated herein by reference.

BACKGROUND Hepatitis C is recognized as a chronic viral disease of the liver which is characterized by liver disease. Although drugs targeting the liver are in wide use and have shown effectiveness, toxicity and other side effects have limited their usefulness. Inhibitors of hepatitis C virus (HCV) are useful to limit the establishment and ssion of infection by HCV as well as in diagnostic assays for HCV.

There is a need for new HCV therapeutic agents. In particular, there is a need for HCV therapeutic agents that have broad activity against HCV genotypes (e.g. genotypes 1s, 1b, 2a, 3a, 4a). There is also a ular need for agents that are less susceptible to viral ance.

Resistance mutations to inhibitors have been described for HCV NS5A for genotypes 1a and 1b in Antimicrobial Agents and Chemotherapy, ber 2010, Volume 54, p. 3641-3650.

SUMMARY In one embodiment the disclosure provides a compound of the disclosure which is a compound of formula (I): E1a-V1a –C(=O)-P1a -W1a -P1b -V1b-E1b (I) wherein: W1a is Y5 H and W1a is optionally substituted with one or more groups ndently selected from halo, alkyl, haloalkyl, or cyano; Y5 is -O-CH2-, or -CH2-O-; X5 is -CH2-CH2- or -CH=CH-; E1b is -N(H)(alkoxycarbonyl), -N(H)(cycloalkylcarbonyl) or -N(H)(cycloalkyloxycarbonyl); or E1b-V1b taken together are R9b; V1a and V1b are each independently selected from: P1a is selected from: P1b is selected from: ; R9a and R9b are each ndently: N N H H O O ; or a pharmaceutically acceptable salt or prodrug f.

The disclosure also provides ically enriched compounds that are compounds of the disclosure that comprise an enriched isotope at one or more positions in the compound.

The present disclosure also provides a pharmaceutical composition comprising a compound of the disclosure or a pharmaceutically able salt or prodrug thereof and at least one pharmaceutically acceptable carrier.

The present disclosure also provides a pharmaceutical composition for use in treating hepatits C (HCV). In one embodiment the composition comprises at least one additional therapeutic agent for treating HCV. In one embodiment, the therapeutic agent is selected from ribavirin, an NS3 protease inhibitor, a side or nucleotide inhibitor of HCV NS5B polymerase, an glucosidase 1 inhibitor, a hepatoprotectant, a cleoside inhibitor of HCV polymerase, or combinations thereof. In one ment, composition further comprises a nucleoside or nucleotide inhibitor of HCV NS5B polymerase. In one embodiment, the nucleoside or tide tor of HCV NS5B polymerase is selected from ribavirin, viramidine, levovirin, a L-nucleoside, or isatoribine.

In one embodiment is provided a ceutical composition sing a compound as described herein and at least one nucleoside or nucleotide inhibitor of HCV NS5B polymerase, and at least one pharmaceutically acceptable carrier. In one embodiment, the composition further ses an interferon, a pegylated interferon, ribavirin or combinations thereof. In one ment, the compound is the compound exemplified in Example PY. In one embodiment the the nucleoside or nucleotide inhibitor of HCV NS5B polymerase is sofosbuvir.

The present sure also provides a pharmaceutical composition further comprising an interferon or pegylated interferon.

The present disclosure also provides a pharmaceutical composition further comprising a nucleoside analog.

The present disclosure also provides for a ceutical composition wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine and said interferon is α-interferon or pegylated α-interferon.

The present disclosure also provides for a method of treating hepatitis C, said method sing administering to a human patient a pharmaceutical composition which comprises a therapeutically effective amount of a compound of the sure.

The present disclosure also provides a method of inhibiting HCV, comprising administering to a mammal afflicted with a condition ated with HCV activity, an amount of a compound of the disclosure, effective to inhibit HCV.

The present disclosure also provides a compound of the disclosure for use in l therapy (e.g. for use in inhibiting HCV activity or treating a condition associated with HCV activity), as well as the use of a compound of the disclosure for the manufacture of a ment useful for inhibiting HCV or the treatment of a condition associated with HCV activity in a mammal.

The present disclosure also provides synthetic processes and novel intermediates disclosed herein which are useful for preparing compounds of the disclosure. Some of the compounds of the disclosure are useful to prepare other compounds of the sure.

In another aspect the disclosure provides a compound of the disclosure, or a pharmaceutically able salt or prodrug thereof, for use in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder.

In another aspect the disclosure provides a method of inhibiting HCV activity in a sample sing treating the sample with a compound of the disclosure. nds of formula (I) have been found to possess useful activity against HCV pes. Additionally certain compounds of formula (I) have significant potency against resistant variants in GT1.

Accordingly, certain compounds of formula (I) s beneficial pharmacological properties that make them well suited to fulfill the current need for HCV agents with such beneficial properties.

In one embodiment the disclosure provides a compound having improved inhibitory or pharmacokinetic properties, including enhanced activity against development of viral resistance, improved oral bioavailability, greater potency (for example, in inhibiting HCV activity) or extended effective half-life in vivo. Certain compounds of the disclosure may have fewer side effects, less complicated dosing schedules, or be orally active.

DETAILED DESCRIPTION nce will now be made in detail to n embodiments of the disclosure, examples of which are rated in the accompanying structures and formulas. While the disclosure will be described in conjunction with the enumerated ments, it will be understood that they are not intended to limit the disclosure to those embodiments. On the contrary, the disclosure is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present disclosure as defined by the embodiments.

Compounds The compounds of the disclosure exclude compounds fore known. r, it is within the disclosure to use compounds that previously were not known to have antiviral properties for antiviral purposes (e.g. to e an anti-viral effect in an animal). With respect to the United States, the compounds or compositions herein exclude compounds that are anticipated under 35 USC §102 or that are obvious under 35 USC §103. er a compound described herein is substituted with more than one of the same designated group, e.g., "R1" or "A3", then it will be understood that the groups may be the same or different, i.e., each group is independently selected.

“Absent” – Some groups are defined such that they can be absent. When a group is absent it becomes a bond connector. The two groups that would ise be connected to that absent group are ted to each other through a bond.

The “P” groups (e.g. P1a and P1b) defined for a (I) herein have one bond to a -C(=O)- of formula (I) and one bond to a W1a group. It is to be understood that a nitrogen of the P group is connected to the -C(=O)- group of formula (I) and that a carbon of the P group is connected to the W1a group.

Y5 H N N N N H X5 In the W1a group a Y5 group is present. When that Y5 group is defined as -O-CH2-, or -CH2-O- group, those Y5 groups have a directionality. The Y5 group is connected to the W1a group in the same left to right directionality that each is drawn. So for example, when Y5 is -O-CH2-, the directly following ure is intended: For example, when Y5 is -CH2-O-, the directly ing structure is intended: In the structure I, the W1a group has a left-to-right directionality as depicted in I and W1a as drawn.

E1a-V1a –C(=O)-P1a -W1a -P1b-C(=O)-V1b-E1b (I) wherein: W1a is Y5 H N N N N H X5 For example, the P1a group is ted to the imidazole group of W1a, and the P1b group is ted to the pentacyclic ring system of W1a.

“Alkyl” is C1-C18 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, npropyl , -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methylpropyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, sbutyl , -CH(CH3)CH2CH3), 2-methylpropyl (t-Bu, l, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2- methylbutyl 3)2CH2CH3), 3-methylbutyl (-CH(CH3)CH(CH3)2), yl butyl (-CH2CH2CH(CH3)2), 2-methylbutyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methylpentyl (-C(CH3)2CH2CH2CH3), 3-methyl pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methylpentyl (-CH(CH3)CH2CH(CH3)2), 3- methylpentyl (-C(CH3)(CH2CH3)2), 2-methylpentyl (-CH(CH2CH3)CH(CH3)2), 2,3- ylbutyl (-C(CH3)2CH(CH3)2), 3,3-dimethylbutyl (-CH(CH3)C(CH3)3, and cyclopropylmethyl .

“Alkenyl” is C2-C18 hydrocarbon containing , ary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp2 double bond.

Examples include, but are not limited to, ethylene or vinyl (-CHCH2), allyl (-CH2CHCH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2 CH2CHCH2).

“Alkynyl” is C2-C18 hydrocarbon containing normal, secondary, ry or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.

Examples include, but are not limited to, acetylenic (-CCH) and propargyl (-CH2CCH).

“Alkylene” refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two ent carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to, methylene (-CH2-) 1,2-ethyl (-CH2CH2-), 1,3- propyl (-CH2CH2CH2-), 1,4-butyl (-CH2CH2CH2CH2-), and the like.

“Alkenylene” refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene ls include, but are not limited to, 1,2-ethylene (-CHCH-).

“Alkynylene” refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical lene radicals include, but are not limited to, acetylene (-CC-), propargyl (-CH2CC-), and 4-pentynyl (-CH2CH2CH2CCH).

The term "alkoxy" or oxy,” as used herein, refers to an alkyl group ed to the parent molecular moiety h an oxygen atom.

The term "alkoxycarbonyl," as used herein, refers to an alkoxy group attached to the parent lar moiety through a carbonyl group.

The term "cycloalkyl," as used herein, refers to a saturated clic, hydrocarbon ring system having three to seven carbon atoms and zero heteroatoms. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. The cycloalkyl groups of the present disclosure are optionally tuted with one, two, three, four, or five substituents independently selected from alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, heterocyclyl, hydroxy, hydroxyalkyl, nitro, and -NRxRy wherein the aryl and the heterocyclyl are further optionally substituted with one, two, or three tuents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and nitro.

The term “cycloalkylcarbonyl,” as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through a carbonyl group.

The term "cycloalkyloxy," as used herein, refers to a cycloalkyl group ed to the parent molecular moiety through an oxygen atom.

The term “cycloalkyloxycarbonyl,” as used herein, refers to a lkyloxy group attached to the parent molecular moiety through a carbonyl group.

“Aryl” means a monovalent ic arbon radical of 6-20 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, radicals derived from benzene, substituted benzene, naphthalene, anthracene, biphenyl, and the like.

“Arylalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a al or sp3 carbon atom, is ed with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, ylethanyl, naphthylmethyl, 2-naphthylethanyl, naphthobenzyl, 2-naphthophenylethanyl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g., the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.

“Substituted , “substituted aryl”, and “substituted arylalkyl” mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each ndently replaced with a non-hydrogen substituent. Typical tuents include, but are not limited to: halo (e.g. F, Cl, Br, I), -R, -OR, -SR, -NR2, -CF3, -CCl3, -OCF3, -CN, -NO2, -N(R)C(=O)R, R, -OC(=O)R, -C(O)OR, -C(=O)NRR, -S(=O)R, -S(=O)2OR, -S(=O)2R, -OS(=O)2OR, -S(=O)2NRR, and each R is independently -H, alkyl, aryl, arylalkyl, or heterocycle. Alkylene, alkenylene, and alkynylene groups may also be similarly substituted.

The term “optionally substituted” in reference to a particular moiety of the compound of formula I, (e.g., an optionally substituted aryl group) refers to a moiety having 0, 1, 2, or more substituents.

The symbol “-----“ in a ring structure means that a bond is a single or double bond. In E L E L E L D L L a miting example, can be D or D .

“Haloalkyl” as used herein includes an alkyl group substituted with one or more halogens (e.g. F, Cl, Br, or I). Representative examples of haloalkyl include trifluoromethyl, 2,2,2-trifluoroethyl, and 2,2,2-trifluoro(trifluoromethyl)ethyl.

“Heterocycle” or “heterocyclyl” as used herein includes by way of example and not limitation these heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The try of Heterocyclic Compounds, A Series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J.

Am. Chem. Soc. (1960) 82:5566. In one specific ment, “heterocycle” es a “carbocycle” as defined herein, wherein one or more (e.g. 1, 2, 3, or 4) carbon atoms have been ed with a heteroatom (e.g. O, N, or S). The term cycle also includes “heteroaryl” which is a heterocycle wherein at least one cyclic rings is aromatic.

Examples of heterocycles include by way of e and not tion pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, dinyl, furanyl, thienyl, yl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4H-carbazolyl, carbazolyl, β-carbolinyl, thridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, azinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, zinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, oyl, and bis-tetrahydrofuranyl: O .

By way of e and not limitation, carbon bonded cycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an noline. Still more lly, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4- thiazolyl, or 5-thiazolyl.

By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, ine, pyrrole, pyrrolidine, oline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, le, pyrazoline, 2-pyrazoline, 3- pyrazoline, dine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a line, and position 9 of a ole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1- imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

“Carbocycle” refers to a saturated, unsaturated or aromatic ring having up to about 25 carbon atoms. Typically, a carbocycle has about 3 to 7 carbon atoms as a monocycle, about 7 to 12 carbon atoms as a bicycle, and up to about 25 carbon atoms as a polycycle. Monocyclic carbocycles typically have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles typically have 7 to 12 ring atoms, e.g., arranged as a o [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. The term carbocycle includes “cycloalkyl” which is a saturated or unsaturated carbocycle. Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, entyl, 1-cyclopentenyl, opentenyl, 1-cyclopentenyl, cyclohexyl, 1-cyclohexenyl, 1-cyclohexenyl, 1- exenyl, phenyl, spiryl and naphthyl.

The term “amino,” as used herein, refers to -NH2.

The term “chiral” refers to molecules which have the property of nonsuperimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.

The term “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

“Diastereomer” refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., g points, boiling points, al properties, and reactivities.

Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.

“Enantiomers” refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.

The term “treatment” or “treating,” to the extent it relates to a disease or condition includes preventing the disease or condition from occurring, inhibiting the disease or condition, eliminating the disease or ion, and/or relieving one or more ms of the disease or condition.

Stereochemical definitions and conventions used herein generally follow S. P.

Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes (D and L) or (R and S) are used to denote the absolute configuration of the molecule about its chiral center(s). The es d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is rotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no selection or stereospecificity in a chemical reaction or process. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity. The disclosure includes all stereoisomers of the compounds described .

Prodrugs The term “prodrug” as used herein refers to any compound that when administered to a ical system generates a compound of the disclosure that inhibits HCV activity (“the active inhibitory compound”). The compound may be formed from the prodrug as a result of: (i) spontaneous chemical reaction(s), (ii) enzyme catalyzed chemical reaction(s), (iii) photolysis, and/or (iv) metabolic al reaction(s).

“Prodrug moiety” refers to a labile onal group which separates from the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, tic cleavage, or by some other process (Bundgaard, Hans, “Design and Application of Prodrugs” in A ok of Drug Design and Development (1991), P. Krogsgaard-Larsen and H.

Bundgaard, Eds. Harwood Academic hers, pp. 113-191). Enzymes which are capable of an enzymatic activation ism with the prodrug compounds of the disclosure e, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphases. Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to ze drug delivery, bioavailability and efficacy. A prodrug moiety may include an active metabolite or drug itself.

Exemplary prodrug moieties include the hydrolytically sensitive or labile acyloxymethyl esters CH2OC(=O)R99 and acyloxymethyl carbonates CH2OC(=O)OR99 where R99 is C1C6 alkyl, C1C6 substituted alkyl, C6C20 aryl or C6C20 tuted aryl.

The acyloxyalkyl ester was first used as a prodrug strategy for ylic acids and then applied to phosphates and phosphonates by Farquhar et al. (1983) J. Pharm. Sci. 72: 324; also US Patent Nos. 4816570, 4968788, 5663159 and 5792756. Subsequently, the acyloxyalkyl ester was used to deliver phosphonic acids across cell membranes and to enhance oral bioavailability. A close variant of the acyloxyalkyl ester, the carbonyloxyalkyl ester (carbonate), may also enhance oral bioavailability as a prodrug moiety in the compounds of the combinations of the disclosure. An ary acyloxymethyl ester is pivaloyloxymethoxy, (POM) CH2OC(=O)C(CH3)3. An exemplary acyloxymethyl carbonate g moiety is pivaloyloxymethylcarbonate (POC)  CH2OC(=O)OC(CH3)3.

Aryl esters of phosphorus groups, especially phenyl esters, are reported to enhance oral bioavailability (De Lombaert et al. (1994) J. Med. Chem. 37: 498). Phenyl esters containing a ylic ester ortho to a phosphate have also been described (Khamnei and Torrence, (1996) J. Med. Chem. 39:4109-4115). Benzyl esters are reported to generate parent phosphonic acids. In some cases, substituents at the ortho- or para- position may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of s, e.g., esterases, oxidases, etc., which in turn undergoes cleavage at the benzylic CO bond to generate phosphoric acid and a quinone methide intermediate. Examples of this class of prodrugs are described by Mitchell et al. (1992) J. Chem. Soc. Perkin Trans. II 2345; Glazier WO 91/19721. Still other benzylic prodrugs have been described containing a carboxylic containing group attached to the benzylic methylene (Glazier WO 91/19721). Thio-containing gs are ed to be useful for the intracellular delivery of phosphonate drugs. These proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined with another thiol group to form a disulfide. rification or reduction of the disulfide generates the free thio intermediate which subsequently breaks down to the phosphoric acid and fide (Puech et al. (1993) Antiviral Res., 22: 155-174; Benzaria et al. (1996) J. Med. Chem. 39: 4958).

Protecting Groups In the context of the present disclosure, protecting groups include prodrug moieties and chemical protecting groups.

“Protecting group” refers to a moiety of a compound that masks or alters the properties of a functional group or the ties of the compound as a whole. Chemical protecting groups and strategies for protection/deprotection are well known in the art. See e.g., Protective Groups in Organic try, ra W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion. tion of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. ally protected ediates may themselves be biologically active or inactive.

Protected compounds may also exhibit d, and in some cases, optimized properties in vitro and in vivo, such as passage through cellular membranes and ance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the g in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, gs may possess r potency in vivo than the parental drug. Protecting groups are removed either in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g., alcohols, be logically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the disclosure. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical protecting group “PG” will be dependent upon the try of the reaction to be protected against (e.g., , basic, oxidative, reductive or other conditions) and the intended direction of the synthesis.

PGs do not need to be, and generally are not, the same if the compound is substituted with le PGs. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of deprotection to yield free deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the artisan.

Various functional groups of the compounds of the disclosure may be ted. For example, protecting groups for –OH groups er hydroxyl, carboxylic acid, phosphonic acid, or other ons) include “ether- or ester-forming groups”. Ether- or ester-forming groups are capable of functioning as chemical protecting groups in the synthetic schemes set forth herein. However, some hydroxyl and thio protecting groups are neither ether- nor esterforming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.

A very large number of hydroxyl protecting groups and amide-forming groups and corresponding chemical cleavage reactions are described in Protective Groups in Organic Synthesis, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991, ISBN 0 62301-6) (“Greene”). See also Kocienski, Philip J.; Protecting Groups (Georg Thieme Verlag art, New York, 1994), which is orated by reference in its entirety herein.

In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, r 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages 155-184. For protecting groups for carboxylic acid, phosphonic acid, onate, sulfonic acid and other protecting groups for acids see Greene as set forth below.

By way of example and not limitation, les described herein may recursive tuents in certain embodiments. lly, each of these may independently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, times in a given embodiment. More typically, each of these may independently occur 12 or fewer times in a given embodiment. er a compound described herein is substituted with more than one of the same designated group, e.g., “R1” or “R3”, then it will be understood that the groups may be the same or different, i.e., each group is independently selected. Wavy lines te the site of covalent bond attachments to the adjoining , moieties, or atoms.

In one embodiment of the disclosure, the compound is in an isolated and purified form. Generally, the term “isolated and purified” means that the compound is substantially free from biological materials (e.g. blood, tissue, cells, etc.). In one specific embodiment of the sure, the term means that the nd or conjugate of the disclosure is at least about 50 wt.% free from biological materials; in another ic embodiment, the term means that the compound or conjugate of the disclosure is at least about 75 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the disclosure is at least about 90 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the disclosure is at least about 98 wt.% free from biological materials; and in another embodiment, the term means that the compound or conjugate of the disclosure is at least about 99 wt.% free from biological materials. In another specific embodiment, the disclosure provides a compound or conjugate of the disclosure that has been synthetically prepared (e.g., ex vivo).

Stereoisomers The nds of the sure may have chiral centers, e.g., chiral carbon or phosphorus atoms. The compounds of the disclosure thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers. In addition, the compounds of the disclosure include ed or resolved optical s at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the ions are provided as the chiral isomers or racemic mixtures. Both racemic and diastereomeric mixtures, as well as the individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are all within the scope of the disclosure.

The racemic mixtures are separated into their dual, substantially lly pure isomers through well-known techniques such as, for example, the tion of diastereomeric salts formed with optically active ts, e.g., acids or bases followed by conversion back to the optically active substances. In most instances, the desired optical isomer is synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.

The nds of the disclosure can also exist as tautomeric isomers in certain cases.

Although only one tautomer may be depicted, all such forms are contemplated within the scope of the disclosure. For example, ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and ole systems and all their possible tautomeric forms are within the scope of the disclosure.

Salts and Hydrates Examples of physiologically or pharmaceutically acceptable salts of the nds of the disclosure include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth metal (for example, magnesium), ammonium and NX4+ (wherein X is C1-C4 alkyl). logically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as , benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic ic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hloric, sulfuric, phosphoric and sulfamic acids.

Physiologically acceptable salts of a compound of a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+ and NX4+ (wherein X is independently selected from H or a C1C4 alkyl group).

For therapeutic use, salts of active ingredients of the compounds of the disclosure will typically be physiologically acceptable, i.e. they will be salts derived from a physiologically able acid or base. However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not d from a physiologically acceptable acid or base, are within the scope of the present disclosure.

Metal salts typically are prepared by reacting the metal hydroxide with a compound of this disclosure. Examples of metal salts which are prepared in this way are salts containing Li+, Na+, and K+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by on of the suitable metal compound.

In addition, salts may be formed from acid on of certain organic and inorganic acids, e.g., HCl, HBr, H2SO4, H3PO4 or organic sulfonic acids, to basic centers, typically , or to acidic groups. Finally, it is to be understood that the compositions herein comprise compounds of the disclosure in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.

Also ed within the scope of this disclosure are the salts of the parental nds with one or more amino acids. Any of the natural or unnatural amino acids are suitable, especially the lly-occurring amino acids found as protein components, although the amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.

Methods of Inhibition of HCV Another aspect of the disclosure relates to methods of inhibiting the activity of HCV comprising the step of treating a sample suspected of containing HCV with a compound or composition of the disclosure.

Compounds of the disclosure may act as inhibitors of HCV, as intermediates for such inhibitors or have other ies as bed below. The inhibitors will lly bind to locations on the surface or in a cavity of the liver. nds binding in the liver may bind with varying degrees of reversibility. Those compounds g substantially irreversibly are ideal candidates for use in this method of the disclosure. Once labeled, the ntially irreversibly binding compounds are useful as probes for the detection of HCV. Accordingly, the sure relates to methods of detecting NS3 in a sample suspected of ning HCV comprising the steps of: treating a sample suspected of containing HCV with a composition comprising a compound of the disclosure bound to a label; and observing the effect of the sample on the ty of the label. Suitable labels are well known in the diagnostics field and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups and chromogens. The compounds herein are labeled in conventional fashion using functional groups such as hydroxyl or amino. In one embodiment the sure provides a compound of any one of formulae (I) and (A1)-(A4) that comprises or that is bound or linked to one or more detectable labels. Within the context of the disclosure samples suspected of containing HCV include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like); laboratory samples; food, water, or air samples; bioproduct samples such as ts of cells, particularly recombinant cells synthesizing a desired glycoprotein; and the like. Typically the sample will be suspected of containing HCV. Samples can be ned in any medium including water and organic solvent/water mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.

The treating step of the sure comprises adding the compound of the disclosure to the sample or it comprises adding a precursor of the composition to the sample. The addition step ses any method of administration as described above.

If desired, the activity of HCV after application of the compound can be observed by any method ing direct and indirect methods of detecting HCV activity. Quantitative, qualitative, and semiquantitative s of determining HCV activity are all contemplated. lly one of the screening s described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.

Many organisms contain HCV. The compounds of this disclosure are useful in the treatment or laxis of conditions associated with HCV activation in animals or in man.

However, in screening compounds capable of inhibiting HCV activity it should be kept in mind that the results of enzyme assays may not always correlate with cell culture assays. Thus, a cell based assay should lly be the primary screening tool.

Pharmaceutical ations The compounds of this disclosure are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, s and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral stration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, c acid and the like. The pH of the ations ranges from about 3 to about 11, but is ordinarily about 7 to 10. Typically, the compound will be stered in a dose from 0.01 milligrams to 2 grams. In one embodiment, the dose will be from about 10 milligrams to 450 milligrams. In r embodiment, the dosage will be from about 25 to about 250 rams. In another embodiment, the dosage will be about 50 or 100 milligrams. In one embodiment, the dosage will be about 100 milligrams. It is plated that the compound may be administered once, twice or three times a day.

While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the disclosure comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.

The formulations include those suitable for the foregoing administration routes. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in ton’s Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by mly and intimately bringing into association the active ient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations of the present disclosure suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or ueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be stered as a bolus, electuary or paste.

A tablet is made by compression or molding, optionally with one or more ory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a , lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and ally are formulated so as to provide slow or controlled release of the active ingredient therefrom.

For administration to the eye or other al tissues e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a watermiscible nt base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.

If desired, the aqueous phase of the cream base may include, for example, at least % w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, ol and polyethylene glycol (including PEG 400) and es thereof. The topical formulations may desirably include a compound which enhances absorption or ation of the active ingredient h the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related s.

The oily phase of the emulsions of this disclosure may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic fier which acts as a stabilizer. It is also red to include both an oil and a fat. Together, the emulsifier(s) with or t stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the ed fying ointment base which forms the oily dispersed phase of the cream formulations.

Emulgents and emulsion stabilizers suitable for use in the formulation of the disclosure include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. The cream should ably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.

Straight or branched chain, mono- or c alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, pyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.

Pharmaceutical formulations ing to the present sure comprise one or more nds of the disclosure together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of ceutical compositions and such compositions may contain one or more agents ing sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with xic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose drate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline ose, starch, gelatin or acacia; and ating , such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques ing microencapsulation to delay disintegration and tion in the gastrointestinal tract and thereby e a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

Aqueous suspensions of the disclosure n the active als in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a ding agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl celluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ne oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or rin.

Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as s oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules of the disclosure suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or g agents and suspending agents are exemplified by those disclosed above.

Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the disclosure may also be in the form of oil-in- water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable fying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, lly occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as an eate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also n sweetening and flavoring . Syrups and elixirs may be formulated with sweetening agents, such as glycerol, ol or sucrose. Such formulations may also contain a demulcent, a vative, a flavoring or a coloring agent.

The pharmaceutical compositions of the disclosure may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and ding agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic erally acceptable diluent or solvent, such as a solution in tane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and ts that may be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a t or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release ation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight:weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 µg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.

Formulations suitable for stration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a tration of 0.5 to 20%, advantageously 0.5 to 10% ularly about 1.5% w/w.

Formulations suitable for topical administration in the mouth include lozenges sing the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal stration may be presented as a suppository with a suitable base sing for example cocoa butter or a salicylate.

Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 s ding particle sizes in a range between 0.1 and 500 s in increments such as 0.5 microns, 1 micron, 30 microns, 35 microns, etc.), which is administered by rapid inhalation through the nasal e or by inhalation h the mouth so as to reach the ar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as nds heretofore used in the treatment or prophylaxis of conditions ated with HCV activity.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may n anti-oxidants, s, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and ning agents.

The formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the on of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, es and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.

It should be tood that in addition to the ingredients particularly mentioned above the formulations of this disclosure may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include ing .

The disclosure further provides veterinary compositions sing at least one active ingredient as above defined together with a veterinary carrier or.

Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the nary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route. nds of the disclosure can also be formulated to provide controlled release of the active ient to allow less frequent dosing or to improve the pharmacokinetic or toxicity e of the active ingredient. Accordingly, the disclosure also provides compositions sing one or more compounds of the disclosure formulated for sustained or controlled release.

Effective dose of active ingredient depends at least on the nature of the condition being d, toxicity, whether the nd is being used prophylactically (lower doses), the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies.

Routes of Administration One or more compounds of the disclosure (herein referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral ding subcutaneous, intramuscular, enous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of the compounds of this disclosure is that they are orally bioavailable and can be dosed orally.

HCV ation Therapy In r embodiment, non-limiting examples of suitable combinations include ations of one or more compounds of formula (I) and (A1-A4) with one or more interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or nucleotide tors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers, and other drugs or therapeutic agents for treating HCV.

More specifically, one or more compounds as described herein may be combined with one or more compounds selected from the group consisting of: 1) interferons, e.g., pegylated rIFN-alpha 2b (PEG-Intron), pegylated rIFN-alpha 2a (Pegasys), rIFN-alpha 2b (Intron A), rIFN-alpha 2a (Roferon-A), interferon alpha (MOR-22, OPC-18, Alfaferone, Alfanative, eron, subalin), interferon n-1 (Infergen), interferon alpha-n1 (Wellferon), interferon alpha-n3 on), interferon-beta (Avonex, DL- 8234), interferon-omega (omega DUROS, Biomed 510), albinterferon alpha-2b (Albuferon), IFN alpha-2b XL, BLX-883 (Locteron), DA-3021, glycosylated interferon alpha-2b (AVI- 005), PEG-Infergen, PEGylated eron lambda-1 (PEGylated IL-29), and belerofon; 2) ribavirin and its analogs, e.g., ribavirin (Rebetol, Copegus), and taribavirin (Viramidine); 3) HCV NS3 protease inhibitors, e.g., evir (SCH-503034, , telaprevir (VX-950), TMC435350, BI-1335, BI-1230, MK-7009, VBY-376, VX-500, GS-9256, GS- 9451, BMS-605339, PHX-1766, AS-101, YH-5258, YH5530, YH5531, ABT-450, ACH- 1625, ITMN-191, MK5172, MK6325, and MK2748; 4) alpha-glucosidase 1 inhibitors, e.g., celgosivir (MX-3253), ol, and UT-231B; ) protectants, e.g., emericasan (IDN-6556), 8, GS-9450 (LB-84451), silibilin, and MitoQ; 6) nucleoside or nucleotide inhibitors of HCV NS5B polymerase, e.g., R1626, R7128 (R4048), IDX184, 2, BCX-4678, valopicitabine (NM-283), MK-0608, sofosbuvir (GS-7977 (formerly PSI-7977)), and 9 (now BMS986094); 7) cleoside tors of HCV NS5B polymerase, e.g., PF-868554, VCH-759, VCH-916, JTK-652, MK-3281, GS-9190, VBY-708, VCH-222, A848837, ANA-598, 7, GL59728, A-63890, A-48773, A-48547, BC-2329, VCH-796 (nesbuvir), GSK625433, BILN-1941, XTL-2125, ABT-072, ABT-333, GS-9669, 92, and GS- 9190; 8) HCV NS5A inhibitors, e.g., AZD-2836 (A-831), BMS-790052, ACH-3102, ACH- 2928, MK8325, MK4882, MK8742, PSI-461, IDX719, and A-689; 9) TLR-7 agonists, e.g., imiquimod, 852A, GS-9524, ANA-773, ANA-975, AZD- 8848 (DSP-3025), and SM-360320; 10) cyclophillin inhibitors, e.g., 025, SCY-635, and NIM811; 11) HCV IRES inhibitors, e.g., MCI-067; 12) cokinetic enhancers, e.g., BAS-100, SPI-452, PF-4194477, TMC-41629, GS-9350, GS-9585, and romycin; and 13) other drugs for treating HCV, e.g., thymosin alpha 1 (Zadaxin), nitazoxanide (Alinea, NTZ), BIVN-401 (virostat), PYN-17 (altirex), 03002, actilon (CPG-10101), GS-9525, KRN-7000, civacir, GI-5005, XTL-6865, BIT225, PTX-111, ITX2865, TT-033i, ANA 971, NOV-205, tarvacin, EHC-18, VGX-410C, EMZ-702, AVI 4065, BMS-650032, BMS-791325, Bavituximab, MDX-1106 (ONO-4538), Oglufanide, and VX-497 (merimepodib).

More ically, one or more compounds as described herein may be combined with one or more compounds ed from the group consisting of non-nucleoside tors of HCV NS5B polymerase (ABT-072 and ABT-333), HCV NS5A inhibitors (ACH-3102 and ACH-2928) and HCV NS3 protease inhibitors(ABT-450 and ACH-1625).

In yet another embodiment, the present application ses pharmaceutical compositions comprising a compound as described herein, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or ent.

According to one embodiment, the therapeutic agent used in combination with the compound as described herein can be any agent having a therapeutic effect when used in combination with the compound as described herein. For example, the therapeutic agent used in ation with the compound as described herein can be interferons, ribavirin analogs, NS3 se inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside tors of HCV, and other drugs for treating HCV.

In another embodiment, the present application provides pharmaceutical compositions sing a compound of formula (I), or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, IFN alpha-2b XL, rIFN-alpha 2a, consensus IFN alpha, infergen, rebif, locteron, AVI-005, PEG- infergen, pegylated IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha, r-IFN- beta, infergen + actimmune, IFN-omega with DUROS, albuferon, rebetol, copegus, levovirin, VX-497, dine (taribavirin), A-831, A-689, NM-283, citabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, MK-0608, NM-107, R7128, 9, PF-868554, GSK625433, XTL-2125, SCH-503034 (SCH-7), VX-950 (Telaprevir), ITMN-191, and BILN-2065, MX-3253 (celgosivir), UT-231B, IDN-6556, ME 3738, MitoQ, and LB-84451, benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, and alanine derivatives, zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanide, PYN-17, KPE02003002, actilon (CPG- 10101), KRN-7000, civacir, GI-5005, ANA-975 (isatoribine), 65, ANA 971, NOV- 205, in, EHC-18, and NIM811 and a pharmaceutically acceptable r or excipient.

In yet another ment, the present application es a combination pharmaceutical agent comprising: a) a first pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or ester thereof; and b) a second pharmaceutical composition comprising at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV tide inhibitors of reverse transcriptase, HIV integrase tors, gp41 inhibitors, CXCR4 inhibitors, gp120 tors, CCR5 tors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 tors, hepatoprotectants, nonnucleoside inhibitors of HCV, and other drugs for treating HCV, and combinations thereof.

In another embodiment is provided a pharmaceutical composition comprising a compound of formula (I) as described herein and a nucleoside or nucleotide inhibitors of HCV NS5B polymerase and optionally an interferon or ribavirin. In one embodiment, the compound is methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2R) [(methoxycarbonyl)amino]phenylacetyl}(methoxymethyl)pyrrolidinyl]-1H- imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate having the formula: and the inhibitor is sofosbuvir.

Combinations of the compounds of a I and additional active therapeutic agents may be selected to treat patients infected with HCV and other conditions such as HIV infections. Accordingly, the compounds of formula I may be ed with one or more compounds useful in treating HIV, for example HIV protease inhibiting compounds, nonnucleoside inhibitors of HIV reverse riptase, HIV nucleoside inhibitors of reverse transcriptase, HIV tide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 tors, interferons, ribavirin analogs, NS3 protease tors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

More specifically, one or more compounds of formula (I) or (A1)-(A4) may be combined with one or more compounds ed from the group consisting of 1) HIV protease inhibitors, e.g., amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, lopinavir + ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC- 126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), AG1859, DG35, L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100, 2) a HIV non-nucleoside inhibitor of e transcriptase, e.g., capravirine, emivirine, delaviridine, efavirenz, pine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, 0, and TMC-120, TMC-278 (rilpivirine), enz, BILR 355 BS, VRX , UK-453,061, RDEA806, 3) a HIV side inhibitor of reverse transcriptase, e.g., zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (-FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, fosalvudine tidoxil, apricitibine (AVX754), amdoxovir, KP- 1461, abacavir + lamivudine, abacavir + lamivudine + zidovudine, zidovudine + lamivudine, 4) a HIV nucleotide inhibitor of reverse transcriptase, e.g., tenofovir, tenofovir disoproxil fumarate + emtricitabine, tenofovir disoproxil fumarate + emtricitabine + efavirenz, and adefovir, 5) a HIV integrase inhibitor, e.g., in, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, tives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L-870810, MK-0518 (raltegravir), BMS-707035, 8, BA-011, BMS-538158, GSK364735C, 6) a gp41 inhibitor, e.g., enfuvirtide, sifuvirtide, FB006M, TRI-1144, SPC3, DES6, Locus gp41, CovX, and REP 9, 7) a CXCR4 inhibitor, e.g., AMD-070, 8) an entry inhibitor, e.g., SP01A, TNX-355, 9) a gp120 inhibitor, e.g., BMS-488043 and BlockAide/CR, 10) a G6PD and NADH-oxidase inhibitor, e.g., tin, 11) a CCR5 inhibitor, e.g., aplaviroc, vicriviroc, INCB9471, PRO-140, INCB15050, PF-232798, CCR5mAb004, and maraviroc, 12) an interferon, e.g., pegylated lpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, IFN alpha- 2b XL, lpha 2a, consensus IFN alpha, en, rebif, on, AVI-005, PEG- infergen, pegylated IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha, r-IFN- beta, infergen + actimmune, IFN-omega with DUROS, and albuferon, 13) ribavirin analogs, e.g., rebetol, copegus, levovirin, VX-497, and viramidine (taribavirin), 14) NS5a inhibitors, e.g., A-831, A-689, and BMS-790052, 15) NS5b polymerase inhibitors, e.g., , valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, MK-0608, NM-107, R7128, VCH-759, PF-868554, GSK625433, and 25, 16) NS3 protease inhibitors, e.g., SCH-503034 (SCH-7), VX-950 revir), ITMN-191, and BILN-2065, 17) lucosidase 1 tors, e.g., MX-3253 (celgosivir) and B, 18) hepatoprotectants, e.g., IDN-6556, ME 3738, MitoQ, and LB-84451, 19) cleoside inhibitors of HCV, e.g., benzimidazole tives, benzo-1,2,4-thiadiazine derivatives, and phenylalanine derivatives, 20) other drugs for treating Hepatitis C, e.g., zadaxin, nitazoxanide a), BIVN-401 (virostat), DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanide, PYN-17, KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975 (isatoribine), XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, and NIM811, ) pharmacokinetic enhancers, e.g., BAS-100 and SPI452, 21) RNAse H tors, e.g., ODN-93 and ODN-112, 22) other anti-HIV agents, e.g., VGV-1, PA-457 (bevirimat), ampligen, HRG214, cytolin, polymun, VGX-410, KD247, AMZ 0026, CYT 99007, A-221 HIV, BAY 50-4798, MDX010 (iplimumab), PBS119, ALG889, and PA-1050040.

It is contemplated that the second therapeutic agent will be administered in a manner that is known in the art and the dosage may be selected by someone of skill in the art. For e, the second agent may be administered in a dose from about 0.01 milligrams to about 2 grams per day.

Metabolites of the Compounds Also falling within the scope of this disclosure are the in vivo metabolic ts of the compounds described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered nd, primarily due to enzymatic processes. Accordingly, the disclosure includes compounds ed by a process comprising contacting a compound of this disclosure with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products typically are identified by preparing a radiolabelled (e.g., C14 or H3) compound of the disclosure, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples. These ts are easily isolated since they are labeled (others are ed by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug lism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for eutic dosing of the compounds of the disclosure even if they possess no HCV –inhibitory activity of their own.

Methods for determining ity of compounds in surrogate gastrointestinal secretions are known.

Exemplary s of Making the Compounds The sure also relates to methods of making the compositions of the disclosure.

The compositions are prepared by any of the applicable techniques of organic synthesis.

Many such techniques are well known in the art. However, many of the known techniques are elaborated in Compendium of Organic Synthetic Methods (John Wiley & Sons, New York), Vol. 1, Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. on and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G.

Wade, Jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and Vol. 6, Michael B. Smith; as well as March, J., Advanced Organic Chemistry, Third Edition, (John Wiley & Sons, New York, 1985), Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry. In 9 Volumes, Barry M. Trost, Editor-in-Chief (Pergamon Press, New York, 1993 printing). Other methods suitable for preparing compounds of the disclosure are described in International Patent Application Publication Number .

A number of exemplary methods for the preparation of the compositions of the disclosure are provided in the schemes and examples below. These methods are ed to illustrate the nature of such preparations and are not intended to limit the scope of applicable methods.

Generally, the reaction conditions such as temperature, on time, solvents, workup ures, and the like, will be those common in the art for the particular reaction to be performed. The cited reference al, together with al cited therein, contains detailed descriptions of such conditions. Typically the temperatures will be -100°C to 200°C, solvents will be aprotic or protic, and reaction times will be 10 seconds to 10 days. Work-up typically consists of ing any unreacted reagents followed by partition between a water/organic layer system (extraction) and separating the layer containing the product.

Oxidation and reduction reactions are typically carried out at temperatures near room temperature (about 20°C), although for metal hydride reductions frequently the temperature is reduced to 0°C to , solvents are typically aprotic for reductions and may be either protic or aprotic for oxidations. Reaction times are adjusted to achieve desired conversions.

Condensation reactions are lly carried out at temperatures near room temperature, although for non-equilibrating, kinetically controlled condensations reduced temperatures (0°C to -100°C) are also common. Solvents can be either protic (common in brating ons) or aprotic (common in kinetically controlled reactions).

Standard synthetic techniques such as azeotropic removal of reaction by-products and use of anhydrous reaction conditions (e.g., inert gas environments) are common in the art and will be applied when applicable.

The terms “treated”, “treating”, “treatment”, and the like, when used in tion with a chemical synthetic operation, mean contacting, , reacting, allowing to react, bringing into t, and other terms common in the art for indicating that one or more chemical entities is treated in such a manner as to convert it to one or more other chemical entities. This means that “treating compound one with nd two” is synonymous with ing compound one to react with compound two”, “contacting compound one with compound two”, “reacting compound one with compound two”, and other expressions common in the art of organic synthesis for reasonably indicating that nd one was “treated”, “reacted”, “allowed to react”, etc., with compound two. For example, treating indicates the reasonable and usual manner in which organic chemicals are allowed to react.

Normal concentrations (0.01M to 10M, typically 0.1M to 1M), temperatures C to 250°C, typically -78°C to 150°C, more typically -78°C to 100°C, still more typically 0°C to 100°C), reaction vessels (typically glass, plastic, metal), solvents, pressures, heres (typically air for oxygen and water insensitive reactions or nitrogen or argon for oxygen or water sensitive), etc., are intended unless otherwise indicated. The knowledge of similar reactions known in the art of organic synthesis is used in selecting the ions and apparatus for “treating” in a given process. In particular, one of ry skill in the art of organic synthesis selects conditions and tus reasonably expected to successfully carry out the chemical reactions of the described ses based on the knowledge in the art. cations of each of the exemplary schemes and in the Examples (hereafter “exemplary schemes”) leads to various analogs of the specific exemplary materials produced.

The cited citations describing suitable methods of organic synthesis are applicable to such modifications.

In each of the exemplary schemes it may be advantageous to separate reaction products from one r and/or from starting materials. The desired products of each step or series of steps is separated and/or ed (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: e-phase and normal phase; size exclusion; ion ge; high, medium, and low pressure liquid chromatography methods and tus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.

Another class of separation methods involves treatment of a mixture with a reagent selected to bind to or render otherwise separable a desired product, unreacted starting material, reaction by product, or the like. Such ts include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media, or the like. Alternatively, the reagents can be acids in the case of a basic material, bases in the case of an acidic material, binding reagents such as antibodies, binding ns, selective chelators such as crown ethers, liquid/liquid ion extraction reagents (LIX), or the like.

Selection of appropriate methods of separation depends on the nature of the materials involved. For example, boiling point, and molecular weight in lation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction, and the like. One skilled in the art will apply techniques most likely to achieve the desired separation.

A single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of reomers using lly active resolving agents (Stereochemistry of Carbon Compounds, (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J.

Chromatogr., 113, 3) 283-302). Racemic mixtures of chiral compounds of the disclosure can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) tion of the substantially pure or enriched isomers ly under chiral conditions.

Under method (1), reomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, -methyl-- phenylethylamine (amphetamine), and the like with asymmetric compounds g acidic functionality, such as carboxylic acid and sulfonic acid. The reomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.

Alternatively, by method (2), the substrate to be resolved is reacted with one enantiomer of a chiral nd to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) chemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322).

Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by tion of the reomers and hydrolysis to yield the free, enantiomerically enriched substrate. A method of ining optical purity involves making chiral esters, such as a menthyl ester, e.g., (-) menthyl chloroformate in the presence of base, or Mosher ester, - methoxy--(trifluoromethyl)phenyl acetate (Jacob III. (1982) J. Org. Chem. 47:4165), of the c mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers of atropisomeric compounds can be separated and isolated by - and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111). By method (3), a racemic mixture of two enantiomers can be separated by chromatography using a chiral nary phase (Chiral Liquid Chromatography (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) J. of Chromatogr. 513:375-378). Enriched or purified enantiomers can be distinguished by s used to distinguish other chiral les with asymmetric carbon atoms, such as optical rotation and circular dichroism.

Schemes and Examples General aspects of these exemplary methods are bed below and in the Examples. Each of the products of the following processes is optionally ted, ed, and/or purified prior to its use in subsequent processes.

A number of exemplary methods for the preparation of compounds of the disclosure are provided herein, for example, in the Examples below. These methods are intended to illustrate the nature of such preparations and are not intended to limit the scope of applicable methods. Certain compounds of the disclosure can be used as intermediates for the preparation of other compounds of the disclosure. In the exemplary methods described herein, the fragment E-V- can also be written as R9-. PG represents a protecting group common for the given functional group that it is attached. The lation and removal of the ting group can be accomplished using standard techniques, such as those described in Wuts, P. G. M., Greene, T. Protective Groups in Organic Synthesis, 4th ed.; John Wiley & Sons, Inc.: n, New Jersey, 2007.

Scheme 1. Representative synthesis of E-V-C(=O)-P-W-P-C(=O)-V-E O Cl O H2N V-C(=O)-P-W-P-C(=O)-V-E NH-V-C(=O)-P-W-P-C(=O)-V-E 1a 1b O Cl O O H2N V-C(=O)-P-W-P-C(=O)-V NH2 NH-V-C(=O)-P-W-P-C(=O)-V-NH O O 1c 1d Scheme 1 shows a general sis of an E-V-C(=O)-P-W-P-C(=O)-V-E molecule of the disclosure wherein, for illustrative purposes, E is methoxycarbonylamino. The treatment of either 1a or 1c with one or two equivalents respectively of methyl chloroformate under basic conditions (e.g. sodium hydroxide) provides the molecule 1b or 1d.

Scheme 2. Representative synthesis of E-V-C(=O)-P-W-P-C(=O)-V-E E-V-C(=O)-P-W V-E E-V-C(=O)-P-W N O N 2a H 2b 2c H O N HO W 2 V-E N O H N 2d 2b 2e O V-E Scheme 2 shows a general synthesis of an =O)-P-W-P-C(=O)-V-E molecule of the disclosure wherein, for rative purposes, P is pyrrolidine. Coupling of amine 2a with acid 2b is accomplished using a peptide ng reagent (e.g. HATU) to afford 2c.

Alternatively, amine 2d is coupled with two equivalents of 2b under similar conditions to provide 2e.

Scheme 6. entative synthesis of R1-V-C(=O)-P-R2 E-V-C(=O)-P-W V-NH-PG E-V-C(=O)-P-W N O N 6a H 6b 6c V-NH-PG PG-HN-V-C(=O)-P-W V-E PG-HN-V-C(=O)-P-W N O N 6d H 6e 6f PG-HN-V-C(=O)-P-W V-NH-PG PG-HN-V-C(=O)-P-W N O N 6d H 6b 6g V-NH-PG PG-HN-P-W V-E PG-HN-P-W N O N 6h H 6e 6i PG-HN-P-W V-NH-PG PG-HN-P-W N O N 6h H 6b 6j W V-E PG-HN-W N O N 6k H 6e 6l PG-HN-W V-NH-PG W N O N 6k H 6b 6m V-NH-PG Scheme 6 shows a general synthesis of an R1-V-C(=O)-P-R2 intermediate wherein, for illustrative purposes, P is pyrrolidine, R1 is a generic group that is depicted as either -E or a amino protecting group, and R2 is a generic group that is depicted as -W-P-C(=O)-V-E, - W-P-C(=O)-V-NH-PG, -W-P-NH-PG, or -W-NH-PG. Coupling of amine 6a (or 6d, 6h, 6k) with acid 6b or 6e is accomplished using a peptide coupling reagent (e.g. HATU) to afford 6c (or 6f, 6g, 6i, 6j, 6l, 6m) respectively.

Scheme 7. Representative synthesis of E-V-C(=O)-R1 O Cl O H2N V-C(=O)-P-W-P-C(=O)-V-NH-PG NH-V-C(=O)-P-W-P-C(=O)-V-NH-PG 7a 7b O Cl O H2N V-C(=O)-P-W-P-PG NH-V-C(=O)-P-W-P-PG 7c 7d O Cl O H2N V-C(=O)-P-W-PG NH-V-C(=O)-P-W-PG 7e 7f O Cl O H2N V-C(=O)-P-PG NH-V-C(=O)-P-PG 7g O 7h O Cl O H2N V-C(=O)-O-PG NH-V-C(=O)-O-PG 7i 7j Scheme 7 shows a l synthesis of an E-V-C(=O)-R1 intermediate wherein, for illustrative es, E is methoxycarbonylamino and R1 is a generic group that is ed as either -P-W-P-C(=O)-V-NH-PG, -P-W-P-PG, -P-W-PG, -P-PG, or -O-PG. Treatment of 7a (or 7c, 7e, 7g, 7i) with methyl chloroformate under basic conditions (e.g. sodium hydroxide) provides the molecule 7b (or 7d, 7f, 7h, 7j).

Scheme 9. Representative sis of R1-P-R2 NH2 HO P-C(=O)-V-E NH2 Br NH2 O Br NH 9b P-C(=O)-V-E 9c O N P-C(=O)-V-E Br N NH2 HO P-PG NH2 Br NH2 O Br NH 9e P-PG 9f O N P-PG Br N Scheme 9 shows a general synthesis of an 2 intermediate wherein, for illustrative purposes, R1 is -C(=O)-V-E or a protecting group and R2 is a substituted benzimidazole. The formation of the benzimidazole is accomplished by coupling the acid 9b or 9e with an arylamine 9a, using a peptide coupling reagent such as HATU, to afford 9c or 9f. Cyclization of the amide in the presence of an acid (such as acetic acid) affords the benzimidazole containing le 9d or 9g.

The formation of multiple benzimidazoles is performed in the same , starting with a bis-diamine to provide the corresponding bis-benzimidazole.

Scheme 20. Representative synthesis of R1-P-W-P-R2 Scheme 20 shows a general synthesis of an R1-P-W-P-R2 intermediate of the disclosure wherein, for rative purposes, R1 and R2 are independent protecting groups and W is a two aromatic ring unit constructed via a transition metal mediated cyclization.

Alkylation of phenol 20b with an alkyl bromide, such as 20a, provides the ether 20c.

Cyclization of the ic rings in the ce of a palladium catalyst provides the compound 20d. Treatment of 20d with CuBr2 provides the α-haloketone 20e, which es 20f upon addition of an acid under basic conditions (e.g. Et3N). Reaction of 20f with an amine or amine salt (e.g. ammonium acetate) affords the imidazole containing molecule 20g.

Oxidation of 20g, 20i, or 20l can be accomplished by g in the presence of MnO2 to e 20h, 20j, or 20m, respectively. Conversion of 20g or 20h with a palladium catalyst, such as Pd2dba3 and X-Phos, and a boron source such as nacolato)diboron provides the boronic ester 20i or 20j. The boronic ester is coupled with an appropriate coupling partner (e.g. 20k) using a palladium catalyst, such as Pd(PPh3)4 or PdCl2(dppf), to afford 20l or 20m.

For each transition metal mediated cross-coupling reaction, the roles of the nucleophile and electrophile can be reversed to provide the same coupling product. Other transition metal mediated cross couplings that enable the construction of W, but employ ative coupling partners and reagents, include, but are not limited to, the Negishi, Kumada, Stille, and Ullman ngs. For the preparation of alternate two aromatic ring containing W groups, this general scheme can be applied through the appropriate choice of the ng reagents.

Scheme 21. Representative synthesis of R1-P-W-P-R2 O O O O Cl 20d O O PG-P O 21b O O Br PG-P O O 21d O O P-PG PG-P O N N P-PG N N PG-P H 21f/g Scheme 21 shows a general synthesis of an R1-P-W-P-R2 intermediate of the disclosure wherein, for illustrative purposes, R1 and R2 are independent protecting groups and W is a two aromatic ring unit constructed via a transition metal ed cyclization.

Treatment of 20d with an activated vinyl reagent (e.g. potassium rifluoroborate) in the presence of a palladium st (e.g. palladium acetate and S-Phos) provides the vinyl compound 21a. Conversion to the corresponding α-halo ketone can be accomplished by bromination with N-bromosuccinimide, followed by oxidation with MnO2. Displacement of the α-halo ketone proceeds by the addition of an acid under basic conditions (e.g. Et3N).

Bromination of 21c proceeds upon treatment with pyridinium tribromide, and is followed by the on of a second acid under basic conditions to provide the diester 21e. Reaction of 21e with an amine or amine salt (e.g. ammonium e) affords the imidazole containing molecule 21f. Oxidation of 21f can be lished in the presence of MnO2 to provide 21g.

Scheme 22. Representative synthesis of E-V-C(=O)-P-W-P-R O O E-V-C(=O)-P O 21b O O Br E-V-C(=O)-P O O 22b O O P-PG E-V-C(=O)-P O N N P-PG E-V-C(=O)-P N 22d/e Scheme 22 shows a l synthesis of an E-V-C(=O)-P-W-P-R intermediate of the disclosure wherein, for illustrative purposes, R is a protecting group and W is a two ic ring unit. Displacement of the α-halo ketone 21b proceeds by the addition of an acid under basic conditions (e.g. Et3N). Bromination of 22a proceeds upon treatment with pyridinium mide, and is followed by the addition of a second acid under basic conditions to provide the diester 22c. Reaction of 22c with an amine or amine salt (e.g. ammonium acetate) affords the imidazole containing molecule 22d. Oxidation of 22d can be accomplished in the ce of MnO2 to provide 22e.

Scheme 23. Representative synthesis of R-P-W-P-C(=O)-V-E Scheme 23 shows a general synthesis of an E-V-C(=O)-P-W-P-R intermediate of the sure wherein, for illustrative es, R is a protecting group and W is a two aromatic ring unit. Displacement of the α-halo ketone 21d proceeds by the addition of an acid under basic conditions (e.g. Et3N). Reaction of 23a with an amine or amine salt (e.g. ammonium acetate) affords the imidazole containing molecule 23b. Oxidation of 23b can be accomplished in the presence of MnO2 to e 23c.

Scheme 25. Representative synthesis of E-V-C(=O)-P-W-P-C(=O)-V-E Scheme 25 shows a general synthesis of an E-V-C(=O)-P-W-P-C(=O)-V-E molecule of the disclosure n, for illustrative purposes, E is ethylcarbonylamino. The treatment of either 25a or 25c with one or two lents respectively of propionyl de under basic conditions (e.g. sodium hydroxide) provides the molecule 25b or 25d.

Scheme 26. Representative syntheses of E-V-C(=O)-P-R and R1-P-R Scheme 26 shows a general sis of an E-V-C(=O)-P-R and an R1-P-R molecule of the disclosure wherein, for illustrative purposes R is a idazole. Treatment of the aldehyde 26a with glyoxal, in the presence of ammonium hydroxide provides the imidazole 26b. Treatment with either osuccinamide or iodine provides the corresponding haloimidazole 26c and 26d respectively. Separation from the corresponding bis-halogenated compound can be accomplished by preparative HPLC chromatography. The conversion of the bis-haloimidazole to the mono-haloimidazole can also be accomplished upon heating in the presence of sodium sulfite. Further functionalization of the P group can be accomplished upon removal of the protecting group and coupling with an appropriate acid (E-V-C(=O)- OH).

Scheme 27. Representative synthesis of R1-P-W-P-R2 O O Br O 27a O Br PG-P O O 21d O O P-PG PG-P O N N P-PG PG-P N 21f/g Scheme 27 shows an alternate general synthesis of an R1-P-W-P-R2 intermediate of the invention wherein, for illustrative purposes, R1 and R2 are independent protecting groups and W is a two aromatic ring unit constructed via a tion metal mediated cyclization.

Bromination of 21b with a brominating agent (i.e. pyridinium tribromide) provides the dibromide 27a. Displacement of the primary e then proceeds by the on of an acid under basic conditions (e.g. K2CO3) to provide 21d. Conversion to 21f or 21g can be accomplished following methods described in Scheme 21.

Scheme 28. Representative synthesis of E-V-C(=O)-P-W-P-R O O Br O 27a O Br E-V-C(=O)-P O O 22b O O P-PG E-V-C(=O)-P O N N P-PG E-V-C(=O)-P N 22d/e Scheme 28 shows an alternate general synthesis of an E-V-C(=O)-P-W-P-R intermediate of the ion wherein, for illustrative purposes, R is a protecting group and W is a two ic ring unit. Bromination of 21b with a brominating agent (i.e. pyridinium tribromide) provides the dibromide 27a. Displacement of the primary bromide then proceeds by the addition of an acid under basic conditions (e.g. K2CO3) to provide 22d. Conversion to 22d or 22e can be accomplished ing methods bed in Scheme 22.

Specific Embodiments In one embodiment the disclosure provides a compound which has formula: O H N P1b-C(=O)-V1b-E1b N N E1a-V1a-C(=O)-P1a H (A1) O H N P1b-C(=O)-V1b-E1b N N E1a-V1a-C(=O)-P1a H (A2) N N P1b-C(=O)-V1b-E1b N N E1a-V1a-C(=O)-P1a H (A3) O H N N =O)-V1b-E1b N N E1a-V1a-C(=O)-P1a H (A4) wherein the imidazole ring shown in formula A1, A2, A3, and A4 is optionally substituted with one or more groups independently selected from halo, haloalkyl, cyano, or alkyl; or a pharmaceutically acceptable salt or prodrug thereof.

In one embodiment the sure provides a compound which has formula: O H N N P1b-C(=O)-V1b-E1b N N E1a-V1a-C(=O)-P1a H (A2) or O H N P1b-C(=O)-V1b-E1b N N E1a-V1a-C(=O)-P1a H (A4) wherein the imidazole ring shown in formula A2 and A4 is optionally substituted with one or more groups independently selected from halo, kyl, cyano, or alkyl; or a pharmaceutically acceptable salt or g thereof.

In one embodiment at least one of E1a and E1b is -N(H)(alkoxycarbonyl).

In one ment at least one of E1a and E1b is -N(H)C(=O)OMe.

In one embodiment both of E1a and E1b are -N(H)C(=O)OMe.

In one embodiment at least one of E1a and E1b is -N(H)(cycloalkylcarbonyl) or -N(H)(cycloalkyloxycarbonyl).

In one embodiment at least one of E1a and E1b is cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino or cyclobutyloxycarbonylamino.

In one embodiment E1a and E1b are each independently selected from cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino or methoxycarbonylamino.

In one ment at least one of V1a and V1b is: .

In one embodiment E1a-V1a taken together are R9a or wherein E1b-V1b taken together are R9b.

In one embodiment at least one of P1a and P1b is selected from: In one embodiment P1a and P1b are each independently selected from: In one embodiment one of P1a and P1b is: and the other of P1a and P1b is: In one embodiment one of P1a and P1b is: O and the other of P1a and P1b is: In one embodiment at least one of P1a and P1b is: F O F .

In one embodiment at least one of P1a and P1b is: O .

In one embodiment at least one of -V1a -P1a – and -P1b-C(=O)-V1b- is: or O O .

In one embodiment at least one of -V1a –C(=O)-P1a – and -P1b-C(=O)-V1b- is: O O N O N N O OMe N O N or O .

In one embodiment both of -V1a -P1a – and -P1b-C(=O)-V1b- are independently selected from: O O N O N N O OMe N O N or O .

In one embodiment one of -V1a –C(=O)-P1a – and -P1b-C(=O)-V1b- is: O O O O N O O N N N N OMe OMe O O N N N O . and the other of -V1a -P1a – and -P1b-C(=O)-V1b- is: O O N O N N O OMe N O N or O .

In one embodiment the disclosure provides a nd of formula: H O O N O H N N N N N O N O O N O H O N N N N N N O N O O O H O H N O O N N N N N N O O O N H O H O H O O N N O O N N HN O N O H O N N N O O N N N O H N O O O HN H N N N O N N N H O HN O H O O N O H N N O N N N O N O O H O H N O O N N N N N N O O N H O O H O O N N N N N N O O O H O H H N O N N O N N N O H O O N O H O N N N N N N O H N O O H O O NH O N HN N N N O O H O H O O N N N N O O O O O N O H O N N N N N H O O NH O H O N N N N N N O H HN O H O H O O N N N O N N O or a pharmaceutically acceptable salt or g thereof.

In one embodiment the disclosure provides a compound of formula: O N O H N N N N N N O H N O O H or a pharmaceutically acceptable salt or prodrug thereof.

In one ment the disclosure provides a compound of formula: O O H NH O N HN N N N O O O H O H N O O N N N N N N O O N H H O O O N O H O N N N N N N O H N O O H O H O H H N O N N O N N N O H N O H O H O O N N N N O O O N O H O N N N O O N N N O H N O or a pharmaceutically acceptable salt or prodrug thereof.

The disclosure will now be illustrated by the following non-limiting Examples. The ing abbreviations are used throughout the specification, including the Examples. (aq) Aqueous (g) Gas (s) Solid °C Degree Celsius Ac Acetate ACN Acetonitrile apprx Approximate Bis- Bis(pinacolato)diboron pinB/(Bpin)2/(pinB)2 BOC/Boc tert-Butoxycarbonyl calc'd ated CC50 50% Cytotoxicity concentration COMU 1-[(1-(Cyanoethoxy oxoethylideneaminooxy)dimethylaminomorpholino)] uronium hexafluorophosphate d Doublet dba dibenzalacetone DCM romethane dd Doublet of doublets ddd Doublet of doublet of doublets DIPEA/DIEA N,N-Diisopropylethylamine DMA N,N-Dimethylacetamide DMAP 4-Dimethylaminopyridine DME Dimethoxyethane DMEM Eagle's minimal essential medium DMF ylformamide mso Dimethylsulfoxide dppf 1,1'-bis( diphenylphosphanyl) ferrocene dt Doublet of triplets EC50 Half maximal effective concentration ESI Electrospray tion Et Ethyl ext. External FBS Fetal bovine serum g Gram HATU 2-(1HAzabenzotriazolyl)-1,1,3,3-tetramethyl uronium hexafluorophosphate aminium HPLC High performance liquid chromatography hr/h Hour Hz Hertz J Coupling constant LCMS Liquid chromatography mass spectrometry M Molar m Multiplet m/z Mass to charge M+ Mass peak Me Methyl mg Milligram MHz rtz min Minute mL Milliliter mmol Millimole Moc Methoxycarbonyl MS Mass spectrometry MTBE Methyl tert-butyl ether N Normal NADPH Nicotinamide adenine dinucleotide phosphate NBS N-Bromosuccinimide NMM N-Methylmorpholine NMR Nuclear magnetic resonance o/n Over night Papp Apparent bility PBS Phosphate buffer system Pd/C ium on carbon Ph Phenyl Phg/PhGly Phenyl glycine Piv Pivalate Pro Proline pyr Pyridine q Quartet qd Quartet of doublets quant Quantitative quint Quintet rt/RT Room temperature s Singlet SPhos 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl t Triplet t-Bu tert-Butyl TEMPO (2,2,6,6-Tetramethyl-piperidinyl)oxyl Tf Trifluoromethanesulfonate TFA Trifluoroacetic acid THF Tetrahydrofuran Thr Threonine TLC Thin layer chromatography tol. Toluene UV iolet Val Valine w/v Weight to volume w/w Weight to weight X-Phos/XPOS/Xphos 2-Dicyclohexylphosphino-2′,4′,6′- triisopropylbiphenyl δ Chemical shift μg Microgram μL Microliter EXAMPLES Example LQ Br O O HO O K2CO3, DMF Cl Br Br rt, 18 hr. 7-hydroxytetralone 89% Cl 1-bromo(bromomethyl)- robenzene romochlorobenzyloxy)- 3,4-dihydronaphthalen-1(2H)-one Pd(OPiv)2, P(4-F-Ph)3, t-BuCO2H, CuBr2, CHCl3, EtOAc 80 oC, 2 hr.

K2CO3, DMA, 60 oC, 24 hr.

Cl 80 - 95% 67 - 85% 3-chloro-10,11-dihydro-5H- dibenzo[c,g]chromen-8(9H)-one 1. HO O N O Boc O O H DIPEA, CH3CN, 50°C Cl N Cl N Br 2. NH4Cl, Toluene, N Boc 2-methoxyethanol, 110°C tert-butyl 2-(9-chloro-1,4,5,11- 9-bromochloro-10,11-dihydro-5H- tetrahydroisochromeno[4',3':6,7]naph dibenzo[c,g]chromen-8(9H)-one tho[1,2-d]imidazolyl)pyrrolidine carboxylate O O H B B MnO2, CH2Cl2, rt N O O Cl N N Boc Pd2dba3, KOAc, XPOS, tert-butyl 2-(9-chloro-1,11- dioxane, 90°C dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)pyrrolidinecarboxylate O H O O O N N O N H B N O N Boc Pd(PPh3)4, PdCl2(dppf), K2CO3, DME/ DMF, 85°C tert-butyl 4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinecarboxylate O 1. HCl, EtOH, 60°C H O N H O O N N 2.

N N N Boc O H O H N O O H tert-butyl 2-[9-(2-{1-[N-(methoxycarbonyl)valyl]pyrrolidin yl}-1H-imidazolyl)-1,11- COMU, DIPEA, DMF, RT dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol rolidinecarboxylate O H O N H O O N N N N N H O N O [1-(2-{5-[2-(1- {[(methoxycarbonyl)amino](phenyl)acetyl}pyrrolidin yl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]-1H-imidazolyl}pyrrolidinyl) methyloxobutanyl]carbamic acid 7-(2-bromochlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)-one To a stirred solution of 7-hydroxytetralone (13.9 g, 85.7 mmol) and 1-bromo (bromomethyl)chlorobenzene (25.6 g, 90.0 mmol) in dimethylformamide (850 mL) was added potassium carbonate (24 g, 172 mmol). The reaction was stirred under argon for 18 hours then diluted with ethyl acetate (1 L). The organics were washed three times with water and once with brine. The c layer was then dried with magnesium sulfate, filtered and concentrated. To the resulting oil was added methanol (500 mL) and the suspension was agitated for thirty s. romochlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)- one (27.8 g, 89% yield) was isolated by filtration. 3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one To a 1 L flask containing palladium(II) pivalate (1.18 g, 3.8 mmol), tri(4- phenyl)phosphine (1.20 g, 3.8 mmol), pivalic acid (2.33 g, 22.8 mmol) and potassium carbonate (31.8 g, 228 mmol) was added a solution of 7-(2-bromochlorobenzyloxy)-3,4- dihydronaphthalen-1(2H)-one (27.8 g, 76.2 mmol) in dimethylacetamide (380 mL). The flask was evacuated and backfilled with argon 5 times and then stirred under argon at 60 oC for 24 hours. The reaction was cooled to room temperature and diluted with MTBE and water. The resulting biphasic mixture was stirred for 3 hours and filtered through Celite, g with MTBE. The organic layer of the filtrate was separated and then washed twice with water and once with brine. The organics were then dried with magnesium sulfate, filtered, concentrated and purified by flash column chromatography (Hexanes/DCM) to yield ro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (14.4 g, 67% yield) as an offwhite solid. 9-bromochloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one To a mixture of 3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (14.8 g, 52 mmol) in chloroform (50 mL) and ethyl acetate (50 mL) was added copper(II) bromide (24.3 g, 104 mmol). The reaction was heated to 80 oC for 2 hours and then cooled to room temperature. The mixture was diluted with dichloromethane and washed twice with a 5:1 solution of saturated s ammonium de and aqueous ammonium hydroxide (~38%), and washed once with water. The organic layer was dried with magnesium sulfate, filtered and concentrated to yield 9-bromochloro-10,11-dihydro-5H-dibenzo[c,g]chromen- 8(9H)-one (18.5 g, >95% yield) with >95% purity.

Note: This reaction is not always this clean. Sometimes there is over-bromination and sometimes there is significant starting material. These impurities can be removed by flash column chromatography. tert-Butyl 2-(9-chloro-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 2-yl)pyrrolidinecarboxylate To a solution of (1R)(tert-butoxycarbonyl)cyclopentanecarboxylic acid (10.17 g, 47.25 mmol) and ochloro-10,11-dihydro-6H-naphtho[2,3-c]chromen-8(9H)-one (5.7 mg, 15.7 mmol) in itrile (50 mL) was added diisopropylethylamine (11.11 mL, 64 mmol). The reaction was stirred at 50 oC for 4 hours and was then diluted with ethyl acetate.

The organics were washed with water and brine, dried (MgSO4) and concentrated. The resulting crude residue was purified by flash chromatography to yield (2S)tert-butyl 2-(3- chlorooxo-8,9,10,11-tetrahydro-5H-naphtho[c,g]chromenyl) pyrrolidine-1,2- dicarboxylate (4.52 g, 58%). To a solution of (2S)tert-butyl 2-(3-chlorooxo-8,9,10,11- tetrahydro-6H-naphtho[2,3-c]chromenyl) pyrrolidine-1,2-dicarboxylate (3.27 mg, 6.56 mmol) in a mixture of toluene (11 mL) and 2-methoxyethanol (0.7 mL) was added ammonium acetate (5.06 g, 65.6 mmol). The reaction mixture was heated to 110 °C for 3 hours, cooled to room temperature and diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and trated. The crude residue was purified by flash chromatography to yield tert-butyl 2-(9-chloro-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (1.95 g, 61%). LCMS-ESI+: calculated for ClN3O34 2: 477.98; observed [M+1]+: 478.47 utyl 2-(9-chloro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol rolidinecarboxylate To a solution of utyl 2-(9-chloro-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (1.9 g, 3.96 mmol) in dichloromethane (35 mL) was added manganese(IV) oxide (17 g, 198 mmol). The reaction mixture was stirred at room temperature for 18 hours, diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated.

The crude residue was purified by flash chromatography to yield tert-butyl 2-(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (1.52 g, 81%). LCMS-ESI+: calculated for C27H26ClN3O3: 475.9; observed [M+1]+: 476.45. tert-Butyl 2-[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate A degassed mixture of tert-butyl hloro-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (1.52 g, 3.17 mmol), bis(pinacolato)diboron (1.21 g, 4.75 mmol), potassium acetate (934 mg, 9.52 mmol), tris(dibenzylideneacetone)palladium (116 mg, 0.13 mmol) and 2- dicyclohexylphosphino-2’, 4’, 6’-tri-i-propyl-1, henyl (121 mg, 0.08 mmol) in 1,4- dioxane (16 mL) was heated to 90 oC for 1.5 hours, cooled to room ature and diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield tert-butyl 2- [9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate (1.7 g, 94%) tert-Butyl 2-[9-(2-{1-[N-(methoxycarbonyl)valyl]pyrrolidinyl}-1H-imidazolyl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidine carboxylate To a solution of methyl (S)((S)(5-bromo-1H-imidazolyl)pyrrolidinyl) methyloxobutanylcarbamate (1.48 g, 3.97 mmol), tert-butyl 2-[9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinecarboxylate (1.88 g, 1.48 mmol), tetrakis(triphenyl phosphine)palladium(0) (191 mg, 0.16 mmol) and dichloro[1,1'-bis(diphenylphosphino) ferrocene]palladium(II) (242 mg, 0.33 mmol) in a mixture of 1,2-dimethoxyethane (37.0 mL) and dimethylformamide (6 mL) was added a solution of potassium carbonate (2M in water, 5 mL, 9.93 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room ature, the reaction was d with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield tert-butyl 2-[9-(2-{1-[N- xycarbonyl)valyl]pyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate (1.45 mg, 59%). LCMS-ESI+: calculated for C41H47N7O6 +: 734.87. 73 733.86; observed [M+1] [1-(2-{5-[2-(1-{[(Methoxycarbonyl)amino](phenyl)acetyl}pyrrolidinyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]-1H-imidazol yl}pyrrolidinyl)methyloxobutanyl]carbamic acid A solution of tert-butyl 2-[9-(2-{1-[N-(methoxycarbonyl)valyl]pyrrolidinyl}-1H- imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidine- 1-carboxylate (462 mg, 0.63 mmol), l (6 mL) and concentrated HCl (2 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was concentrated and to this material was added a solution of (R) (methoxycarbonylamino)phenylacetic acid (172 mg, 0.82 mmol) and COMU (311 mg, 0.73 mmol) in DMF (6 mL). To the resulting on was added diisopropylethylamine (330 L, 1.89 mmol). After stirring for 18 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by ative reverse phase HPLC (Gemini, 15 to 45% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give [1-(2-{5-[2-(1- {[(methoxycarbonyl)amino](phenyl)acetyl}pyrrolidinyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]-1H-imidazolyl}pyrrolidin yl)methyloxobutanyl]carbamic acid (231 mg, 45%). LCMS-ESI+: calculated for C46H48N8O78: 824.92; ed [M+1]+: 826.00. e LR CN 1) HCl, MeOH CO2Me 2) Boc2O, NaHCO3 NaOH H H MeO2C N Boc MeO2C N (2S,4S)tert-butyl 2-methyl 4-cyanopyrrolidine- 1,2-dicarboxylate (2S,4S)tert-butyl 2,4- dimethyl pyrrolidine-1,2,4- tricarboxylate CO2H 1) l MeI (t-Bu)2pyr 2) NaBH4 H MeO2C N Boc MeO2C N AgOTf (3S,5S)(tert-butoxycarbonyl) (2S,4S)tert-butyl 2-methyl 4- (methoxycarbonyl)pyrrolidinecarboxylic acid (hydroxymethyl)pyrrolidine-1,2- dicarboxylate O O LiOH H H MeO2C N HO2C N Boc Boc (2S,4S)tert-butyl 2-methyl (2S,4S)(tert-butoxycarbonyl) 4-(methoxymethyl)pyrrolidine- (methoxymethyl)pyrrolidine 1,2-dicarboxylate carboxylic acid (2S,4S)tert-butyl methyl pyrrolidine-1,2,4-tricarboxylate To a solution of (2S,4S)tert-butyl 2-methyl 4-cyanopyrrolidine-1,2-dicarboxylate (9.0 g, 35.4 mmol) in MeOH (196 mL) was added HCl (4M in 1,4-dioxane, 100 mL, 403 mmol). The solution was stirred at room temperature for 16h and concentrated in vacuo. The crude intermediate was dissolved in EtOAc (180 mL) and basified with aqueous bicarbonate (sat.). t-butyl dicarbonate (8.5 g, 38.9 mmol) was added and the biphasic solution was stirred at room temperature for 12h. The layers were then separated and the aqueous layer was tracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The crude oil was ed by silica gel chromatography (15% to 40% to 100% EtOAc/Hexanes) to provide (2S,4S)tert-butyl 2,4-dimethyl pyrrolidine-1,2,4-tricarboxylate (9.56 g, 94%). (3S,5S)(tert-butoxycarbonyl)(methoxycarbonyl)pyrrolidinecarboxylic acid To a solution of (2S,4S)tert-butyl 2,4-dimethyl pyrrolidine-1,2,4-tricarboxylate (9.56 g, 33.3 mmol) in THF (70 mL) at 0 °C (external temperature, ice bath) was added NaOH (1N aqueous, 33 mL, 33.3 mmol) dropwise over 15 min. The solution was stirred at 0 °C for 5h before acidification with HCl (1N). The solution was extracted with EtOAc (3x).

The combined organic layers were dried over Na2SO4 and concentrated. The crude oil was ed by silica gel chromatography (2% to 5% to 10% MeOH/CH2Cl2) to provide (3S,5S)- 1-(tert-butoxycarbonyl)(methoxycarbonyl)pyrrolidinecarboxylic acid (6.38g, 70%). (2S,4S)tert-butyl 2-methyl roxymethyl)pyrrolidine-1,2-dicarboxylate To a solution of (3S,5S)(tert-butoxycarbonyl)(methoxycarbonyl)pyrrolidine carboxylic acid (6.38 g, 23.3 mmol) in THF (116 mL) at 0 °C (external temperature, ice bath) was added Et3N (4.9 mL, 35.0 mmol) and ethyl chloroformate (2.7 mL, 28.0 mmol). The ing solution was stirred at 0 °C for 45 min, during which time a white precipitate forms.

The reaction mixture was filtered through celite and concentrated.

The crude intermediate was dissolved in THF (59 mL) and cooled to 0 °C (external temperature, ice bath). NaBH4 (4.41 g, 116.7 mmol) in H2O (59 mL) was slowly added and the resulting solution was stirred at 0 °C for 2 h. The reaction mixture was diluted with EtOAc and washed with H2O. The aqueous layer was tracted with EtOAc. The combined c layers were dried over Na2SO4 and concentrated. The crude oil was purified by silica gel chromatography (42% to 69% to 100% EtOAc/Hexanes) to provide (2S,4S)tert-butyl 2-methyl 4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylate (3.63 g, 60%). (2S,4S)tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate To a solution of (2S,4S)tert-butyl 2-methyl 4-(hydroxymethyl)pyrrolidine-1,2- dicarboxylate (2.57 g, 9.9 mmol) in CH2Cl2 (50 mL) was added AgOTf (4.07 g, 15.8 mmol) and 2,6-di-tert-butylpyridine (4.4 mL, 19.8 mmol). The reaction mixture was cooled to 0 °C (external temperature, ice bath) and MeI (0.98 mL, 15.8 mmol) was slowly added. The resulting slurry was stirred at 0 °C for 1.5 h and at room temperature for 1.5 h. The slurry was diluted with CH2Cl2 and filtered through celite. The filtrate was concentrated to dryness, dissolved in Et2O, and washed with HCl (1N) and brine. The aqueous layers were backextracted with Et2O and the combined organic layers were dried over Na2SO4 and concentrated. The crude oil was ed by silica gel chromatography (10% to 75% to 100% EtOAc/Hexanes) to provide (2S,4S)tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-1,2- dicarboxylate (2.11 g, 78%). 1H-NMR: 400 MHz, (CDCl 3) δ: re of rotamers, major ed) 4.20 (t, 1H), 3.71 (s, 3H), 3.67 (m, 1H), 3.34 (m, 2H), 3.30 (s, 3H), 3.16 (t, 1H), 2.43 (m, 2H), 1.74 (m, 1H), 1.38 (s, 9H). (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid To a solution of (2S,4S)tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-1,2- dicarboxylate (2.11 g, 7.7 mmol) in a mixture of THF (38 mL) and MeOH (15 mL) was added LiOH (2.5 M aqueous, 15 mL, 38.6 mmol). The resulting on was stirred at room temperature for 2h, and acidified with aqueous HCl (1N). The desired t was extracted with CH2Cl2 (4x). The combined organic layers were dried over Na2SO4 and concentrated to provide (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid (2.0 g, 99%). 1H-NMR: 400 MHz, (CDCl 3) δ: (mixture of rotamers, major reported) 4.33 (t, 1H), 3.65 (m, 1H), 3.35 (m, 2H), 3.32 (s, 3H), 3.16 (t, 1H), 2.45 (m, 2H), 2.12 (m, 1H), 1.46 (s, 9H).

Example LR-1 Cl N N Boc 1. O (2S,4R)-tert-butyl 2-(9-chloro-4,5-dihydro- 5H-naphtho HO [c,g]chromeno[8,9-d]imidazolyl) O N (methoxymethyl) O O Boc idinecarboxylate Cl DIPEA, CH3CN, 50°C Br O 2. NH4OAc, Toluene, 2-methoxyethanol, O 9-bromochloro-10,11-dihydro- 110°C H 5H-dibenzo[c,g]chromen-8(9H)- N one Cl N Boc (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H- naphtho [c,g]chromeno[8,9-d]imidazolyl) (methoxymethyl) pyrrolidinecarboxylate H O O N B B MnO2, CH2Cl2, rt Cl O O N Boc (2S,4S)-tert-butyl 2-(9-chloro-5H-naphtho[ Pd2dba3, KOAc, XPOS, c,g]chromeno[8,9-d]imidazolyl) e, 90°C (methoxymethyl)pyrrolidinecarboxylate (2S,4S)-tert-butyl(9-chloro-4,5-dihydro-5H-naphtho[2,3-c]chromeno[8,9-d]imidazol- 2-yl)(methoxymethyl)pyrrolidinecarboxylate: To a solution of ((S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine carboxylic acid (5.9 g, 23.1 mmol) and 9-bromochloro-10,11-dihydro-5H- naphtho[c,g]chromen-8(9H)-one (5.6 mg, 15.4 mmol) in acetonitrile (60 mL) was added diisopropylethylamine (5.35 mL, 30.8 mmol). The reaction was stirred at 50 oC for 18 hours and was then diluted with ethyl e. The organics were washed with water and brine, dried (MgSO4) and concentrated. The resulting crude residue was purified by flash chromatography to yield (2S)tert-butyl(3-chlorooxo-8,9,10,11-tetrahydro-6H- naphtho[2,3-c]chromenyl)-4(methoxymethyl) pyrrolidine-1,2-dicarboxylate (5.12 g, 61%).

To a solution of (2S)tert-butyl(3-chlorooxo-8,9,10,11-tetrahydro-6H-naphtho[2,3- c]chromenyl)-4(methoxymethyl)pyrrolidine-1,2-dicarboxylate (5.11 mg, 9.42 mmol) in a mixture of toluene (94 mL) and 2-methoxyethanol (0.1 mL) was added ammonium acetate (23.5 g, 304 mmol). The reaction mixture was heated to 110 °C for 18 hours, cooled to room temperature and diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (2S,4R)-tert-butyl 2-(9-chloro-4,5-dihydro-5H-naphtho[c,g]chromeno[8,9-d]imidazol- 2-yl)(methoxymethyl)pyrrolidinecarboxylate (1.05g, 21%) and (2S,4S)-tert-butyl(9- chloro-4,5-dihydro-6H-naphtho[2,3-c]chromeno[8,9-d]imidazolyl) (methoxymethyl)pyrrolidinecarboxylate (2.0 g, 41%). LCMS-ESI+: calculated for C29H32ClN3O4 2: 522.0; observed [M+1]+: 522.2. (2S,4S)-tert-butyl(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl) (methoxymethyl)pyrrolidinecarboxylate.

To a solution of )-tert-butyl(9-chloro-4,5-dihydro-5H- o[c,g]chromeno[8,9-d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (1.99 g, 3.82 mmol) in dichloromethane (30 mL) was added manganese(IV) oxide (10 g, 115 mmol). The reaction mixture was stirred at room temperature for 18 hours, diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated.

The crude residue was purified by flash chromatography to yield(2S,4S)-tert-butyl(9- chloro-6H-naphtho[2,3-c]chromeno[8,9-d]imidazolyl)methoxymethyl)pyrrolidine ylate (1.05g, 21%) and (2S,4S)-tert-butyl(9-chloro-4,5-dihydro-6H-naphtho[2,3- c]chromeno[8,9-d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (1.64 g, 82%). LCMS-ESI+: ated for C29H30ClN3O42: 520.02; observed [M+1]+: 520.97. (2S,4S)-tert-butyl(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)- htho[c,g]chromeno[8,9-d]imidazolyl)pyrrolidinecarboxylate: A degassed mixture of (2S,4S)-tert-butyl(9-chloro-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)(methoxymethyl) pyrrolidinecarboxylate (649 mg1.25 mmol), bis(pinacolato)diboron (635 mg, 2.5 mmol), potassium acetate (368 mg, 3.7 mmol), tris(dibenzylideneacetone)palladium (46 mg, 0.05 mmol) and 2- ohexylphosphino-2’, 4’, 6’-tri-i-propyl-1, 1’-biphenyl (60 mg, 0.12 mmol) in 1,4- dioxane (7 mL) was heated to 90 oC for 3 hours, cooled to room temperature and diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (2S,4S)-tertbutyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)pyrrolidinecarboxylate (467 mg, 61%) LCMSESI +: calculated for C35H42BN3O6: 611.54; observed [M+1]+: 612.96. (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-5H-naphtho[c,g]chromeno[8,9- d]imidazolyl)-4(methoxymethyl)pyrrolidinecarboxylate To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl)pyrrolidine carboxylate (467 mg, 0.76 mmol), methyl (S)((S)(5-bromo-1H-imidazol yl)pyrrolidinyl)methyloxobutanylcarbamate (342 mg, 0.92 mmol), tetrakis(triphenylphosphine) palladium(0) (44 mg, 0.04 mmol) and dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(II) (56 mg, 0.07 mmol) in a mixture of 1,2- oxyethane (11.0 mL) and dimethylformamide (1.9 mL) was added a solution of potassium carbonate (2M in water, 1.15 mL, 2.29 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-5H-naphtho[c,g] no [8,9- d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (180 mg, 67%). LCMS-ESI+: calculated for N7O73 777.91; observed [M+1]+: 778.84. methyl {2-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)- 1H-imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate A solution of )-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) butanoyl)pyrrolidinyl)-1H-imidazolyl)-5H-naphtho[c,g]chromeno[8,9- d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (196 mg, 0.25 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was trated and to this material was added a solution of (R)(methoxycarbonylamino) phenylacetic acid (69 mg, 0.33 mmol) and COMU (124 mg, 029 mmol) in DMF (4 mL). To the resulting solution was added ropylethylamine (130 L, 0.76 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative e phase HPLC (Gemini, 15 to 45% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {2-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidin yl)-1H-imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (84 mg, 39%). LCMSESI +: calculated for C48H52N8O8: 868.98; observed [M+1]+: 870.11 Example LS methyl {1-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)- dazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-5H-naphtho[c,g]chromeno[8,9- d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (116 mg, 0.15 mmol), ethanol (5 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (10 mL). This solution was concentrated and to this material was added a solution of 2-methoxycarbonylamino methylbutyric acid (38 mg, 0.22 mmol) and HATU (79 mg, 0.21 mmol) in DMF (1.4 mL).

To the resulting solution was added ropylethylamine (270 L, 1.5 mmol). After stirring for 18 hours at room ature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), trated and purified by preparative reverse phase HPLC (Gemini, 15 to 45% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {1-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidin yl)-1H-imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate (58 mg, 13%).

LCMS-ESI+: calculated for C45H54N8O8: 834.96; observed [M+1]+: 835.70.

Example LT O H O O O N N N H H O N B N O N Boc Pd(PPh3)4, PdCl2(dppf), K2CO3, DME/ DMF, 85°C )-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)-5H-naphtho [c,g]chromeno[8,9-d]imidazolyl)pyrrolidine- 1-carboxylate (2S,4S)-tert-butyl(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)azabicyclo[3.1.0]hexanyl)-1H-imidazolyl)-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)(methoxymethyl)pyrrolidine carboxylate To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl)pyrrolidine carboxylate (557 mg, 0.91 mmol), methyl (S)((1S,3S,5S)(5-bromo-1H-imidazolyl)- icyclo[3.1.0]hexanyl)methyloxobutanylcarbamate (350 mg, 0.91 mmol), is(triphenylphosphine) palladium(0) (53 mg, 0.04 mmol) and dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(II) (67 mg, 0.07 mmol) in a mixture of 1,2- dimethoxyethane (11.0 mL) and dimethylformamide (1.9 mL) was added a solution of potassium carbonate (2M in water, 1.37 mL, 2.7 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The cs were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (2S,4S)-tert-butyl 2-((S)((S)(methoxycarbonylamino) methylbutanoyl)azabicyclo[3.1.0]hexanyl)-1H-imidazolyl)-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (271 mg, 38%). LCMS-ESI+: calculated for N7O7. 789.92; observed [M+1]+: 790.76. methyl {2-[2-{9-[2-(2-{2-[(methoxycarbonyl)amino]methylbutanoyl} azabicyclo[3.1.0]hexyl)-1H-imidazolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate: A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)azabicyclo[3.1.0]hexanyl)-1H-imidazolyl)-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (196 mg, 0.25 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude al dissolved in DCM (6 mL). This on was concentrated and to this material was added a solution of (R) (methoxycarbonylamino)phenylacetic acid (69 mg, 0.33 mmol) and COMU (124 mg, 0.29 mmol) in DMF (4 mL). To the resulting solution was added ropylethylamine (130 L, 0.76 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 45% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {2-[2-{9-[2-(2-{2-[(methoxycarbonyl)amino] methylbutanoyl}azabicyclo[3.1.0]hexyl)-1H-imidazolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}(methoxymethyl)pyrrolidin yl]oxophenylethyl}carbamate (84 mg, 39%). LCMS-ESI+: calculated for C49H52N8O8: 880.99; observed [M+1]+: 882.09 Example LZ O O O O NH O (Bpin)2, Pd2(dba)3, X-Phos, O NH O Cl B N N N N KOAc, dioxane, 90 oC O tert-butyl (2S)(9-chloro-3,7- tert-butyl -[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolandihydroisochromeno [3',4':5,6]naphtho[1,2- 2-yl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2- d]imidazolyl)pyrrolidinecarboxylate d]imidazolyl]pyrrolidinecarboxylate -(2-bromochlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)-one To a stirred solution of 5-hydroxytetralone (2.0 g, 12.3 mmol) and 1-bromo (bromomethyl)chlorobenzene (3.6 g, 12.7 mmol) in ylformamide (125 mL) was added potassium carbonate (3.5 g, 25.1 mmol). The reaction was stirred under argon for 1 hour then diluted with ethyl acetate (1 L). The organics were washed three times with water and once with brine. The organic layer was then dried with ium sulfate, filtered and concentrated. To the resulting oil was added methanol (100 mL) and the suspension was agitated for thirty s. 5-(2-bromochlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)- one (4.25 g, 94% yield) was isolated by filtration. 8-chloro-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenone To a flask containing palladium(II) pivalate (68 mg, 0.22 mmol), tri(4- fluorophenyl)phosphine (70 mg, 0.22 mmol), pivalic acid (135 mg, 1.3 mmol) and potassium carbonate (1.83 g, 13.1 mmol) was added a solution of 5-(2-bromochlorobenzyloxy)-3,4- dihydronaphthalen-1(2H)-one (1.61 g, 4.4 mmol) in yacetamide (23 mL). The flask was evacuated and backfilled with argon 5 times and then stirred under argon at 60 oC for 24 hours. The reaction was poured directly onto a silica gel column and purified by flash column chromatography (hexanes/DCM) to yield 8-chloro-2,3,4,6-tetrahydro- enzo[c,h]chromenone (1.22 g, 97% yield) as an off-white solid. 2-bromochloro-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenone To a mixture of 8-chloro-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenone (2.58 g, 9.1 mmol) in chloroform (9.1 mL) and ethyl acetate (9.1 mL) was added copper(II) e (4.65 g, 19.9 mmol). The reaction was heated to 80 oC for 5 hours and then cooled to room temperature. The mixture was diluted with dichloromethane and washed twice with a 5:1 solution of saturated aqueous ammonium chloride and aqueous um hydroxide (~28%), and washed once with water. The organic layer was dried with magnesium sulfate, filtered and concentrated. The crude material was purified by flash column chromatography (hexanes/DCM) to yield 2-bromochloro-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromen one (2.45 g, 75% yield). (2S)tert-butyl 2-(8-chlorooxo-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenyl) pyrrolidine-1,2-dicarboxylate To a solution of 2-bromochloro-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenone (1.05 g, 2.9 mmol) and Boc-Pro-OH (1.75 g, 8.1 mmol) in itrile (9.0 mL) was added diisopropylethylamine (1.5 mL, 8.7 mmol). The solution was stirred under argon at 50 oC for two hours. Extra Boc-Pro-OH (620 mg, 2.9 mmol) and diisopropylethylamine (0.5 mL, 2.9 mmol) were added and the reaction was d at 50 oC for 16 hours. The reaction was cooled to room temperature and d with ethyl acetate. The organics were washed with water and brine, dried with magnesium sulfate and concentrated. The crude material was purified by flash column tography and the product (2S)tert-butyl 2-(8-chloro oxo-2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenyl) pyrrolidine-1,2-dicarboxylate was isolated as a mixture of diastereomers (0.99 g, 69% yield). tert-butyl -(9-chloro-3,4,5,7-tetrahydroisochromeno[3',4':5,6]naphtho[1,2- d]imidazolyl)pyrrolidinecarboxylate To a solution of (2S)tert-butyl 2-(8-chlorooxo-2,3,4,6-tetrahydro-1H- dibenzo[c,h]chromenyl) pyrrolidine-1,2-dicarboxylate (2.2 g, 4.4 mmol) in toluene (40 mL) was added ammonium acetate (7 g, 91 mmol). The reaction mixture was vigorously refluxed for 3 hours, then cooled to room temperature and diluted with ethyl acetate. The organics were washed with water and brine, dried with magnesium sulfate and concentrated.

The crude material was purified by flash column chromatography to yield utyl (2S) (9-chloro-3,4,5,7-tetrahydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl)pyrrolidine carboxylate (1.13 g, 54% yield) as well as red (2S)tert-butyl hlorooxo- 2,3,4,6-tetrahydro-1H-dibenzo[c,h]chromenyl) pyrrolidine-1,2-dicarboxylate (0.8 g, 36%).

). LCMS-ESI+: calculated for C27H28N3O3: ; observed [M+1]+: 478.54. tert-butyl (2S)(9-chloro-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate To a solution of Intermediate tert-butyl (2S)(9-chloro-3,4,5,7- tetrahydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (1.43 g, 3.0 mmol) in dichloromethane (30 mL) was added manganese(IV) oxide (15 g, 198 mmol).

The mixture was stirred for four hours at room temperature then filtered through Celite. The MnO2 was thoroughly rinsed with dichloromethane and the total filtrate was concentrated to yield tert-butyl (2S)(9-chloro-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (1.37 g, 96% . This material was used without further purification. tert-butyl (2S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate To a solution of tert-butyl (2S)(9-chloro-3,7- oisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (1.4 g, 2.9 mmol) in dioxane (20 mL) was added bis(pinacolato)diboron (1.5 g, 5.9 mmol), tris(dibenzylideneacetone)dipalladium(0) (110 mg, 0.12 mmol), X-Phos (145 mg, 0.30 mmol) and potassium acetate (870 mg, 8.9 mmol). The mixture was degassed with a stream of argon for ten minutes. The degassed reaction was heated under argon to 90 oC for 2.5 hours then cooled to room temperature and diluted with ethyl acetate. The organics were washed with water and brine, dried with magnesium sulfate and concentrated. The crude material was purified by flash column chromatography (DCM/EtOAc) to yield tert-butyl (2S)[9- ,5-tetramethyl-1,3,2-dioxaborolanyl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2- azolyl]pyrrolidinecarboxylate (1.5 g, 90% . methyl [(2S)methyloxo{(2S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)- 3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl]pyrrolidinyl}butan yl]carbamate A solution of tert-butyl (2S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate (0.98 g, 1.7 mmol), concentrated HCl (2 mL) and ethanol (20 mL) was heated to 60 oC for 2 hours.

The reaction was concentrated and redissolved in a minimal amount of methanol. An equal volume of dichloromethane was added and the solution was again concentrated.

Dichloromethane was added to the resulting e and concentrated off two more times.

The resulting crude material was dissolved in dimethylformamide (17 mL). To this solution was added (S)(methoxycarbonylamino)methylbutanoic acid (455 mg, 2.6 mmol), HATU (955 mg, 2.5 mmol) and diisopropylethylamine (3 mL, 17 mmol). The reaction was stirred at room temperature for one hour then diluted with ethyl acetate. The cs were washed with water (x2) and brine, dried with magnesium sulfate and concentrated. The resulting residue was purified by flash column tography to yield Intermediate methyl [(2S)methyloxo{(2S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl]pyrrolidinyl}butan yl]carbamate (780 mg, 72% yield over 2 steps). tert-butyl (2R)[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]pyrrolidinecarboxylate A mixture of Pentacyclic Intermediate methyl [(2S)methyloxo{(2S)[9- (4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2- d]imidazolyl]pyrrolidinyl}butanyl]carbamate (780 mg, 1.3 mmol), (S)-tert-butyl 2- (5-bromo-1H-imidazolyl)pyrrolidinecarboxylate (450 mg, 1.4 mmol), tetrakis(triphenylphosphine)palladium(0) (30 mg, 0.03 mmol), PdCl2(dppf) (60 mg, 0.08 mmol), 2M aqueous potassium ate (1.9 mL, 3.9 mmol), dimethoxyethane (10 mL) and dimethylformamide (2 mL) was degassed with argon for 15 s. The reaction was then heated to 85 oC for 3 hours. Upon completion, the reaction was cooled to room temperature, diluted with ethyl acetate and ed through Celite. The filtrate was washed with water and brine, dried (MgSO4) and concentrated. The ing crude material was purified by flash column tography (EtOAc/MeOH) to yield Intermediate tert-butyl (2R)[5-(2-{(2S)- 1-[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate (390 mg, 43% yield). methyl {(2S)[(2R)(5-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate A mixture of Intermediate tert-butyl (2R)[5-(2-{(2S)[N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]pyrrolidinecarboxylate (390 mg, 0.53 mmol), concentrated HCl (2 mL) and l (10 mL) was heated to 60 oC for 2 hours. The reaction was concentrated and redissolved in a l amount of methanol. An equal volume of dichloromethane was added and the solution was again concentrated. Dichloromethane was added to the resulting residue and concentrated off two more times. One half of the crude al (~0.27 mmol) was dissolved in dimethylformamide (2.5 mL). To this solution was added (S) (methoxycarbonylamino)methylbutanoic acid (66 mg, 0.38 mmol), HATU (140 mg, 0.37 mmol) and diisopropylethylamine (0.48 mL, 2.7 mmol). The reaction was stirred at room temperature for 2 hours, and then diluted with acetonitrile (2 mL) and methanol (2 mL). To this solution was added ten drops of 5M aqueous NaOH solution and stirring was continued for 30 minutes. The reaction was diluted with ethyl acetate and the organic layer was washed with water and brine. The combined aqueous washings were extracted three times with ethyl acetate, and the combined organic layers were dried (MgSO4) and concentrated. The crude material was purified by e phase HPLC (Gemini, 15 to 45% ACN/H2O + 0.1% TFA) to yield methyl {(2S)[(2R)(5-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate (140 mg, 67% yield over 2 . LCMS-ESI+: calculated for N8O7: 790.91; observed [M+1]+: 791.71.

Example MA This compound was made in an analogous manner to methyl 1-[(2R)(5-{2- 1-{(2S)[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]methyloxobutanyl}carbamate, substituting (R)(methoxycarbonylamino) phenylacetic acid for (S)(methoxycarbonylamino)methylbutanoic acid and substituting COMU for HATU in the final amide coupling step. LCMS-ESI+: calculated for C46H48N8O7: 824.92; observed [M+1]+: 825.72.

Example MB tert-butyl (2S)[9-(2-{(2R)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-1H- imidazolyl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol yl]pyrrolidinecarboxylate A mixture of tert-butyl (2S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate (450 mg, 0.79 mmol), methyl (S)((S)(5-bromo-1H-imidazolyl)pyrrolidinyl)methyl- 1-oxobutanylcarbamate (325 mg, 0.87 mmol), tetrakis(triphenylphosphine)palladium(0) (30 mg, 0.02 mmol), PdCl2(dppf) (35 mg, 0.05 mmol), 2M s potassium ate (1.2 mL, 2.4 mmol), dimethoxyethane (6.8 mL) and dimethylformamide (1.2 mL) was degassed with argon for 15 minutes. The reaction was then heated to 85 oC for 2.5 hours. Upon completion, the reaction was cooled to room temperature, diluted with ethyl acetate and filtered through Celite. The filtrate was washed with water and brine, dried (MgSO4) and concentrated. The resulting crude material was purified by flash column chromatography (EtOAc/MeOH) to yield tert-butyl (2S)[9-(2-{(2R)[N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-1H-imidazolyl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2- azolyl]pyrrolidinecarboxylate (270 mg, 46% yield). methyl {(2S)[(2R)(5-{2-[(2S){(2R)[(methoxycarbonyl)amino] phenylacetyl}pyrrolidinyl]-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate: A e of tert-butyl -[9-(2-{(2R)[N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-1H-imidazolyl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2- d]imidazolyl]pyrrolidinecarboxylate (270 mg, 0.37 mmol), trated HCl (1.5 mL) and ethanol (8 mL) was heated to 60 oC for 1 hour. The reaction was concentrated and redissolved in a minimal amount of methanol. An equal volume of dichloromethane was added and the solution was again concentrated. Dichloromethane was added to the resulting residue and concentrated off two more times. The crude al was dissolved in 5:1 dichloromethane/dimethylformamide (3.8 mL). To this solution was added (R) (methoxycarbonylamino)phenylacetic acid (96 mg, 0.46 mmol), COMU (190 mg, 0.44 mmol) and diisopropylethylamine (0.20 mL, 1.1 mmol). The reaction was stirred at 0 oC for minutes then warmed to room temperature. Upon completion, the reaction was diluted with acetonitrile (2 mL) and methanol (2 mL). To this solution was added ten drops of 5M aqueous NaOH solution and stirring was continued for 30 minutes. The on was diluted with ethyl acetate and the organic layer was washed with water and brine. The combined aqueous washings were extracted three times with ethyl acetate, and the combined organic layers were dried (MgSO4) and concentrated. The crude material was purified by reverse phase HPLC (Gemini, 15 to 45% ACN/H2O + 0.1% TFA) to yield methyl {(2S)[(2R) (5-{2-[(2S){(2R)[(methoxycarbonyl)amino]phenylacetyl}pyrrolidinyl]-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]methyloxobutanyl}carbamate (155 mg, 51% yield over 2 steps). LCMS-ESI+: calculated for C46H48N8O7: 824.92; ed [M+1]+: 825.67.

Example MC dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'l-pyrrolidinyl)-5H-naphtho[c,g]chromeno[8,9- d]imidazolyl)-1H-imidazolyl)pyrrolidinyl))bis(3-methyloxobutane-2,1- diyl)dicarbamate This compound was made in an analogous manner to methyl {(2S)[(2R)(5-{2- [(2S){(2S)[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]methyloxobutanyl}carbamate, substituting 7-hydroxytetralone for 5-hydroxy- 1-tetralone in the first step of the sequence. All reactions in the sis gave r product yields as in the synthesis of methyl {(2S)[(2R)(5-{2-[(2S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]- 3-methyloxobutanyl}carbamate. LCMS-ESI+: calculated for N8O7: 790.91; observed : 791.6.

Example MD NH O O O O N NH N N N H O methyl [1-(2-{5-[2-(1-{[(methoxycarbonyl)amino]methyl anyl}pyrrolidinyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]-1H- imidazolyl}pyrrolidinyl)-phenyloxoacetyl]carbamate This compound was made in an analogous manner to dimethyl (2S,2'S)-1,1'-((2S,2'S)- 2,2'l-pyrrolidinyl)-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl)-1H-imidazol yl)pyrrolidinyl))bis(3-methyloxobutane-2,1-diyl)dicarbamate, substituting (R) (methoxycarbonylamino)phenylacetic acid for (S)(methoxycarbonylamino) methylbutanoic acid and substituting COMU for HATU in the final amide coupling step.

LCMS-ESI+: calculated for C46H48N8O7: 824.92; observed [M+1]+: 825.67.

Example ME dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'l-pyrrolidinyl)-7H-dihydro- naphtho[c,g]chromeno[8,9-d]imidazolyl)-1H-imidazolyl)pyrrolidinyl))bis(3- methyloxobutane-2,1-diyl)dicarbamate This compound was made in an analogous manner to dimethyl S)-1,1'-((2S,2'S)- 2,2'l-pyrrolidinyl)-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl)-1H-imidazol yl)pyrrolidinyl))bis(3-methyloxobutane-2,1-diyl)dicarbamate, omitting the MnO2 oxidation of tert-butyl 2-(9-chloro-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)pyrrolidinecarboxylate. LCMS-ESI+: ated for C43H52N8O7: 792.40; observed [M+1]+: .

Example MF methyl [1-(2-{5-[2-(1-{[(methoxycarbonyl)amino]methyloxobutanyl}pyrrolidin- 2-yl)-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]-1H- imidazolyl}pyrrolidinyl)-phenyloxoacetyl]carbamate This compound was made in an analogous manner to dimethyl (2S,2'S)-1,1'-((2S,2'S)- 2,2'l-pyrrolidinyl)-7H-dihydro-naphtho[c,g]chromeno[8,9-d]imidazolyl)-1H-imidazol- 2-yl)pyrrolidinyl))bis(3-methyloxobutane-2,1-diyl)dicarbamate, substituting (R) (methoxycarbonylamino)phenylacetic acid for (methoxycarbonylamino) methylbutanoic acid and substituting COMU for HATU in the final amide coupling step.

LCMS-ESI+: calculated for C46H50N8O7: 826.94; observed [M+1]+: 827.71.

Example MG O O O N O NH O 3)4, PdCl2(dppf), Br B N N O N N K2CO3, DME, DMF, 85 oC methyl (S)((S)(5-bromo-1H- tert-butyl (2S)[9-(4,4,5,5-tetramethylimidazolyl )pyrrolidinyl) 1,3,2-dioxaborolanyl)-3,4,5,11- methyloxobutanylcarbamate ydroisochromeno[4',3':6,7]naphtho[ 1,2-d]imidazolyl]pyrrolidine carboxylate O O NH 1) HCl, EtOH, 60 oC O O HN O NH O N O O 2) Moc-Val-OH, COMU, N N N N DIPEA, DMF H HO tert-butyl (2S)[9-(2-{(2R)[N-(methoxycarbonyl)-L- (methoxycarbonylamino)- valyl]pyrrolidinyl}-1H-imidazolyl)-3,4,5,11- 2-phenylacetic acid tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 2-yl]pyrrolidinecarboxylate NH O O O O N NH N N N N [1-(2-{5-[2-(1-{[(methoxycarbonyl)amino](phenyl)acetyl}pyrrolidinyl)-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]-1H-imidazol yl}pyrrolidinyl)methyloxobutanyl]carbamic acid This compound was made in an analogous manner to methyl 1-[(2R)(5-{2- [(2S){(2R)[(methoxycarbonyl)amino]phenylacetyl}pyrrolidinyl]-3,7- dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]methyloxobutanyl}carbamate, substituting tert-butyl (2S)[9-(2-{(2R)[N- (methoxycarbonyl)-L-valyl]pyrrolidinyl}-1H-imidazolyl)-3,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinecarboxylate for tert-butyl (2S)[9-(2-{(2R)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-1H-imidazol- 5-yl)-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazolyl]pyrrolidine carboxylate. LCMS-ESI+: calculated for C46H50N8O7: 826.94; observed [M+1]+: 827.64.

Example MM O 1. HCl, EtOH, 60°C O N N 2.

B O O N Boc O H N O (2S,4S)-tert-butyl hoxymethyl)(9-(4,4,5,5- O H tetramethyl-1,3,2-dioxaborolanyl)-1,11- HATU, DIPEA, DMF, RT dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidine- 1-carboxylate O Boc N H Br O N N N B N H O N N O Pd(PPh3)4, PdCl2(dppf), H K2CO3, DME/ DMF, 85°C (2S,4S)-methyl {4-(methoxymethyl)[(9-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 2-yl)pyrrolidin-1yl]methyloxobutanyl}carbamate H 1. HCl, EtOH, 60°C Boc N N N N N H O N O H O O H N O tert-butyl (2S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)- L-valyl]methylpyrrolidinyl}-1,11-dihydroisochromeno O H [4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl COMU, DIPEA, DMF, RT ]pyrrolidinecarboxylate H O O O H N N N N N N O methyl {(1R)[(2S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl) amino]methylbutanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol- 2-yl)pyrrolidinyl]oxophenylethyl}carbamate (2S,4S)-methyl {4-(methoxymethyl)[(9-(4,4,5,5-tetramethyl-1,3,2-dioxa borolanyl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) pyrrolidin-1yl] methyloxobutanyl}carbamate A solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]-imidazol yl)pyrrolidinecarboxylate (424 mg, 0.69 mmol), ethanol (6 mL) and concentrated HCl (2 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (10 mL). This solution was concentrated and to this material was added a solution of 2-methoxycarbonylaminomethylbutyric acid (152 mg, 0.86 mmol) and HATU (303 mg, 0.79 mmol) in DMF (6 mL). To the resulting solution was added ropylethylamine (360 L, 2.08 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with 5% NaHCO3 on, water and brine, dried (Na2SO4), concentrated and dried under vacuum to give )-methyl {4- (methoxymethyl)[(9-(4,4,5,5-tetramethyl-1,3,2-dioxaboro lanyl)-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinyl]methyl oxobutanyl}carbamate. tert-butyl(2S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]methylpyrroli din yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]pyrrolidinecarboxylate To a solution of (2S, 4S)-methyl{4-(methoxymethyl)[(9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroiso chromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidin-1yl]methyloxobutanyl}carbamate (0.69 mmol), (S)-tert-butyl 2-(5- bromo-1H-imidazolyl)pyrrolidinecarboxylate (220 mg, 0.69 mmol), tetrakis(triphenylphosphine) palladium(0) (24 mg, 0.02 mmol) and dichloro[1,1'- bis(diphenylphosphino) ferrocene]palladium(II) (31 mg, 0.04 mmol) in a e of 1,2- dimethoxyethane (6.0 mL) and dimethylformamide (1.0 mL) was added a solution of potassium carbonate (2M in water, 1.04 mL, 2.0 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the on was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (tert-butyl -[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]pyrrolidinecarboxylate (145 mg, 27%). methyl{(1R)[(2S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}(methoxymethyl)pyrrolidinyl]-1,11-dihydroiso chromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidinyl] oxophenylethyl}carbamate A solution of utyl (2S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]pyrrolidinecarboxylate (145 mg, 0.18 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was concentrated and to this material was added a solution of (R)(methoxycarbonylamino)phenylacetic acid (51 mg, 0.24 mmol) and COMU (92 mg, 021 mmol) in DMF (3 mL). To the resulting solution was added diisopropylethylamine (100 L, 0.56 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 43% ACN/H2O + 0.1% TFA). The product ons were lyophilized to give methyl 2- [(2S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methylbutanoyl} (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2- azolyl}-1H-imidazolyl)pyrrolidinyl]oxophenylethyl}carbamate (68 mg, 39%). MS (ESI) m/z 870 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.71 (s, 1H), 8.22 (d, 1H, J = 8 Hz), 8.09 (m, 1H), 7.88 – 7.63 (m, 6H), 7.36 - 7.29 (m, 6H), 5.41 (d, 1H, J = 8.4 Hz), .30 – 5.24 (m, 2H), 5.14 – 5.10 (m, 1H), 4.13 -3.09 (m, 15H), 2.47 - 1.80 (m, 8H), 0.80 (dd, 6H, J = 6.4 Hz, J = 23 Hz).

Example MN tert-butyl(2S,4S)[9-(2-{(2S4S)[N-(methoxycarbonyl)-L-valyl]methyl pyrrolidin- 2-yl}-1H-imidazolyl)-3,11-dihydroisochromeno[4',3':6,7]naphtho [1,2-d]imidazol yl](methoxymethyl)pyrrolidinecarboxylate To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7] o [1,2-d]imidazol yl)pyrrolidinecarboxylate (438 mg, 0.72 mmol), methyl (S)((2S,4S)(5-bromo-1H- imidazolyl)methylpyrrolidinyl)methyloxobutanylcarbamate (276 mg, 0.72 mmol), is(triphenylphosphine) palladium(0) (41 mg, 0.04 mmol) and dichloro[1,1'- bis(diphenylphosphino) ferrocene]palladium(II) (52 mg, 0.07 mmol) in a mixture of 1,2- oxyethane (8.6 mL) and dimethylformamide (1.5 mL) was added a solution of potassium carbonate (2M in water, 1.07 mL, 2.15 mmol). The ing mixture was ed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1H-imidazolyl)-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]- 4-(methoxymethyl)pyrrolidinecarboxylate (182 mg, 32%). methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}(methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate A solution of tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-3,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- azolyl](methoxy )pyrrolidinecarboxylate (182 mg, 0.18 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was concentrated and to this material was added a solution of (R)(methoxycarbonylamino) phenylacetic acid (47 mg, 0.23 mmol) and COMU (85 mg, 0.2 mmol) in DMF (3 mL). To the resulting solution was added diisopropylethylamine (90 L, 0.52 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 49% O + 0.1% TFA). The product fractions were lyophilized to give methyl{(2S)[(2S,4S)(5-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}(methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)-methylpyrrolidinyl]methyl- 1-oxobutanyl}carbamate (32 mg, 39%). MS (ESI) m/z 884 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.70 (s, 1H), 8.21 (d, 1H, J = 8 Hz), 8.08 (s, 1H), 7.90 – 7.64 (m, 6H), 7.34 – 7.31 (m, 3H), 7.64 (d, 1H, J = 8.4 Hz), 5.47 (d, 1H, J = 7.6 Hz), 5.28 – .25 (m, 3H), 5.05 – 5.01 (m, 1H), 4.19 – 4.04 (m, 3H), 3.67 – 3.15 (m, 15H), 2.51 -2.46 (m, 4H), 1.95 – 1.92 (m, 2H), 1.82 – 1.76 (m, 1H), 1.10 (d, 3H, J = 6 Hz), 0.75 (dd, 6H, J = 6.8 Hz, J = 14 Hz). e MO methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methoxymethylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate To a solution of methyl 1-[(2S,4S)(5-{2-[(2S,4S) (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7] naphtho[1,2- d]imidazolyl}-1H-imidazolyl)(methyl)pyrrolidinyl]methyloxobutan yl}carbamate (57 mg, 0.08 mmol), 2-methoxycarbonylaminomethylbutyric acid (19 mg, 0.1 mmol), HATU (303 mg, 0.79 mmol) in DMF (1 mL) was added diisopropylethylamine (43 L, 0.24 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with 5% NaHCO3 solution, water and brine, dried (Na2SO4), concentrated and purified by ative reverse phase HPLC (Gemini, 15 to 43% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {(2S)[(2S,4S)(5- {2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methyl butanoyl} methoxymethylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)methylpyrrolidinyl]methyl- utanyl}carbamate. (13 mg, 19%). MS (ESI) m/z 850 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.66 (s, 1H), 8.28 – 8.13 (m, 1H), 8.12 – 7.99 (m, 1H), 7.90 – 7.75 (m, 3H), 7.73 – 7.65 (m, 1H), 7.63 – 7.57 (m, 1H), 7.34 – 7.19 (m, 2H), 5.30 – .24 (m, 2H), 5.21 – 4.95 (m, 2H), 4.33 – 3.93 (m, 6H), 3.23 -3.58 (m, 12H), 2.76 – 2.59 (m, 2H), 2.02 – 1.73 (m, 6H), 1.12 – 1.07 (m, 3H), 0.86 – 0.68 (m, 12H).

Example MP tert-butyl(2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methyl pyrrolidin- 2-yl}-1H-imidazolyl)-3,11-dihydroisochromeno[4',3':6,7]naphtho [1,2-d]imidazol yl](methoxymethyl)pyrrolidinecarboxylate To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (217 mg, 0.35 mmol), methyl (S)((2S,5S)(5-bromo-1H- imidazolyl)methylpyrrolidinyl)methyloxobutanylcarbamate (170 mg, 0.39 mmol), tetrakis(triphenylphosphine) palladium(0) (21 mg, 0.02 mmol) and ro[1,1'- bis(diphenylphosphino) ferrocene]palladium(II) (26 mg, 0.04 mmol) in a mixture of 1,2- dimethoxyethane (4.3 mL) and dimethylformamide (0.75 mL) was added a solution of potassium carbonate (2M in water, 0.53 mL, 1.06 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and trated. The crude residue was purified by flash chromatography to yield tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1H-imidazolyl)-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxy methyl)pyrrolidine- 1-carboxylate (110 mg, 39%). methyl{(2S)[(2S,5S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methoxymethylpyrrolidinyl]-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate A solution of tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-3,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxy methyl)pyrrolidinecarboxylate (108 mg, 0.14 mmol), ethanol (2 mL) and concentrated HCl (0.7 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (10 mL). This solution was trated and to this al was added a solution of 2-methoxycarbonylamino methylbutyric acid (31 mg, 0.18 mmol) and HATU (60 mg, 0.16 mmol) in DMF (2 mL). To the resulting solution was added diisopropylethylamine (70 L, 0.41 mmol). After stirring for 2 hours at room temperature, the on was diluted with ethyl acetate, washed with 5% NaHCO3 solution, water and brine, dried (Na2SO4). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with 5% NaHCO3 solution, water and brine, dried (Na2SO4), concentrated and purified by ative reverse phase HPLC (Gemini, 15 to 43% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methoxy methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) pyrrolidinyl]methyloxobutanyl}carbamate (52 mg, 45%). MS (ESI) m/z 850 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.69 (s, 1H), 8.18 (d, 1H, J = 7.6 Hz), 7.99 – 7.86 (m, 4H), 7.72 (s, 1H), 7.64 (d, 1H, J = 8.8 Hz), 7.51 (d, 1H, J = 8 Hz), 7.23 (d, 1H, J = 8.4 Hz), .29 (s, 2H), 5.22 – 5.18 (m, 1H), 5.01 – 4.70 (m, 1H), 4.64 – 4.61 (m, 1H), 4.21-4.17 (m, 1H), 4.09-4.05 (m, 1H), 3.92 – 3.88 (m, 1H), 3.59 – 3.08 (m, 14H), 2.67 – 1.83 (m, 7H), 1.43 (d, 3H, J = 6.4 Hz), 0..91-0.71 (m, 12H). e MQ (2S,4R)-tert-butyl(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) pyrrolidine carboxylate A degassed mixture of (2S,4R)-tert-butyl(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl) pyrrolidine- 1-carboxylate (335 mg, 0.64 mmol), bis(pinacolato)diboron (246 mg, 0.96 mmol), potassium acetate (190 mg, 1.9 mmol), tris(dibenzylideneacetone) palladium (24 mg, 0.02 mmol) and 2- dicyclohexylphosphino-2’, 4’, 6’-tri-i-propyl-1, 1’-biphenyl (31 mg, 0.06 mmol) in 1,4- dioxane (3.3 mL) was heated to 90 oC for 3 hours, cooled to room temperature and diluted with ethyl e. The cs were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash tography to yield (2S,4R)-tertbutyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (379 mg, 96%). (2S,4R)-tert-butyl(9-(2-((S)((S)(methoxycarbonylamino)methyl butanoyl)pyrrolidinyl)-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7] naphtho[1,2-d]imidazol yl)-4(methoxymethyl) idinecarboxylate.

To a solution of (2S,4R)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)- ihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) pyrrolidinecarboxylate (299 mg, 0.49 mmol), methyl (S)((S)(5-bromo-1H-imidazol- 2-yl)pyrrolidinyl)methyloxobutanylcarbamate (217 mg, 0.58 mmol), tetrakis(triphenylphosphine) ium(0) (28 mg, 0.02 mmol) and dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(II) (35 mg, 0.04 mmol) in a mixture of 1,2- dimethoxyethane (4.3 mL) and dimethylformamide (0.75 mL) was added a on of potassium carbonate (2M in water, 0.73 mL, 1.46 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (2S,4R)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxylate (170 mg, 45%). methyl{(1R)[(2S,4R)(9-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl)-1H-imidazolyl]-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}(methoxymethyl)pyrrolidinyl]oxophenylethyl }carbamate A solution of (2S,4R)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxy late (170 mg, 0.22 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was concentrated and to this material was added a solution of (R) xycarbonylamino)phenylacetic acid (59 mg, 0.28 mmol) and COMU (108 mg, 0.25 mmol) in DMF (3 mL). To the resulting solution was added diisopropylethylamine (110 L, 0.66 mmol). After stirring for 2 hours at room ature, the on was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 44% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {(1R)[(2S,4R)(9-{2-[(2S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)-1H-imidazolyl]-1,11- dihydroisochromeno[4',3':6,7]-naphtho[1,2-d]imidazolyl}-(methoxymethyl) pyrrolidin yl]oxo-phenylethyl}carbamate (67 mg, 35%). MS (ESI) m/z 870 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.71 (s, 1H), 8.20 (d, 1H, J = 8.4 Hz), 8.01 (m, 1H), 7.91 – 7.64 (m, 6H), 7.38 - 7.28 (m, 6H), 6.85 (s, 1H), 5.51 (d, 1H, J = 7.2 Hz), 5.39 – 5.29 (m, 3H), 5.13 – 5.09 (m, 1H), 4.11 -3.04 (m, 15H), 2.77 - 1.98 (m, 8H), 0.79 (dd, 6H, J = 6.8 Hz, J = 12.8 Hz).

Example MR O O O O O O Cl N Pd2dba3, KOAc, XPOS, N Boc dioxane, 90°C (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)(methoxymethyl)pyrrolidinecarboxylate O H O O O N N H H O N B N O N Boc Pd(PPh3)4, PdCl2(dppf), K2CO3, DME/ DMF, 85°C (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)-4,5-dihydro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate H O N H O O N 1. HCl, EtOH, 60°C N N N N N Boc 2. (2S,4S)-tert-butyl 2-((S)((S)(methoxycarbonyl O H N O amino)methylbutanoyl)pyrrolidinyl)-1H-imidazol- -yl-4,5-dihydro-1,11-dihydroisochromeno[4',3':6,7]naphtho O H [1,2-d]imidazolyl)(methoxymethyl)pyrrolidine COMU, DIPEA, DMF, RT ylate H O N H O O N N N N N N O methyl {(1R)[(2S,4S)(9-{2-[(2S){(2S)[(methoxy carbonyl)amino]methylbutanoyl}pyrrolidinyl)-1H-imidazol- -yl]-1,11-dihydroisochromeno[4',3':6,7]-4,5-dihydro-naphtho[1,2-d] imidazolyl}(methoxymethyl)pyrrolidinyl]oxo phenylethyl}carbamate (2S,4S)-tert-butyl4-(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxaboro lan yl)-4,5-dihydro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate A degassed mixture of (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)(methoxymethyl)pyrrolidine- 1-carboxylate (322 mg, 0.61 mmol), bis(pinacolato) diboron (235 mg, 0.92 mmol), potassium acetate (182 mg, 1.9 mmol), tris(dibenzylideneacetone)palladium (23 mg, 0.02 mmol) and 2- dicyclohexylphosphino-2’, 4’, 6’-tri-i-propyl-1, 1’-biphenyl (29 mg, 0.06 mmol) in 1,4- dioxane (3.3 mL) was heated to 90 oC for 3 hours, cooled to room temperature and diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to yield (2S,4S)-tertbutyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-4,5-dihydro- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinecarboxylate (267 mg, 70%). (2S,4S)-tert-butyl(9-(2-((S)((S)(methoxycarbonylamino)methylbutano yl)pyrrolidinyl)-1H-imidazolyl-4,5-dihydro-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-4,5-dihydro-1,11-dihydroisochrome no[4',3':6,7]naphtho[1,2- d]imidazolyl)pyrrolidinecarboxylate (267 mg, 0.52 mmol), methyl (S)((S)(5- bromo-1H-imidazolyl)pyrrolidinyl)methyloxobutanylcarbamate (195 mg, 0.52 mmol), tetrakis (triphenylphosphine) palladium(0) (25 mg, 0.02 mmol) and dichloro[1,1'- bis(diphenylphosphino)ferrocene] palladium(II) (32 mg, 0.04 mmol) in a mixture of 1,2- dimethoxyethane (4.3 mL) and dimethylformamide (0.75 mL) was added a on of potassium carbonate (2M in water, 0.65 mL, 1.3 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room ature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried 4), and trated. The crude residue was ed by flash chromatography to yield (2S,4S)-tert-butyl 2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl-4,5-dihydro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxy late (75 mg, 22%). methyl{(1R)[(2S,4S)(9-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl)-1H-imidazolyl]-1,11-dihydroisochromeno [4',3':6,7]- 4,5-dihydro-naphtho[1,2-d]imidazolyl}-(methoxymethyl)pyrrolidinyl]oxo phenylethyl}carbamate A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxy carbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl-4,5-dihydro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl) pyrrolidine- 1-carboxylate (75 mg, 0.09 mmol), l (2 mL) and concentrated HCl (0.6 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was concentrated and to this material was added a solution of (R)(methoxycarbonylamino)phenylacetic acid (26 mg, 0.13 mmol) and COMU (47 mg, 0.11 mmol) in DMF (2 mL). To the ing solution was added diisopropylethylamine (50 L, 0.29 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl e, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 44% O + 0.1% TFA). The product fractions were lyophilized to give methyl {(1R)[(2S,4S)(9-{2-[(2S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)-1H-imidazolyl]-1,11- dihydroisochromeno[4',3':6,7]-4,5-dihydro-naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (15 mg, 18%).

MS (ESI) m/z 872 [M + H]+. 1H NMR (400 MHz, dmso) δ 7.95 – 7.63 (m, 6H), 7.35 - 7.25 (m, 7H), 6.97 (s, 1H), .42 (d, 1H, J = 6.8 Hz), 5.18 (s, 2H), 5.09 (s, 2H), 4.28 -2.63 (m, 19H), 2.47 - 1.80 (m, 8H), 0.77 (dd, 6H, J = 4.8 Hz, J = 12.4 Hz).

Example MS (2S,4S)-tert-butyl(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-benzo[d]imidazolyl)- 1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl) pyrrolidinecarboxylate To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)- 1,11-dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol rolidinecarboxylate (400 mg, 0.85 mmol), methyl (S)((S)(6-bromo-1H- benzo[d]imidazolyl)pyrrolidinyl)methyloxobutanylcarbamate (360 mg, 0.85 mmol), tetrakis(triphenylphosphine) palladium(0) (38 mg, 0.03 mmol) and dichloro[1,1'- bis(diphenylphosphino) ferrocene]palladium(II) (48 mg, 0.07 mmol) in a mixture of 1,2- dimethoxyethane (8.0 mL) and dimethylformamide (1.4 mL) was added a solution of potassium carbonate (2M in water, 0.98 mL, 1.96 mmol). The resulting mixture was ed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and trated. The crude residue was purified by flash chromatography to (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-benzo[d]imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxylate (156 mg, 29%). methyl{(2S)[[(2S,4S){9-[2-((2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl)-1H-benzo[d]imidazoly]-1,11-dihydroiso chromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}(methoxymethyl)pyrrolidinyl] phenylethyl}carbamate A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-benzo[d] imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxylate (156 mg, 0.18 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material ved in DCM (6 mL). This solution was concentrated and to (90 mg, 0.12 mmol) of this al was added a solution of (R)(methoxycarbonylamino)phenylacetic acid (34 mg, 0.16 mmol) and COMU (61 mg, 014 mmol) in DMF (2 mL). To the resulting solution was added diisopropylethylamine (60 L, 0.37 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 49% O + 0.1% TFA). The product fractions were lyophilized to give methyl {(2S)[[(2S,4S){9- [2-((2S){(2S)[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)-1H- benzo[d]imidazoly]-1,11-dihydroisochrome 3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (62 mg, 56%). MS (ESI) m/z 920 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.73 (s, 1H), 8.17 (d, 2H, J = 8.4 Hz), 7.94 (d, 3H, J = 8.8 Hz), 7.84 – 7.67 (m, 6H), 7.37 - 7.29 (m, 6H), 5.48 (d, 1H, J = 7.6 Hz), 5.35 – 5.20 (m, 5H), 4.14 -3.12 (m, 15H), 2.52 - 1.92 (m, 8H), 0.80 (dd, 6H, J = 6.8 Hz, J = 6.4 Hz).

Example MT methyl{(2S)[(2S,4S){9-[2-((2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl)-1H-benzo[d]imidazoly]-1,11-dihydroiso chromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}(methoxymethyl)pyrrolidinyl] methyloxobutanyl}carbamate A solution of (2S,4S)-tert-butyl(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-benzo [d]imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxylate (156 mg, 0.18 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (6 mL). This solution was trated and to 68 mg (0.09 mmol) of this material was added a solution of (S)(methoxycarbonylamino)methylbutanoic acid (21 mg, 0.12 mmol) and HATU (41 mg, 0.1 mmol) in DMF (1 mL). To the ing solution was added diisopropylethylamine (50 L, 0.28 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl e, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 44% O + 0.1% TFA). The product fractions were lyophilized to give methyl {(2S)[(2S,4S){9- [2-((2S){(2S)[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)-1H- benzo[d]imidazoly]-1,11-dihydroisochrome no[4',3':6,7]naphtho[1,2-d]imidazolyl} (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate (32 mg, 40%). MS (ESI) m/z 886 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.71 (s, 1H), 8.15 (d, 1H, J = 8 Hz), 7.95 – 7.64 (m, 8H), 7.28 (dd, 2H, J = 8.8 Hz, J = 14.4 Hz), 5.31 (s, 2H), 5.23 – 5.19 (m, 2H), 4.09 – 3.85 (m, 5H), 3.58 -3.28 (m, 14H), 2.47 – 1.89 (m, 9H), 0.83 – 0.72 (m, 12H).

Example MU Boc N O N Br H H O N O B N O N N O Pd(PPh3)4, PdCl2(dppf), H K2CO3, DME/ DMF, 85°C (2S)-methyl {[(9-(4,4,5,5-tetramethyl-1,3,2- orolanyl)-1,11-dihydroisochromeno[4',3':6,7] naphtho[1,2-d]imidazolyl)pyrrolidin-1yl]methyl oxobutanyl}carbamate N N Boc N 1. HCl, EtOH, 60°C N N N H O N O H O O O H N O tert-butyl )[5-(2-{(2S,4S)[N-(methoxycarbonyl)- O H L-valyl]-pyrrolidinyl}-1,11-dihydroisochromeno COMU, DIPEA, DMF, RT [4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate H O N H O O N N N N N N O O O methyl {(1R)[(2S,4S)(5-{2-[(2S){(2S)[(methoxycarbonyl) amino]methylbutanoyl}-pyrrolidinyl]-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)- 4-(methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]-pyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate To a on of (2S)-methyl {[(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)- 1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinyl]methyl oxobutanyl} carbamate (460 mg, 0.74 mmol), (2S,4S)-tert-butyl 2-(5-bromo-1H-imidazol- 2-yl)(methoxymethyl)pyrrolidinecarboxylate (250 mg, 0.61 mmol), tetrakis (triphenylphosphine) palladium(0) (35 mg, 0.03 mmol) and dichloro[1,1'-bis nylphosphino) ferrocene]palladium(II) (45 mg, 0.06 mmol) in a mixture of 1,2- oxyethane (9.0 mL) and dimethylformamide (1.5 mL) was added a solution of potassium carbonate (2M in water, 0.92 mL, 1.84 mmol). The resulting mixture was degassed and then heated to 85 °C under argon for 18 hours. After cooling to room temperature, the reaction was diluted with ethyl e. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]- pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7] naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (123 mg) methyl{(1R)[(2S,4S)(5-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}-pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d] imidazolyl}-1H-imidazolyl)(methoxymethyl)pyrrolidinyl]oxo phenylethyl}carbamate A solution of tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxy carbonyl)-L-valyl]- pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d] imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidine-carboxylate (122 mg, 0.16 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (3 mL). This solution was concentrated and to this al was added a on of (R)(methoxycarbonylamino) phenylacetic acid (43 mg, 0.2 mmol) and COMU (77 mg, 018 mmol) in DMF (3 mL). To the resulting solution was added diisopropylethylamine (80 L, 0.37 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), trated and purified by preparative reverse phase HPLC (Gemini, 15 to 44% ACN/H2O + 0.1% TFA). The t fractions were lyophilized to give methyl {(1R)[(2S,4S)(5-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}-pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)(methoxymethyl)pyrrolidinyl]oxo phenylethyl}carbamate (60 mg, 44%). MS (ESI) m/z 870 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.71 (s, 1H), 8.22 (d, 1H, J = 8 Hz), 8.09 (m, 1H), 7.88 – 7.63 (m, 6H), 7.36 - 7.29 (m, 6H), 5.41 (d, 1H, J = 8.4 Hz), 5.30 – 5.24 (m, 2H), 5.14 – .10 (m, 1H), 4.13 -3.09 (m, 15H), 2.47 - 1.80 (m, 8H), 0.80 (dd, 6H, J = 6.4 Hz, J = 23 Hz).

Example MV O N O N H N O N N Br B N O N Boc O Pd(PPh3)4, PdCl2(dppf), (1R,3S,5R)-tert-butyl (9-(4,4,5,5-tetramethyl- K2CO3, Dioxane/ DMSO, 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno 95°C [4',3':6,7]naphtho[1,2-d]imidazolyl)azabicyclo [3.1.0]hexanecarboxylate H O O O H N N N 1. HCl, EtOH, 60°C N N N Boc H 2.

O O (1R,3S,5R)-tert-butyl 3-(9-(2-((S)((S)(methoxy O H N O carbonylamino)methylbutanoyl)methoxymethyl O H pyrrolidinyl)-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol COMU, DIPEA, DMF, RT yl)azabicyclo[3.1.0]hexanecarboxylate H O O O H N N N N N N O O O methyl {(1R)[(1R,3S,5R)(9-{2-[(2S,5S){(2S)[(methoxy carbonyl)amino]methylbutanoyl}methoxymethylpyrrolidinyl]- dazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d] imidazolyl)azabicyclo[3.1.0]hexyl]oxophenylethyl}carbamate (1R,3S,5R)-tert-butyl(9-(2-((S)((S)(methoxycarbonylamino)methylbutanoyl)- 4-methoxymethylpyrrolidinyl)-1H-imidazolyl)- 1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)azabicyclo[3.1.0] hexane- 2-carboxylate To a solution of (1R,3S,5R)-tert-butyl (9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)azabicyclo [3.1.0]hexanecarboxylate (213 mg, 0.37 mmol), methyl (S)((2S,4S)(5-bromo-1H- imidazolyl)(methoxymethyl)pyrrolidinyl)methyloxobutanylcarbamate (142 mg, 0.31 mmol), tetrakis (triphenylphosphine) palladium(0) (35 mg, 0.03 mmol) and dichloro[1,1'-bis nylphosphino) ene]palladium(II) (22 mg, 0.03 mmol) in a mixture of 1,4-dioxane (3.0 mL) and dimethylsulfoxide (3.0 mL) was added a solution of potassium carbonate (2M in water, 0.46 mL, 0.9 mmol). The resulting mixture was degassed and then heated to 95 °C under argon for 7 hours. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with water and brine, dried (Na2SO4), and concentrated. The crude residue was purified by flash chromatography to (1R,3S,5R)-tert-butyl 3-(9-(2-((S)((S)(methoxycarbonyl amino)methylbutanoyl)- 4-methoxymethylpyrrolidinyl)-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)azabicyclo[3.1.0] carboxylate (101 mg, 42%). methyl{(1R)[(1R,3S,5R)(9-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methoxymethylpyrrolidinyl]-1H-imidazolyl}-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-azabicyclo[3.1.0]hexyl] oxophenylethyl}carbamate A solution (1R,3S,5R)-tert-butyl 3-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)methoxymethylpyrrolidinyl)-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)aza o[3.1.0]hexane carboxylate (101 mg, 0.16 mmol), ethanol (3 mL) and concentrated HCl (1 mL) was heated to 60 °C for 1 hour. The reaction was concentrated and the crude material dissolved in DCM (3 mL). This solution was concentrated and to this material was added a solution of (R) (methoxycarbonylamino)phenylacetic acid (35 mg, 0.17 mmol) and COMU (63 mg, 015 mmol) in DMF (3 mL). To the resulting solution was added diisopropylethylamine (70 L, 0.38 mmol). After stirring for 2 hours at room ature, the on was diluted with ethyl acetate, washed with water and brine, dried (Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini, 15 to 44% ACN/H2O + 0.1% TFA). The product fractions were lyophilized to give methyl {(1R)[(1R,3S,5R)(9-{2-[(2S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methoxymethylpyrrolidinyl]-1H- imidazol-5 yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)azabicyclo [3.1.0]hexyl]oxophenylethyl}carbamate (71 mg, 63%).

MS (ESI) m/z 882 [M + H]+. 1H NMR (400 MHz, dmso) δ 8.66 (s, 1H), 8.17 (d, 1H, J = 8.8 Hz), 8.04 (s, 1H), 7.87 – 7.59 (m, 6H), 7.39 - 7.22 (m, 6H), 5.72 (d, 1H, J = 7.6 Hz), 5.68 (s, 1H), 5.25 (s, 1H), 5 .13 – 5.01 (m, 2H), 4.12 -4.00 (m, 2H), 3.81 – 3.00 (m, 13H), 2.60 (m, 1H), 2.43 – 2.37 (m, 3H), 1.92-1.82 (m, 3H), 0.83 – 0.58 (m, 7H), 0.59 (s, 1H), 0.00 (s, 1H).

Example MW This compound was synthesized using the same conditions as example OO substituting with the respective (1R,3S,5R)((S)(methoxycarbonylamino) butanoyl)azabicyclo[3.1.0]hexanecarboxylic acid and (2S,4S)(tertbutoxycarbonyl )((difluoromethoxy)methyl)pyrrolidinecarboxylic acid as appropriate.

MS (ESI) m/z 918 [M + H]+. e MX H O N H O O N N N N N O O N O methyl {(1R)[(2S,4S)(9-{2-[(1R,3S,5R){(2S,3S)- 3-methoxy[(methoxycarbonyl)amino]butanoyl}azabicyclo [3.1.0]hexyl]-1H-imidazolyl}-1,11-dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl)(difluoromethoxy) methylpyrrolidinyl]oxophenylethyl}carbamate This compound was synthesized using the same conditions as example OO substituting with the respective (1R,3S,5R)((2S,3S)methoxy-2 (methoxycarbonylamino) butanoyl)azabicyclo[3.1.0]hexanecarboxylic acid and (2S,3R)methoxy(methoxycarbonylamino)butanoic acid as appropriate.

MS (ESI) m/z 898 [M + H]+.

Example MY O NH H bis(pinacolato)diboron O N O B N X-Phos, Pd2dba3, KOAc N + O N Boc e N 100 °C N Br H (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5-tetramethylmethyl ((S)((S)(5-bromo-1H- 1,3,2-dioxaborolanyl)- 1,11-dihydroisochromeno imidazolyl)pyrrolidinyl) [4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidine methyloxobutanyl)carbamate carboxylate O NH Pd(PPh3)4, O O Pd(dppf)2Cl2, K2CO3 1. HCl N H N N 2. COMU, DIPEA, DMF DME N N Boc 85 °C H (2S,4S)-tert-butyl 2-(9-(2-((S)((S) OH (methoxycarbonylamino)methylbutanoyl)pyrrolidin- O N 2-yl)-1H-imidazolyl)-5H-naphtho[c,g]chromeno[8,9- O d]imidazolyl)methylpyrrolidinecarboxylate (R) ((methoxycarbonyl)ami O no)phenylacetic acid O NH O O N H N N N N H O HN O methyl {2-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino] O butanoyl}pyrrolidinyl)-1H-imidazolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} methylpyrrolidinyl]oxophenylethyl}carbamate (2S,4S)tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl) 4-methylpyrrolidine-1,2-dicarboxylate To a solution of 9-bromochloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)- one (1.32 g, 3.63 mmol) in MeCN (40 mL) was added (2S,4S)(tert-butoxycarbonyl) methylpyrrolidinecarboxylic acid (1.0 g, 4.36 mmol) and DIPEA (0.7 mL, 3.99 mmol).

After stirring for 18 h, the solution was diluted with EtOAc and washed successively with ted aqueous NaHCO3 and brine. The organics were dried over MgSO4, ed and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (10% to 40% EtOAc/hexanes) to afford (2S,4S)tert-butyl 2-(3-chloro oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) 4-methylpyrrolidine-1,2- dicarboxylate (1.31 g, 70%). (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H-naphtho[c,g]chromeno[8,9-d]imidazol yl)methylpyrrolidinecarboxylate (2S,4S)tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl) 4-methylpyrrolidine-1,2-dicarboxylate (1.31 g, 2.56 mmol) was added xylenes (25 mL) and ammonium acetate (3.95 g, 51.2 mmol) and the solution was heated to 136 °C and stirred overnight. The ing g, the solution was cooled to rt and was diluted with EtOAc and washed successively with water, saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude e was purified by silica column chromatography (60% to 100 % EtOAc/hexanes) to afford (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)methylpyrrolidinecarboxylate (711 mg, 56%). (2S,4S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl) methylpyrrolidinecarboxylate To a on of (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)(methyl)pyrrolidinecarboxylate (935 mg, 1.9 mmol) in CH2Cl2 (20 mL) was added MnO2 (8.25 g, 95 mmol). The reaction mixture was stirred for 3 h, and then filtered over celite. The filter cake was washed with copious CH2Cl2 and MeOH, and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 10 % MeOH/EtOAc) to afford (2S,4S)-tertbutyl hloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl)methylpyrrolidine carboxylate (692 mg, 74%). (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- oisochromeno [4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (2S,4S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl) methylpyrrolidinecarboxylate (692 mg, 1.41 mmol) in dioxane (15 mL) was added nacolato)diboron (1.07 g, 4.23 mmol), KOAc (415 mg, 4.23 mmol), X-Phos (52 mg, 0.11 mmol), and Pd2dba3 (26 mg, 0.03 mmol). The solution was degassed with N2 for 10 min, then heated to 100 °C for 16 h. The solution was cooled to rt, diluted with EtOAc, washed with saturated aqueous NaHCO3, brine, dried with MgSO4, and concentrated.

Purified by silica gel chromatography (0% to 30 % MeOH/EtOAc) to afford (2S,4S)-tert- butyl 4-methyl(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol pyrrolidinecarboxylate (821 mg, quant). (2S,4S)-tert-butyl 2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-5H-naphtho[c,g]chromeno[8,9- d]imidazolyl)-4(methyl)pyrrolidinecarboxylate To a solution of (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (821 mg, 1.41 mmol), methyl (S)((S)(5-bromo-1H- imidazolyl)pyrrolidinyl)methyloxobutanylcarbamate (1.05 g, 2.82 mmol), tetrakis(triphenylphosphine) palladium(0) (162 mg, 0.14 mmol) and dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(II) (102 mg, 0.14 mmol) in DME (15 mL) was added a solution of potassium carbonate (2M in water, 2.32 mL, 4.65 mmol). The resulting mixture was degassed and then heated to 85 °C for 18 hours. After cooling to room temperature, the reaction was d with ethyl e. The organics were washed with saturated sodium bicarbonate and brine, dried over MgSO4 and concentrated. The crude residue was ed by flash chromatography to yield (2S,4S)-tert-butyl 2-(9-(2-((S)((S)- 2-(methoxycarbonylamino)methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)-4methylpyrrolidinecarboxylate (386 mg, 37%).

Methyl {2-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)- 1H-imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} (methyl)pyrrolidinyl]oxophenylethyl}carbamate A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)((S)(methoxycarbonylamino) methylbutanoyl)pyrrolidinyl)-1H-imidazolyl)-5H-naphtho[c,g]chromeno[8,9- d]imidazolyl)-4methylpyrrolidinecarboxylate (386 mg, 0.52 mmol), CH2Cl2 (8 mL), MeOH (2 mL) and HCl (4M in e, 2 mL) and was stirred overnight. The reaction was concentrated and the crude material dissolved in DMF (8 mL). This solution was concentrated and to this material was added a on of (R)(methoxycarbonylamino) phenylacetic acid (108 mg, 0.52 mmol) and COMU (248 mg, 0.52 mmol). To the resulting solution was added diisopropylethylamine (0.45 mL, 2.6 mmol). After stirring for 2 hours at room temperature, the reaction was diluted with 10% MeOH/EtOAc, washed with saturated NaHCO3, water and brine, dried (Na2SO4), concentrated and purified by HPLC to give methyl {2-[2-{9-[2-(1-{2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl)-1H- imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} pyrrolidinyl]oxophenylethyl}carbamate (27 mg, 6%). LCMS-ESI+: calculated for C47H50N8O7: 838.38; observed [M+1]+: 840.12 Example NB (2S,4S)-tert-butyl yl(9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidine carboxylate Methyl [(2S)methyl{(2S,4S)methyl[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl} oxobutanyl]carbamate (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol pyrrolidinecarboxylate (950 mg, 1.63 mmol) was dissolved in DCM (12 mL), MeOH (3 mL) and HCl (4 M in dioxane, 3 mL) was added. The reaction mixture was stirred for 4 h and then concentrated under reduced pressure. The crude residue was treated with (S)(methoxycarbonylamino) methylbutanoic acid (285 mg, 1.63 mmol), HATU (620 mg, 1.63 mmol) and DMF (15 mL), then DIPEA (1.42 mL, 8.15 mmol) was added dropwise. After 1 h, the mixture was diluted with EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The cs were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford methyl [(2S)methyl{(2S,4S)methyl[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}oxobutanyl]carbamate (596 mg, 57%).

Tert-butyl (2S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol rolidinecarboxylate Methyl [(2S)methyl{(2S,4S)methyl[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}oxobutanyl]carbamate (298 mg, 0.47 mmol), (S)-tert-butyl 2-(5- bromo-1H-imidazolyl)pyrrolidinecarboxylate (443 mg, 1.4 mmol), Pd(PPh3)4 (54 mg, 0.05 mmol), PdCl2(dppf)2 (36 mg, 0.05 mmol), and K2CO3 (2M in H2O, 0.78 mL, 1.55 mmol) were combined in DME (5 mL). The mixture was ed with bubbling N2 for 10 min then heated to 85 ˚C for 16 h. After cooling, the reaction mixture was diluted with EtOAc, and washed successively with ted aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was ed by silica column chromatography (0% to 30% MeOH/EtOAc) to afford tert- butyl -[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]pyrrolidinecarboxylate (84 mg, 24%).

Methyl {(1R)[(2S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] butanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinyl]oxophenylethyl}carbamate Tert-butyl (2S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]pyrrolidinecarboxylate (84 mg, 0.11 mmol) was dissolved in DCM (2.5 mL), MeOH (0.5 mL) and HCl (4 M in dioxane, 0.5 mL) was added. The reaction e was stirred for 18 h and then concentrated under reduced pressure. The crude residue was treated with (R)(methoxycarbonylamino)phenylacetic acid (23 mg, 0.11 mmol), COMU (53 mg, 0.11 mmol) and DMF (3 mL), then DIPEA (0.10 mL, 0.56 mmol) was added dropwise. After 30 min, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl {(1R)[(2S)(5-{2-[(2S,4S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin oxophenylethyl}carbamate (41 mg, 45%). LCMS-ESI+: calculated for C47H50N8O7: 838.38; ed [M+1]+: 839.39 e NC Methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate Tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]methylpyrrolidinecarboxylate (164 mg, 0.23 mmol) was dissolved in DCM (2.57 mL), MeOH (0.7 mL) and HCl (4 M in dioxane, 0.7 mL) was added. The reaction mixture was d for 16 h and then concentrated under reduced pressure. The crude residue was treated with (S)(methoxycarbonylamino)methylbutanoic acid (30 mg, 0.17 mmol), HATU (65 mg, 0.17 mmol) and DMF (3 mL), then DIPEA (0.15 mL, 0.85 mmol) was added dropwise. After 45 min, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude e was purified by HPLC to afford methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate (23 mg, 16%).

LCMS-ESI+: calculated for C45H54N8O7: 818.41; observed [M+1]+: 820.70.

Example ND Boc N O H 3)4, N O I + N N Pd(dppf)2Cl2, K2CO3 N B H O N Boc DME 85 °C (2S,4S)-tert-butyl 2-(5- (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5- iodo-1H-imidazolyl) tetramethyl-1,3,2-dioxaborolanyl)-1,11- methylpyrrolidine dihydroisochromeno [4',3':6,7] naphtho[1,2- carboxylate d]imidazol yl)pyrrolidinecarboxylate 1. HCl Boc N H 2. HATU, DIPEA, DMF N N N N Boc H OH O N utyl (2S,4S)(5-{2-[(2S,4S)(tert- H butoxycarbonyl)methylpyrrolidinyl]-1,11- (S)(methoxycarbonylamino)- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol 3-methylbutanoic acid yl}-1H-imidazolyl)methylpyrrolidinecarboxylate O NH O O N H N N N N H O HN O methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S) O [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)- 4-methylpyrrolidinyl]methyloxobutanyl}carbamate Tert-butyl (2S,4S)(5-{2-[(2S,4S)(tert-butoxycarbonyl)methylpyrrolidinyl]- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinecarboxylate (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (293 mg, 0.78 mmol), )-tert-butyl 2-(5-iodo-1H-imidazolyl)methylpyrrolidine carboxylate (300 mg, 0.52 mmol), Pd(PPh3)4 (60 mg, 0.052 mmol), PdCl2(dppf)2 (38 mg, 0.052 mmol), and K2CO3 (2M in H2O, 0.86 mL, 1.72 mmol) were combined in DME (6 mL).

The mixture was degassed with ng N2 for 10 min then heated to 85 ˚C for 16 h. After cooling, the reaction mixture was diluted with EtOAc, and washed successively with saturated s NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (100% EtOAc) to afford tert-butyl (2S,4S)(5-{2-[(2S,4S)(tertbutoxycarbonyl )methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrolidinecarboxylate (183 mg, 50%).

Methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate Tert-butyl (2S,4S)(5-{2-[(2S,4S)(tert-butoxycarbonyl)methylpyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinecarboxylate (183 mg, 0.26 mmol) was dissolved in DCM (4 mL), MeOH (1 mL) and HCl (4 M in dioxane, 1 mL) was added. The on mixture was stirred for 2 h and then trated under reduced pressure. The crude residue was treated with (S) (methoxycarbonylamino)methylbutanoic acid (91 mg, 0.52 mmol), HATU (198 mg, 0.52 mmol) and DMF (5 mL), then DIPEA (0.45 mL, 2.6 mmol) was added se. After 1 h, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The cs were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl {(2S) [(2S,5S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methylbutanoyl} methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazolyl)methylpyrrolidinyl]methyloxobutanyl}carbamate (6 mg, 3%).

LCMS-ESI+: calculated for C45H54N8O7: 818.41; observed [M+1]+: 819.41.

Example NF O NH O H 3)4, O O N K2CO3 N + B N Pd(dppf)2Cl2, N O N Boc DMSO, Dioxane N I 85 °C (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5- methyl -((2S,4S)(5-iodo-1H- tetramethyl-1,3,2-dioxaborolanyl)-1,11- imidazolyl)methylpyrrolidinyl)- dihydroisochromeno [4',3':6,7] naphtho[1,2- 3-methyloxobutanyl)carbamate d]imidazol yl)pyrrolidinecarboxylate 1. HCl O NH 2. COMU, DIPEA, DMF O O N H N N N N Boc O H OH O N tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)- O L-valyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- (R) dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] ((methoxycarbonyl)amino) methylpyrrolidinecarboxylate phenylacetic acid O NH O O N H N N N N H O HN O methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2R) [(methoxycarbonyl)amino]phenylacetyl}methylpyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl}-1H-imidazolyl)methylpyrrolidinyl]methyl oxobutanyl}carbamate Tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidine carboxylate (2S,4S)-tert-butyl 4-methyl(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno [4',3':6,7] naphtho[1,2-d]imidazol yl)pyrrolidinecarboxylate (558 mg, 0.96 mmol), methyl (S)((2S,4S)(5-iodo-1H-imidazolyl)methylpyrrolidin methyloxobutanylcarbamate (501 mg, 1.15 mmol), Pd(PPh3)4 (111 mg, 0.096 mmol), PdCl2(dppf)2 (70 mg, 0.096 mmol), and K2CO3 (2M in H2O, 1.6 mL, 3.17 mmoL) were combined in DMSO (6 mL) and dioxane (6 mL). The mixture was degassed with bubbling N2 for 10 min then heated to 95 ˚C for 14 h. After cooling, the reaction mixture was d with EtOAc, and washed successively with saturated aqueous NaHCO3 and brine. The cs were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0 %- 30% MeOH/EtOAc) to afford tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]methylpyrrolidinecarboxylate (257 mg, 35%).

Methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrolidinyl]methyloxobutan yl}carbamate Tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]methylpyrrolidinecarboxylate (257 mg, 0.34 mmol) was dissolved in DCM (4 mL), MeOH (1 mL) and HCl (4 M in dioxane, 1 mL) was added. The reaction mixture was d for 3 h and then concentrated under reduced pressure. The crude residue was treated with (R)(methoxycarbonylamino)phenylacetic acid (71 mg, 0.34 mmol), COMU (161 mg, 0.34 mmol) and DMF (6 mL), then DIPEA (0.3 mL, 1.67 mmol) was added dropwise. After 15 h, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was ed by HPLC to afford methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2R) [(methoxycarbonyl)amino]phenylacetyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate (152 mg, 53%). SI+: calculated for N8O7: 852.40; observed [M+1]+: 854.26. 'H NMR (CD3OD): 8.677 (s, 1H), 7.837 (m, 5H), 7.695-7.673 (m, 2H), 7.426 (m, 5H), 5.499 (s, 1H), 5.445-5.401 (m, 1H), 5.337 (s, 1H), 5.253-5.208 (q, 1H, J= 7.2 Hz), 4.870 (m, 1H), 4.230 (d, 1H, J= 7.2 Hz), 3.781 (m, 1H), 3.671 (s, 3H), 3.607 (s, 3H), 3.425 (m, 3H), 2.750-2.689 (m, 2H), 2.683 (m, 2H), 2.384 (m, 1H), 1.894 (quint, 2H, J=12 Hz), 1.249-1.151 (m, 6H), 0.974- 0.890 (m, 6H).

Example NG O O O O O Boc O Et3N Br MeCN O 50 °C Boc O (2S,5S)tert-butyl 2-(2-oxo(8- romoacetyl)-10,11-dihydro-5H- N oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromen-8(9H)-one o[c,g]chromenyl)ethyl) 5- methylpyrrolidine-1,2-dicarboxylate (2S,5S)(tertbutoxycarbonyl ) methylpyrrolidine carboxylic acid pyridiunium O O mide Boc O Cs2CO3 N acetone CH2Cl2/MeOH O Br 40 °C (2S,5S)(2-(9-bromooxo-8,9,10,11-tetrahydro- N 5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tert- O Boc butyl 5-methylpyrrolidine-1,2-dicarboxylate (2S,5S)(tertbutoxycarbonyl ) methylpyrrolidine O carboxylic acid Boc O O O N NH4OAc O O N PhMe, MeOEtOH O Boc reflux (2S,5S)(2-(9-((2S,5S)(tert-butoxycarbonyl) methylpyrrolidinecarbonyloxy)oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 5- methylpyrrolidine-1,2-dicarboxylate O O Boc N H Boc N H N MnO2 N N N N N N Boc CH2Cl2 N Boc H N tert-butyl (2S,5S)(9-{2-[(2S,5S)(tert-butoxycarbonyl)- tert-butyl (2S,5S)(5-{2-[(2S,5S)(tert- -methylpyrrolidinyl]-1H-imidazolyl}-1,4,5,11- butoxycarbonyl)methylpyrrolidinyl]-1,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)methylpyrrolidinecarboxylate yl}-1H-imidazolyl)methylpyrrolidinecarboxylate 1. HCl O NH O O 2. HATU, DIPEA, DMF N H O N N OH N O N O H HN O (S) O (methoxycarbonylamino) methyl 1-[(2S,5S)(5-{2-[(2S,5S){(2S) methylbutanoic acid [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidin- 2-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)methylpyrrolidinyl]methyl oxobutanyl}carbamate (2S,5S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl)ethyl) 5-methylpyrrolidine-1,2-dicarboxylate To a solution of 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)- one in MeCN (30 mL) was added (2S,5S)(tert-butoxycarbonyl)methylpyrrolidine carboxylic acid (1.2 g, 3.23 mmol) and triethyl amine (0.48 mL, 3.55 mmol) and the solution was heated to 50 °C. After stirring for 15 h, the solution was cooled to rt, and diluted with EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and trated under reduced pressure. The crude residue was ed by silica column chromatography (20% to 50% EtOAc/hexanes) to afford (2S,5S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl)ethyl) 5-methylpyrrolidine-1,2-dicarboxylate (1.09 g, 65%). (2S,5S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (2S,5S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)ethyl) ylpyrrolidine-1,2-dicarboxylate (1.29 g, 2.48 mmol) was dissolved in a solution of DCM (17.5 mL) and MeOH (7 mL), then treated with pyridinium tribromide (873 mg, 2.73 mmol). After stirring at RT for 1 h, the reaction mixture was diluted with DCM and 10% HCl, and extracted with DCM. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure and the crude material was carried on without further purification. (2S,5S)(2-(9-((2S,5S)(tert-butoxycarbonyl)methylpyrrolidinecarbonyloxy) 9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 5- methylpyrrolidine-1,2-dicarboxylate (2S,5S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (700 mg, 1.17 mmol) was treated with a solution of (2S,5S)(tert-butoxycarbonyl)methylpyrrolidinecarboxylic acid (375 mg, 1.64 mmol) in e (6 mL) and Cs2CO3 (267 mg, 0.82 mmol). The stirred on mixture was heated to 40 ˚C for 16 h, then cooled to RT and d with CH2Cl2 and extracted 3X. The organic phase was washed with brine, then dried over MgSO4, ed and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (40% to 100% EtOAc/hexanes) to afford (2S,5S)(2-(9-((2S,5S)(tertbutoxycarbonyl )methylpyrrolidinecarbonyloxy)oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (464 mg, 53%).

Tert-butyl (2S,5S)(9-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidinyl]- 1H-imidazolyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)methylpyrrolidinecarboxylate (2S,5S)(2-(9-((2S,5S)(tert-butoxycarbonyl)methylpyrrolidine carbonyloxy)oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tertbutyl -methylpyrrolidine-1,2-dicarboxylate (464 mg, 0.62 mmol) and NH4OAc (8.48 g, 110.0 mmol) were suspended in a solution of 10:1 PhMe/2-methoxyethanol (22 mL). The stirred reaction mixture was heated to 110 ˚C for 20 h, then cooled to RT and diluted with EtOAc. The organic phase was washed with water, ted aqueous NaHCO3, and brine, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford tertbutyl (2S,5S)(9-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidinyl]-1H- imidazolyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) methylpyrrolidinecarboxylate (393 mg, 90%).

Tert-butyl )(5-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidinyl]- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) pyrrolidinecarboxylate Tert-butyl (2S,5S)(9-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidin yl]-1H-imidazolyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)methylpyrrolidinecarboxylate (393 mg, 0.55 mmol) was suspended in DCM (7 mL) and activated MnO2 (1.45 g, 16.7 mmol) was added in a single portion. The reaction mixture was heated to 40 °C. After stirring for 2.5 h, the mixture was cooled to rt and the slurry was filtered over . The filter cake was washed with copious CH2Cl2 and MeOH and the filtrate was concentrated under d pressure. The crude material was taken on to the next step without further purification to afford tert-butyl (2S,5S)(5-{2-[(2S,5S)(tertbutoxycarbonyl )methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrolidinecarboxylate (328 mg, 85%).

Methyl 1-[(2S,5S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate Tert-butyl (2S,5S)(5-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) pyrrolidinecarboxylate (164 mg, 0.23 mmol) was dissolved in DCM (7 mL), MeOH (1.5 mL) and HCl (4 M in dioxane, 1.5 mL) was added. The reaction mixture was stirred for 16 h and then concentrated under reduced pressure. The crude residue was treated with (S) (methoxycarbonylamino)methylbutanoic acid (81 mg, 0.46 mmol), HATU (175 mg, 0.46 mmol) and DMF (5 mL), then DIPEA (0.4 mL, 2.34 mmol) was added dropwise. After 35 min, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under d pressure. The crude residue was purified by HPLC to afford methyl {(2S)[(2S,5S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrolidinyl]methyloxobutan yl}carbamate (132 mg, 69%). LCMS-ESI+: calculated for C45H54N8O7: 818.41; observed [M+1]+: 820.19. 'H NMR ): 8.492 (m, 1H), 8.179-7.538 (m, 7H), 5.267-5.201 (m, 3H), 5.125-5.082 (m, 1H), 4.070 (m, 1H), 3.383-3.592 (m, 4 H), 3.225 (s, 3H), 2.466-2.249 (m, 5H), 1.992-1.892 (m, 3H), 1.568 (d, 3H, J=6.4 Hz), 1.490 (d, 3H, J=6.8 Hz), 1.266 (m, 2H), 1.020-0.806 (m, 14H).

Example NI Boc N H N 1. HCl N N N 2. HATU, DIPEA, DMF N Boc H OH O tert-butyl (2S,5S)(5-{2-[(2S,5S)(tert- O HN O carbonyl)methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol O yl}-1H-imidazolyl)methylpyrrolidinecarboxylate (2S,3R)methoxy (methoxycarbonylamin O o)butanoic acid O NH O O N H O N N O N N H O HN O methyl R)methoxy{(2S,5S)[9-(2-{(2S,5S)[N- (methoxycarbonyl)-O-methyl-L-threonyl]methylpyrrolidinyl}-1H- imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol methylpyrrolidinyl}oxobutanyl]carbamate Methyl [(2S,3R)methoxy{(2S,5S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-O- methyl-L-threonyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidinyl} oxobutanyl]carbamate Tert-butyl (2S,5S)(5-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinecarboxylate (164 mg, 0.23 mmol) was ved in DCM (7 mL), MeOH (1.5 mL) and HCl (4 M in dioxane, 1.5 mL) was added. The on mixture was stirred for 16 h and then concentrated under reduced pressure. The crude residue was treated with (2S,3R)methoxy(methoxycarbonylamino)butanoic acid (90 mg, 0.46 mmol), HATU (175 mg, 0.46 mmol) and DMF (6 mL), then DIPEA (0.4 mL, 2.34 mmol) was added dropwise. After 30 min, the e was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl [(2S,3R)methoxy{(2S,5S)[9-(2-{(2S,5S)[N- xycarbonyl)-O-methyl-L-threonyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidinyl} oxobutanyl]carbamate (97 mg, 50%). LCMS-ESI+: calculated for C45H54N8O9: 850.40; observed [M+1]+: 851.58. 'H NMR (CD3OD): 8.631 (s, 1H), 8.191-7.938 (m, 7 H), 6.100 (m, 1 H), 5.925 (m, 1H), 5.303 (m, 3H), 5.179 (t, 1H, J=6.8 Hz), 4.406-4.358 (m, 2H), 3.754- 3.598 (m, 8H), 3.376 (s, 3H), 3.263 (s, 3H), 2.625-2.256 (m, 6H), 2.038-1.955 (m, 2H), 1.598 (d, 3H, J=6.4 Hz), 1.530 (d, 3H, J=6.8 Hz), 1.302-1.099 (m, 6H).

Example NJ Boc O O O Cs2CO3 O Br acetone 40 °C O (2S,5S)(2-(9-bromooxo-8,9,10,11- HO ydro-5H-dibenzo[c,g]chromenyl) N oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2- O Boc oxylate (2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidine carboxylic acid Boc O O O O N NH4OAc O O PhMe, MeOEtOH O Boc reflux (2S,5S)(2-(9-((2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinecarbonyloxy)oxo-8,9,10,11- tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tertbutyl -methylpyrrolidine-1,2-dicarboxylate Boc N H N MnO2 N N N N Boc CH2Cl2 tert-butyl (2S,5S)(9-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) methylpyrrolidinecarboxylate (2S,5S)(2-(9-((2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine carbonyloxy)oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1- tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (2S,5S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (800 mg, 1.34 mmol) was treated with a solution of )(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine carboxylic acid (485 mg, 1.87 mmol) in acetone (6 mL) and Cs2CO3 (306 mg, 0.94 mmol).

The stirred reaction mixture was heated to 40 ˚C for 16 h, then cooled to RT and diluted with CH2Cl2 and extracted 3X. The organic phase was washed with brine, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was ed by silica column tography (40% to 100% EtOAc/hexanes) to afford (2S,5S)(2-(9-((2S,4S)- 1-(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarbonyloxy)oxo-8,9,10,11- tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2- dicarboxylate (680 mg, 65%).

Tert-butyl (2S,5S)(9-{2-[(2S,4S)(tert-butoxycarbonyl) xymethyl)pyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidine carboxylate (2S,5S)(2-(9-((2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine carbonyloxy)oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tertbutyl -methylpyrrolidine-1,2-dicarboxylate (680 mg, 0.87 mmol) and NH4OAc (10.0 g, 130.0 mmol) were suspended in a solution of 10:1 PhMe/2-methoxyethanol (22 mL). The stirred reaction mixture was heated to 110 ˚C for 24 h, then cooled to RT and d with EtOAc. The organic phase was washed with water, saturated aqueous NaHCO3, and brine, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford tertbutyl (2S,5S)(9-{2-[(2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinyl]- 1H-imidazolyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) methylpyrrolidinecarboxylate (461 mg, 72%).

Tert-butyl )(5-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrolidinecarboxylate utyl (2S,5S)(9-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidine carboxylate (461 mg, 0.62 mmol) was suspended in DCM (7 mL) and activated MnO2 (1.6 g, 18.8 mmol) was added in a single portion. The reaction mixture was heated to 40 °C. After stirring for 5.5 h, the mixture was cooled to rt and the slurry was filtered over celite. The filter cake was washed with copious CH2Cl2 and MeOH and the filtrate was concentrated under reduced pressure. The crude material was taken on to the next step without further purification to afford tert-butyl (2S,5S)(5-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)methylpyrrolidinecarboxylate (414 mg, 90%).

Methyl {(2S,3S)[(2S,5S)(5-{2-[(2S,4S){(2S,3S)[(methoxycarbonyl)amino] methylpentanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxopentanyl}carbamate Tert-butyl (2S,5S)(5-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)methylpyrrolidinecarboxylate (207 mg, 0.28 mmol) was ved in DCM (4 mL), MeOH (1 mL) and HCl (4 M in dioxane, 1 mL) was added. The reaction mixture was stirred for 1.5 h and then concentrated under reduced pressure. The crude residue was treated with (2S,3S)(methoxycarbonylamino)methylpentanoic acid (106 mg, 0.56 mmol), HATU (214 mg, 0.56 mmol) and DMF (5 mL), then DIPEA (0.49 mL, 2.8 mmol) was added dropwise. After 30 min, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The cs were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl S)[(2S,5S)(5-{2-[(2S,4S)- 1-{(2S,3S)[(methoxycarbonyl)amino]methylpentanoyl}(methoxymethyl)pyrrolidin- 2-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxopentanyl}carbamate (132 mg, 69%). LCMS-ESI+: calculated for C45H54N8O7: 876.45; observed [M+1]+: 879.02 Example NK (2S,4S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl)ethyl) 4-methylpyrrolidine-1,2-dicarboxylate To a on of 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)- one (647 mg, 1.74 mmol) in MeCN (20 mL) was added ((2S,4S)(tert-butoxycarbonyl) methylpyrrolidinecarboxylic acid (559 mg, 2.44 mmol) and DIPEA (0.36 mL, 2.09 mmol) and the solution was heated to 60 °C. After stirring for 3 h, the solution was cooled to rt, and diluted with EtOAc and washed successively with saturated s NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (20% to 50% EtOAc/hexanes) to afford (2S,4S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)ethyl) ylpyrrolidine-1,2-dicarboxylate (621 mg, 69%). (2S,4S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate (2S,4S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)ethyl) 4-methylpyrrolidine-1,2-dicarboxylate (621 mg, 1.19 mmol) was dissolved in a solution of DCM (10 mL) and MeOH (4 mL), then treated with pyridinium mide (421 mg, 1.3 mmol). After stirring at RT for 1.5 h, the on mixture was diluted with DCM and 10% HCl, and extracted with DCM. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure and the crude material was carried on without further purification. (2S,4S)(2-(9-((2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine carbonyloxy)oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1- tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate (2S,4S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate (709 mg, 1.18 mmol) was treated with a solution of (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine carboxylic acid (614 mg, 2.36 mmol) in Me-THF (12 mL) and Cs2CO3 (384 mg, 1.18 mmol).

The stirred reaction e was heated to 50 ˚C for 16 h, then cooled to RT and diluted with CH2Cl2 and extracted 3X. The organic phase was washed with brine, then dried over MgSO4, ed and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (40% to 100% EtOAc/hexanes) to afford (2S,4S)(2-(9-((2S,4S)- 1-(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarbonyloxy)oxo-8,9,10,11- tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2- oxylate (651 mg, 71%).

Tert-butyl (2S,4S)(9-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidine carboxylate (2S,4S)(2-(9-((2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine yloxy)oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tertbutyl 4-methylpyrrolidine-1,2-dicarboxylate (651 mg, 0.84 mmol) and NH4OAc (10.0 g, 129.7 mmol) were suspended in a solution of 10:1 PhMe/2-methoxyethanol (22 mL). The stirred reaction mixture was heated to 110 ˚C for 20 h, then cooled to RT and d with EtOAc. The organic phase was washed with water, saturated aqueous NaHCO3, and brine, then dried over MgSO4, filtered and concentrated under reduced re. The crude residue was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford tertbutyl (2S,4S)(9-{2-[(2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinyl]- 1H-imidazolyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) pyrrolidinecarboxylate (382 mg, 62%).

Tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] (methoxymethyl)pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]methylpyrrolidinecarboxylate Tert-butyl (2S,4S)(9-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidine carboxylate (382 mg, 0.52 mmol) was suspended in DCM (8 mL) and activated MnO2 (1.35 g, 15.5 mmol) was added in a single portion. The reaction e was heated to 35 °C. After stirring for 15 h, the mixture was cooled to rt and the slurry was filtered over celite. The filter cake was washed with copious CH2Cl2 and MeOH and the te was concentrated under reduced pressure. The crude material was taken on to the next step without further purification to afford tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]- 4-(methoxymethyl)pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]methylpyrrolidinecarboxylate (347 mg, 91%).

Methyl R)methoxy[(2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-O- methyl-L-threonyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinyl]oxobutanyl}carbamate Tert-butyl )[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] (methoxymethyl)pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]methylpyrrolidinecarboxylate (174 mg, 0.24 mmol) was dissolved in DCM (4 mL), MeOH (1 mL) and HCl (4 M in dioxane, 1 mL) was added.

The reaction e was stirred for 5 h and then concentrated under reduced pressure. The crude residue was treated with ((2S,3R)methoxy(methoxycarbonylamino)butanoic acid (92 mg, 0.48 mmol), HATU (182 mg, 0.48 mmol) and DMF (5 mL), then DIPEA (0.31 mL, 2.4 mmol) was added dropwise. After 35 min, the mixture was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl {(2S,3R)methoxy[(2S,4S)[9- (2-{(2S,4S)[N-(methoxycarbonyl)-O-methyl-L-threonyl]methylpyrrolidinyl}-1H- imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinyl]oxobutanyl}carbamate (72 mg, 34%). LCMS-ESI+: calculated for N8O10: 880.41; observed [M+1]+: 882.39. 'H NMR (CD3OD): 8.558 (s, 1H), 8.123-7.572 (m, 7H), 5.436-5.391 (dd, 1H, J=7.2, 3.6 Hz), 5.252 (s, 2H), 5.220 (m, 1H), 4.493-4.444 (m, 2H), 4.287-4.206 (m, 2H), 3.756-3.256 (m, 21H), 2.834 (m, 1H), 2.717- 2.621 (m, 2H), 2.500 (m, 1H), 2.150 (m, 1H), 1.882 (m, 1H), 1.208 (d, 3H, J=6.4 Hz), 1.159- 1.099 (m, 6H). e NL O NH O O MnO2 N H N N CH2Cl2 N N Boc tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}- 1H-imidazolyl)-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] pyrrolidinecarboxylate O NH O O 1. HCl N H N 2. HATU, DIPEA, DMF N O N Boc HO HN O tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- O dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (2S,3R)methoxy methylpyrrolidinecarboxylate (methoxycarbonylami no)butanoic acid O NH O O N H N N O N N H O HN O methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S,3R)methoxy[(methoxycarbonyl)amino]butanoyl} pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)methylpyrrolidinyl]methyloxobutanyl}carbamate (2S,5S)oxo(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)ethyl 1-((S)- 2-(methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylate To a solution of 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)- one (750 mg, 2.02 mmol) in MeCN (20 mL) was added (2S,5S)((S) (methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylic acid (600 mg, 2.09 mmol) and DIPEA (0.35 mL, 2.02 mmol) and the solution was heated to 60 °C. After stirring for 4 h, the solution was cooled to rt, and diluted with EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced re. The crude residue was purified by silica column chromatography (40% to 80% EtOAc/hexanes) to afford (2S,5S)oxo(8- 9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)ethyl 1-((S) xycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylate (1.16 g, quant.). (2S,5S)(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl 1-((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidine carboxylate (2S,5S)oxo(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)ethyl 1- ((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylate (400 mg, 0.61 mmol) was dissolved in a on of DCM (15 mL) and MeOH (6 mL), then treated with pyridinium tribromide (409 mg, 1.28 mmol). At 2 h, an onal portion of pyridinium tribromide (40 mg) was added. After stirring at RT for another 20 min, the reaction mixture was diluted with DCM and 10% HCl, and extracted with DCM. The organic phase was dried over MgSO4, filtered and concentrated under reduced re and the crude al was carried on without further purification. )tert-butyl 2-(3-(2-((2S,5S)((S)(methoxycarbonylamino) methylbutanoyl)methylpyrrolidinecarbonyloxy)acetyl)oxo-8,9,10,11- tetrahydro-5H-dibenzo[c,g]chromenyl) 4-methylpyrrolidine-1,2-dicarboxylate (2S,5S)(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl 1-((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidine carboxylate ) was treated with a solution of (2S,4S)(tert-butoxycarbonyl) methylpyrrolidinecarboxylic acid (280 mg, 1.22 mmol) in Me-THF (6 mL) and Cs2CO3 (199 mg, 0.61 mmol). The stirred reaction e was heated to 50 ˚C for 2.5 h, then cooled to RT and diluted with CH2Cl2 and extracted 3X. The organic phase was washed with brine, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (50% to 100% EtOAc/hexanes) to afford (2S,4S)tert-butyl 2-(3-(2-((2S,5S)((S)(methoxycarbonylamino)methylbutanoyl)- -methylpyrrolidinecarbonyloxy)acetyl)oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl) 4-methylpyrrolidine-1,2-dicarboxylate (441 mg, 90%).

Tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidine carboxylate (2S,4S)tert-butyl 2-(3-(2-((2S,5S)((S)(methoxycarbonylamino) methylbutanoyl)methylpyrrolidinecarbonyloxy)acetyl)oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl) 4-methylpyrrolidine-1,2-dicarboxylate (441 mg, 0.55 mmol) and NH4OAc (5 g, 65.0 mmol) were suspended in a solution of 10:1 PhMe/2-methoxyethanol (11 mL). The stirred reaction mixture was heated to 110 ˚C for 7 h, then cooled to RT and diluted with EtOAc. The organic phase was washed with water, saturated aqueous NaHCO3, and brine, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin yl}-1H-imidazolyl)-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]methylpyrrolidinecarboxylate (266 mg, 63%).

Tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidine carboxylate Tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] pyrrolidinyl}-1H-imidazolyl)-1,4,5,11 tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidine ylate (266 mg, 0.35 mmol) was suspended in DCM (7 mL) and activated MnO2 (908 mg, 10.45 mmol) was added in a single portion. The reaction mixture was stirred overnight.

After stirring for 15 h, additional activated MnO2 (500 mg, 5.75 mmol) was added in a single portion.

After stirring 2 h at 35 °C, the mixture was cooled to rt and the slurry was filtered over celite. The filter cake was washed with copious CH2Cl2 and MeOH and the filtrate was concentrated under d pressure. The crude material was taken on to the next step without further purification to afford tert-butyl (2S,4S)[9-(2-{(2S,5S)[N- (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]methylpyrrolidine ylate (266 mg, quant).

Methyl 1-[(2S,5S)(5-{2-[(2S,4S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) pyrrolidinyl]methyloxobutanyl}carbamate Tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]methylpyrrolidinecarboxylate (266 mg, 0.23 mmol) was dissolved in DCM (4 mL), MeOH (1mL) and HCl (4 M in dioxane, 1 mL) was added. The reaction mixture was stirred for 1.5 h and then concentrated under reduced pressure. The crude residue was treated with (2S,3R)methoxy(methoxycarbonylamino)butanoic acid (44 mg, 0.23 mmol), HATU (87 mg, 0.23 mmol) and DMF (5 mL), then DIPEA (0.3 mL, 1.75 mmol) was added dropwise. After 30 min, the e was diluted with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, ed and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate (59 mg, 31%). LCMS-ESI+: calculated for C45H54N8O8: ; observed [M+1]+: 836.89. 'H NMR (CD3OD): 8.186 (s, 1H), 7.800-7.291 (m, 7H), 5.258-5.213 (dd, 1H, J=7.2, 3.6 Hz), 5.027-4.918 (m, 4H), 4.620 (t, 1H, J=6.8 Hz), 4.246 (m, 1H), 4.116 (m, 1H), 3.972 (d, 1H, J=8.8 Hz), 3.701-3.675 (m, 1H), 3.503 (s, 3H), 3.479 (s, 3H), 3.177 (s, 3H), 2.554-2.191 (m, 3H), 1.906-1.821 (m, 6H), 1.392 (d, 2H, J=6.4 Hz), 1.113-0.728 (m, 12H).

Example NM Tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate Methyl [(2S)methyl{(2S,4S)methyl[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}oxobutanyl]carbamate (312 mg, 0.49 mmol), methyl (S)((2S,4S)- 2-(5-iodo-1H-imidazolyl)(methoxymethyl)pyrrolidinyl)methyloxobutan ylcarbamate (219 mg, 0.54 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol), PdCl2(dppf)2 (36 mg, 0.05 mmol), and K2CO3 (2M in H2O, 0.8 mL, 1.6 mmoL) were combined in DMSO (5 mL) and dioxane (5 mL). The mixture was degassed with bubbling N2 for 10 min then heated to 95 ˚C for 5 h. After g, the reaction mixture was diluted with EtOAc, and washed successively with saturated aqueous NaHCO3 and brine. The cs were dried over MgSO4, filtered and concentrated under reduced pressure. The crude e was purified by silica column chromatography (0 %- 30% MeOH/EtOAc) to afford tert-butyl (2S,4S)[5-(2-{(2S,4S) [N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate (166 mg, 43%).

Methyl {(1R)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate Tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (166 mg, 0.21 mmol) was dissolved in DCM (4 mL), MeOH (1 mL) and HCl (4 M in dioxane, 1 mL) was added. The reaction mixture was stirred for 2 h and then concentrated under reduced pressure. The crude residue was treated with (R)(methoxycarbonylamino)phenylacetic acid (44 mg, 0.21 mmol), COMU (100 mg, 0.21 mmol) and DMF (5 mL), then DIPEA (0.18 mL, 1.05 mmol) was added dropwise. After 1 h, the e was d with 10% MeOH/EtOAc and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to afford methyl {(1R)[(2S,4S)(5-{2-[(2S,4S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (71 mg, 38%). LCMSESI +: ated for C49H54N8O8: 882.41; observed : 884.34. 'H NMR (CD3OD): 8.462 (s, 1H), 8.029-7.471 (m, 7H), 7.394-7.343 (m, 5H), 5.410 (d, 2H, J=6.8 Hz), 5.300 (m, 1H), 5.233 (m, 2H), 4.341 (m, 1H), 4.236 (d, 1H, J=7.2 Hz), 3.603 (s, 3H), 3.551 (s, 3H), 3.522-3.241 (m, 8H), 2.650 (m, 1H), 2.550 (m, 2H), 1.977-1.926 (m, 4H), 1.221 (d, 3H, J=3.2 Hz), 0.779 (dd, 6H, J=19.2, 6.8 Hz). e NO CH3-MgBr Boc TFA CH3 O EtO EtO NH N THF, -40 - 0 oC DCM O O Boc EtO O (S)-ethyl 5-methyl- (S)tert-butyl 2-ethyl 5- hydro-2H- rolidine-1,2- (S)-ethyl 2-(tertpyrrole dicarboxylate butoxycarbonylamino) oxohexanoate carboxylate (Boc)2O LiOH H2 (g) CH3 CH3 EtO EtO N H O Boc EtOH, H2O Pd/C O DIEA, DMAP (2S,5S)tert-butyl 2-ethyl (2S,5S)-ethyl 5- 5-methylpyrrolidine-1,2- methylpyrrolidine dicarboxylate carboxylate TEMPO, NaBr Borane NaClO, NaHCO3 CH3 CH3 HO CH3 H N HO N O Boc Dimethysulfide Boc Boc DCM, 0 oC O (2S,5S)-tert-butyl yl- (2S,5S)(tert- (2S,5S)-tert-butyl 2- butoxycarbonyl) (hydroxymethyl) 5-methylpyrrolidine methylpyrrolidine carboxylate methylpyrrolidine carboxylic acid carboxylate O Na2SO3 O CH3 I2, Na2CO3 CH3 N N N N Ammonia (aq) NH Boc NH Dioxane, H2O Dioxane / H2O MeOH, 10 oC I (2S,5S)-tert-butyl 2-(1H- (2S,5S)-tert-butyl 2-(4,5-diiodoimidazolyl ) 1H-imidazolyl) methylpyrrolidinecarboxylate methylpyrrolidinecarboxylate CH3 N N N 1. HCl / Dioxane N NH O O NH Boc 2. ne MOC I HN I HATU, DIEA O (2S,5S)-tert-butyl 2-(5-iodo-1H- (2S)[(2S,5S)(5-iodo-1H-imidazolyl)- imidazolyl)methylpyrrolidine- 5-methylpyrrolidinyl][(1- 1-carboxylate methoxyethenyl)amino]methylbutanone hyl 2-(tert-butoxycarbonylamino)oxohexanoate A solution of ethyl N-Boc roglutamate (20.0 g, 77.7 mmol) was in anhydrous THF (150 mL) in a two neck round bottom under argon was cooled to -40 oC. magnesium bromide solution (3.0 M in Ether, 28.5 mL, 85.5 mmol) was added to the reaction mixture dropwise over 30 minutes. The reaction was stirred for 4 hrs at -40 oC then for 1 hr at 0 oC. The reaction was partitioned n ethyl acetate and saturated ammonium chloride solution and acidified with 1 N HCl. The aqueous layer was extracted two more times with ethylacetate. The organic layers were combined and dried with sodium e.

The crude material was purified by column chromatography (20% - 40% EtOAc/hexanes) to yield hyl 2-(tert-butoxycarbonylamino)oxohexanoate as a s oil and was used directly in the following step.

(S)-ethyl 5-methyl-3,4-dihydro-2H-pyrrolecarboxylate (S)-ethyl 2-(tert-butoxycarbonylamino)oxohexanoate in a 1 L flask was treated with a trifluoro acetic acid / dichloromethane solution (1:1 mixture, 100 mL). Effervescence was observed and the mixture was allowed to stir for 4 hours at room temperature. After which time the volatiles were removed in vacuo to yield (S)-ethyl 5-methyl-3,4-dihydro-2H- pyrrolecarboxylate as an oil, and used directly in the following step. (2S,5S)-ethyl 5-methylpyrrolidinecarboxylate The crude imine in a 1L flask was dissolved with ethanol (400 mL) was evacuated and charged with argon three times (3x). Palladium on carbon (apprx. 750 mg, 10% w/w, dry) was added and the reaction was ted of gas and charged with hydrogen gas (3x).

The on was allowed to stir under atmospheric hydrogen for 16 hours. The mixture was filtered through a plug of celite and the filtrate was concentrated in vacuo. Diethyl ether was added to the oil and a precipitate formed. The mixture was filtered to yield (2S,5S)-ethyl 5- methylpyrrolidinecarboxylate, as a white solid (10.6 g, 67.4 mmol, 86.7% over three . 1H NMR (400 MHz, cdcl 3) δ 4.48 (dd, 1H), 4.27 (q, 2H), 3.92 – 3.80 (m, 1H), 2.52 – 2.36 (m, 1H), 2.32 – 2.13 (m, 2H), 1.75 – 1.60 (m, 1H), 1.51 (d, 3H), 1.30 (t, 3H). (2S,5S)tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate To a solution of (2S,5S)-ethyl 5-methylpyrrolidinecarboxylate (7.0 g, 44.5 mmol) in dichloromethane (250 mL), ditertbutylanhydride (10.7 g, 49.0 mmol), diisopropylethylamine (17.1 mL, 98.0 mmol) dropwise over 10 minutes, and dimethyl amino pyridine (0.27 g, 2.23 mmol) were added successively. Effervescence was observed and the mixture was allowed to stir for 16 hours at room temperature. The reaction was washed with HCl (250 mL, of 1N). The c layer was then dried with sodium sulfate. The crude material was purified by column chromatography (5% - 25% EtOAc/hexanes) to yield (2S,5S)tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate as an oil (6.46 g, 25.1 mmol, 56%). LCMS-ESI+: calc’d for C13H23NO4: 257.16 (M +); Found: 258.70 (M+H+). (2S,5S)(tert-butoxycarbonyl)methylpyrrolidinecarboxylic acid To a solution of (2S,5S)tert-butyl 2-ethyl ylpyrrolidine-1,2-dicarboxylate (6.46 g, 25.1 mmol) in ethanol (20 mL) was added lithium hydroxide mono hydrate (2.11 g, 50.2 mmol) and zed water (12mL). The mixture was allowed to stir for 16 hours then partitioned between ethylacetate and a 1:1 mixture of saturated brine and 1N HCl. The aqueous layer was extracted an additional time with ethyl acetate. The organic layers were combined, dried with sodium sulfate and the t was removed in vacuo to yield (2S,5S)- 1-(tert-butoxycarbonyl)methylpyrrolidinecarboxylic acid as a white solid (quant.) and was used directly in the following step. (2S,5S)-tert-butyl roxymethyl)methylpyrrolidinecarboxylate To a solution of (2S,5S)(tert-butoxycarbonyl)methylpyrrolidinecarboxylic acid (5.91 g, 25.8 mmol) in tetrahydrofuran at 0 oC, was added borane in dimethylsulfide (1.0 M, 3.4 mL, 34 mmol) dropwise. The reaction was stirred for 4 hours at 0 oC then 18 hours at room temperature. The mixture was then cooled to 0 oC and methanol (70 mL) was added dropwise. The reaction was warmed to room temperature and the solvents were removed in vacuo. The residue was taken up in dichloromethane (200 mL) and extracted with saturated sodium bicarbonate. The organic layer was dried with sodium sulfate and the solvent was removed in vacuo to yield (2S,5S)-tert-butyl 2-(hydroxymethyl)methylpyrrolidine carboxylate as a clear oil (5.15 g, 23.9 mmol, 93%) and was used directly in the following step. )-tert-butyl 2-formylmethylpyrrolidinecarboxylate To a solution of (2S,5S)-tert-butyl 2-(hydroxymethyl)methylpyrrolidine carboxylate (5.15 g, 23.9 mmol) in dichloromethane, was added TEMPO (0.075 g, 0.48 mmol), sodium bromide (0.246 g, 2.39 mmol) and sodium bicarbonate (0.442 g, 5.26 mmol).

Sodium hypochlorite (2.67 g, 35.9 mmol) of a 6% solution was added and the biphasic mixture was vigorously stirred for 2 hours at room ature. The reaction mixture was extracted two times with dichloromethane (2x100mL). The organic layers were combined and washed with saturated sodium lfate solution, dried with sodium sulfate and the solvent was removed in vacuo to yield )-tert-butyl ylmethylpyrrolidine carboxylate (3.9 g, 18.29 mmol, 77%) as a slight colored oil and was used directly in the following step. (2S,5S)-tert-butyl 2-(1H-imidazolyl)methylpyrrolidinecarboxylate To a solution of (2S,5S)-tert-butyl 2-formylmethylpyrrolidinecarboxylate (3.9g, 18.30 mmol) in MeOH (15 mL) and ammonium hydroxide (15 mL, 99.9%), glyoxal (11.7 mL, 40% w/v in water, 102.40 mmol) was added dropwise. The biphasic e turned orange and turbid. The reaction was stirred vigorously overnight at room temperature. The solvent was removed in vacuo. The crude mixture was redissolved in ethyl e and washed with water. The s layer was washed an additional time with ethyl acetate.

The organic layers were combined and washed with brine, dried with sodium sulfate and the solvent was removed in vacuo. The crude material was purified by column chromatography 85% to 100% ethyl acetate in hexanes to yield )-tert-butyl 2-(1H-imidazolyl) methylpyrrolidinecarboxylate as an off white solid (3.47 g, 13.8 mmol, 75%). LCMS- ESI+: calc’d for C13H21N3O2: 251.16 (M +); Found: 252.20 (M+H+). (2S,5S)-tert-butyl 2-(4,5-diiodo-1H-imidazolyl)methylpyrrolidinecarboxylate A 500 mL round bottom flask was charged with (2S,5S)-tert-butyl 2-(1H-imidazol yl)methylpyrrolidinecarboxylate (3.47 g, 13.8 mmol), iodine (7.7 g, 30.4 mmol) and sodium carbonate (4.54 g, 42.8 mmol). Dioxane (70 mL) and water (45 mL) was added to mixture and the reaction was stirred vigorously ght in the dark. The reaction was then partitioned between ethyl e and a 10% aqueous solution of sodium thiosulfate and extracted. The aqueous layer was extracted an additional time with ethyl acetate. The organic layers were combined, dried with sodium sulfate and the solvent was removed in vacuo. The crude material was filtered through a plug of silica with 25% ethyl acetate in hexanes to yield (2S,5S)-tert-butyl 2-(4,5-diiodo-1H-imidazolyl)methylpyrrolidinecarboxylate as a white solid (4.28 g, 8.50 mmol, 62%). LCMS-ESI+: calc’d for C13H19I2N3O2: 502.96 (M +); Found: 503.94 (M+H+). (2S,5S)-tert-butyl 2-(5-iodo-1H-imidazolyl)methylpyrrolidinecarboxylate To a solution of (2S,5S)-tert-butyl -diiodo-1H-imidazolyl) methylpyrrolidinecarboxylate (4.28 g, 8.50 mmol) in ethanol (75 mL) and water (75 mL), sodium thiosulfate (10.72 g, 85.1 mmol) was added and the reaction mixture was stirred vigorously for 1 hour at 100 oC, 16 hours at 90 oC, and 5 hours at 100 oC. The reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was washed additionally with ethyl acetate and the organic layers were combined. The organic layer was dried with sodium e, trated and the crude material was purified by column chromatography to yield (2S,5S)-tert-butyl 2-(5-iodo-1H-imidazolyl)methylpyrrolidine- 1-carboxylate as a white solid (2.34 g, 6.20 mmol, 73%). 1H NMR (400 MHz, cdcl 3) δ 7.04 (s, 1H), 4.89 (dd, 1H), 3.92 (m, 1H), 2.91 (s, 1H), 2.18 – 2.06 (m, 2H), 1.78 (m, 1H), 1.52 (m, 1H), 1.48 (s, 9H), 1.13 (d, 3H). (2S)[(2S,5S)(5-iodo-1H-imidazolyl)methylpyrrolidinyl][(1- methoxyethenyl)amino]methylbutanone A round bottom flask was charged with (2S,5S)-tert-butyl 2-(5-iodo-1H-imidazol yl)methylpyrrolidinecarboxylate (1.5 g, 3.98 mmol) and treated with an excess of hloric acid (100 mL of 4.0M in dioxane). The mixture was stirred vigorously for 3 hours in which time a precipitate formed and the solvent was removed in vacuo. To a mixture of the crude intermediate, (S)(methoxycarbonylamino)methylbutanoic acid (0.836 g, 4.77 mmol), HATU (1.81 g, 4.77 mmol) in dichloromethane (25 mL), diisopropylethylamine (3.46 mL, 19.9 mmol) was then added dropwise and was stirred over night under nitrogen.

The reaction mixture was partitioned ethyl acetate and ted sodium bicarbonate. The organic layer was dried with sodium sulfate, the solvent removed in vacuo. The crude product was ed by column chromatography to yield (2S)[(2S,5S)(5-iodo-1H- imidazolyl)methylpyrrolidinyl][(1-methoxyethenyl)amino]methylbutanone as a white solid (1.63 g, 3.75 mmol, 94%). LCMS-ESI+: calc’d for C15H23IN4O3: 434.08 (M +); Found: 435.51 (M+H+).

Example NP Methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}(methoxymethyl)pyrrolidinyl]-1,11 dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate The synthesis of this compound was prepared according to the procedure of example LR-1 with the following modification. During the Suzuki coupling, -[(2S,5S)(5- iodo-1H-imidazolyl)methylpyrrolidinyl][(1-methoxyethenyl)amino] methylbutanone was used in lieu of (2S)[(2S)(5-bromo-1H-imidazolyl)pyrrolidin- 2-[(1-methoxyethenyl)amino]methylbutanone. The crude material was purified by preparative HPLC to provide methyl {(2S)[(2S,5S)(5-{2-[(2S,4S){(2R) [(methoxycarbonyl)amino]phenylacetyl}(methoxymethyl) pyrrolidinyl]-1,11 dihydroisochromeno [4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate as a white solid (17 mg, 0.019 mmol, 17%). 1H NMR (400 MHz, cd3od) δ 8.63 (s, 1H), 8.19 (d, 1H), 8.04 (m, 1H), 7.87 (m, 2H), 7.66 (m, 2H), 7.52 – 7.39 (m, 6H), 5.50 (m, 2H), 5.32 (s, 2H), 5.16 (m, 1H), 4.12 (m, 1H), 3.80 (m, 4H), 3.66 (s, 6H), 3.43 (m, 4H), 3.23 (s, 3H), 2.72-1.99 (m, 9H), 1.56 (d, 3H), 1.29 (m, 1H), 0.99 (d, 3H), 0.88 (d, 3H).

Example NQ O O O N N O N H B N O N Boc Pd(PPh3)4, PdCl2(dppf), K2CO3, DME/ DMF, 85°C tert-butyl 2-[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinecarboxylate O 1. HCl, EtOH, 60°C H O O O H N N 2.

N N N Boc O H O H N O tert-butyl (2S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]- O H -methylpyrrolidinyl}-1H-imidazolyl)-3,11- COMU, DIPEA, DMF, RT dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinecarboxylate H O O O H N N N N N N O methyl {(2S)[(2S,5S)(5-{2-[(2S){(2R)[(methoxycarbonyl)amino] acetyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrol idinyl]methyloxobutanyl}carbamate Methyl {(2S)[(2S,5S)(5-{2-[(2S){(2R)[(methoxycarbonyl)amino] phenylacetyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)methylpyrrolidinyl]methyloxobutan yl}carbamate The synthesis of this compound was prepared according to the procedure of example LQ with the following modification. During the Suzuki coupling, -[(2S,5S)(5-iodo- dazolyl)methylpyrrolidinyl][(1-methoxyethenyl)amino]methylbutan one was used in lieu of (2S)[(2S)(5-bromo-1H-imidazolyl)pyrrolidinyl][(1- methoxyethenyl)amino]methylbutanone. The crude material was purified by preparative HPLC to provide methyl {(2S)[(2S,5S)(5-{2-[(2S){(2R) [(methoxycarbonyl)amino]phenylacetyl}pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate as a white solid (110 mg, 0.131 mmol, 57 %). 1H NMR (400 MHz, cd 3od) δ 8.65 (s, 1H), 8.21 (d, 1H), 8.04 (m, 2H), 7.91 (s, 1H), 7.81 (m, 1H), 7.67 (m, 2H), 7.46 (m, 6H), 5.59 (s, 1H), 5.50 (dd, 1H), 5.33 (s, 2H), 5.22 – 5.09 (m, 1H), 4.14 (m, 2H), 3.74 (s, 1H), 3.65 (m, 6H), 3.52 – 3.37 (m, 2H), 2.60 – 1.89 (m, 11H), 1.56 (d, 3H), 1.29 (d, 1H), 0.99 (d, 3H), 0.88 (d, 3H).

Example NR H O O O H N N 1. HCl, EtOH, 60°C N N N Boc 2. tert-butyl -[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L- O valyl]methylpyrrolidinyl}-1H-imidazolyl)-3,11- H N O dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol O H yl]pyrrolidinecarboxylate COMU, DIPEA, DMF, RT H O N H O O N N N HCl, Dioxane N N N H Boc methyl {(2S)[(2S,5S)(5-{2-[(2S){(2R)[(tert-butoxycarbonyl)amino]- 2-phenylacetyl}pyrrolidinyl]-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)- ylpyrrolidinyl]methyloxobutanyl}carbamate H O N H O O N N N N N H H methyl [(2S){(2S,5S)[5-(2-{(2S)[(2R)aminophenylacetyl]pyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] methylpyrrolidinyl}methyloxobutanyl]carbamate Methyl [(2S){(2S,5S)[5-(2-{(2S)[(2R)aminophenylacetyl]pyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] methylpyrrolidinyl}methyloxobutanyl]carbamate The synthesis of this compound was prepared according to Example NQ with the ing modifications. During the amide coupling, (R)(tert-butoxycarbonylamino) phenylacetic acid was used in lieu of (R)(methoxycarbonylamino)phenylacetic acid.

This was then treated with an excess of hydrochloric acid (15 mL, 4.0 M in Dioxane) for 2 hours. The crude t was purified by HPLC to provide methyl [(2S){(2S,5S)[5-(2- {(2S)[(2R)aminophenylacetyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] pyrrolidinyl}methyloxobutanyl]carbamate as a white solid (153 mg, 0.196 mmol, 74%). 1H NMR (400 MHz, cd 3od) δ 8.63 (s, 1H), 8.20 (d, 1H), 7.99 (m, 1H), 7.93 (m, 2H), 7.80 (m, 2H), 7.72 – 7.64 (m, 2H), 7.63 – 7.52 (m, 5H), 5.52 (dd, 1H), 5.44 (m, 1H), .33 (s, 2H), 5.21 – 5.10 (m, 1H), 4.80 (m, 2H), 4.14 (m, 1H), 4.02 (m, 1H), 3.75 (s, 1H), 3.67 (s, 3H), 3.12 (dd, 1H), 2.72 – 2.13 (m, 7H), 2.00 (m, 3H), 1.56 (d, 3H), 1.30 (d, 1H), 0.98 (d, 3H), 0.88 (d, 3H).

Example OE (2S,5S)-Ethyl 1-((S)(methoxycarbonylamino)methylbutanoyl) methylpyrrolidinecarboxylate (2S,5S)-Ethyl 5-methylpyrrolidinecarboxylate-TFA (10.0 g, 39.3 mmol), (S) (methoxycarbonylamino)methylbutanoic acid (6.88 g, 39.3 mmol) and HATU (14.9 g, 39.3 mmol) were combined in DMF (100 mL) and DIPEA (15.0 mL, 86.5 mmol) was added.

After ng for 1 h at RT, the reaction mixture was diluted with EtOAc. The organic phase was washed successively with 10% HCl, saturated aqueous NaHCO3 and brine, then dried over MgSO4, filtered and concentrated under reduced pressure to afford (2S,5S)-ethyl 1-((S)- 2-(methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylate. The crude material was carried on without further purification. (2S,5S)((S)(Methoxycarbonylamino)methylbutanoyl)methylpyrrolidine ylic acid (2S,5S)-Ethyl 1-((S)(methoxycarbonylamino)methylbutanoyl) methylpyrrolidinecarboxylate (39.3 mmol, ng complete conversion from the previous transformation) was suspended in MeOH (200 mL) and s LiOH (1.0 M, 100 mL, 100 mmol) was added. The reaction mixture was stirred o/n, then concentrated under reduced pressure to remove most of the MeOH. The aqueous solution was washed 2x with DCM before being acidified to pH~1-2 with 10% HCl. The acidic aqueous phase was then extracted 5x with EtOAc. The combined EtOAc extracts were dried over MgSO4 filtered and concentrated under reduced pressure to afford (2S,5S)((S)(Methoxycarbonylamino) methylbutanoyl)methylpyrrolidinecarboxylic acid (6.89 g, 56% over 2 steps).

Example OF potassium O vinyltrifluoroborate, O O Pd(OAc)2, SPhos, K2CO3 O propanol (reflux) ro-10,11-dihydro-5H- 3-vinyl-10,11-dihydro-5H- dibenzo[c,g]chromen-8(9H)-one dibenzo[c,g]chromen-8(9H)-one O Boc 1. NBS HO2C N Cs2CO3 H2O/THF/DMSO O O + 2-Me-THF 2. MnO2, DCM Br 3-(2-bromoacetyl)-10,11-dihydro-5H- (2S,4S)(tert-butoxycarbonyl) dibenzo[c,g]chromen-8(9H)-one (methoxymethyl)pyrrolidine ylic acid MeO O pyridinium tribromide, O O O DCM/MeOH Boc O (2S,4S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11- tetrahydro-5H-dibenzo[c,g]chromenyl)ethyl) 4- (methoxymethyl)pyrrolidine-1,2-dicarboxylate NHCO2Me MeO O O O O + O N Cs2CO3 Boc O Br HO 2-MeTHF; 50 oC (2S,4S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H- (2S,5S)((S) o[c,g]chromenyl)oxoethyl) 1-tert-butyl 4- (methoxycarbonylamino) (methoxymethyl)pyrrolidine-1,2-dicarboxylate methylbutanoyl)methylpyrrolidine carboxylic acid MeO2CHN H O H N N N N MnO2 N N DCM tert-butyl )[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate MeO2CHN H O H N 1. HCl/dioxane; DCM N N N N 2. HATU, DIPEA, DMF N O NHCO2Me tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- HO (2S,3S) (methoxycarbonylamino) valyl]methylpyrrolidinyl}-1,11- methylpentanoic acid dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate MeO2CHN H O H N N N N N N N O methyl {(2S,3S)[(2S,4S)(5-{2-[(2S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)(methoxymethyl)pyrrolidinyl]methyloxopentanyl}carbamate 3-Vinyl-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one A 3-neck oven-dried 500 mL round-bottom flask was cooled under Ar, then d with 3-Chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (12.0 g, 42.1 mmol), potassium vinyltrifluoroborate (8.47 g, 6.32 mmol), Pd(OAc)2 (473 mg, 2.11 mmol), SPhos (1.74 g, 4.25 mmol), K2CO3 (17.5 g, 126 mmol) and anhydrous propanol (120 mL). The reaction mixture was sparged with Ar for 16 min, then heated to reflux for 5.5 h. Upon completion, the reaction mixture was cooled to RT and concentrated under reduced pressure.

The crude e was suspended in DCM, then washed with H2O and brine. The organic solution was dried over MgSO4, ed and concentrated under reduced pressure. The resulting residue was further purified via silica plug, eluting with DCM to afford 3-vinyl- ,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (10.2 g, 87%). 3-(2-Bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 3-Vinyl-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (9.98 g, 36.1 mmol) was dissolved in a stirred solution of THF (70 mL), DMSO (70 mL) and H2O (35 mL). NBS (6.75 g, 37.9 mmol) was added in a single portion and the reaction mixture was stirred at RT for 33 min. Upon completion, the reaction medium was diluted with EtOAc and washed twice with H2O and once with brine. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The resulting crude bromohydrin was suspended in DCM (200 mL) and treated with activated MnO2 (62.7 g, 722 mmol). After stirring for 15 h at RT, the reaction mixture was filtered over celite and the filter cake was rinsed several times with DCM. The combined te (~400 mL) was treated with MeOH (~100 mL) and the e was gradually concentrated under d pressure, causing solid material to precipitate from solution. When the liquid volume reached ~200 mL, the solid was filtered off and rinsed with MeOH. The concentration/precipitation/filtration/rinsing sequence was performed 2x more, resulting in the collection of 3 crops of powdered romoacetyl)-10,11-dihydro-5H- dibenzo[c,g]chromen-8(9H)-one (7.49 g, 56% over 2 steps). (2S,4S)tert-Butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate romoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (7.47 g, 20.1 mmol) and (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid (5.22 g, 20.1 mmol) were suspended in 2-Me-THF (75 mL) and treated with Cs2CO3 (3.27 g, .1 mmol). After stirring 4 h at RT, the reaction mixture was diluted with DCM. The organic layer was washed with H2O. The aqueous layer was then back extracted 2x with DCM. The combined organics were dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (10% to 50% EtOAc/DCM) to afford (2S,4S)tert-butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro- enzo[c,g]chromenyl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (7.73 g, 70%). (2S,4S)(2-(9-Bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (2S,4S)tert-Butyl 2-(2-oxo(8-oxo-8,9,10,11-tetrahydro-5H- o[c,g]chromenyl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (7.66 g, 13.9 mmol) was ved in a solution of DCM (100 mL) and MeOH (40 mL), then treated with pyridinium mide (4.90 g, 15.3 mmol). After stirring at RT for 1.75 h, the reaction e was diluted with DCM and washed successively with 10% HCl, saturated aqueous NaHCO3 and brine. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure and the crude material was d on without further purification. (2S,4S)tert-Butyl 2-(2-(9-((2S,5S)((S)(methoxycarbonylamino) methylbutanoyl)methylpyrrolidinecarbonyloxy)oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate )(2-(9-Bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (8.76 g, 13.94 mmol) was treated with a solution of (2S,5S)((S)(methoxycarbonylamino)methylbutanoyl)- 5-methylpyrrolidinecarboxylic acid (6.85 g, 23.92 mmol) in 2-Me-THF (70 mL) and Cs2CO3 (3.63 g, 11.15 mmol). The stirred reaction mixture was heated to 50 ˚C for 20 h, then cooled to RT and diluted with EtOAc. The organic phase was washed with H2O and brine, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude e was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford (2S,4S)- 1-tert-butyl 2-(2-(9-((2S,5S)((S)(methoxycarbonylamino)methylbutanoyl) methylpyrrolidinecarbonyloxy)oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl)oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (10.47 g, 90%). tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin- 2-yl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (2S,4S)tert-Butyl 9-((2S,5S)((S)(methoxycarbonylamino) methylbutanoyl)methylpyrrolidinecarbonyloxy)oxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl)oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (10.47 g, 12.56 mmol) and NH4OAc (50.9 g, 660 mmol) were suspended in a on of 10:1 -methoxyethanol (132 mL). The stirred reaction mixture was heated to 110 ˚C for 4.5 h, then cooled to RT and diluted with EtOAc. The organic phase was washed 3x with saturated aqueous NaHCO3, then dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 30% MeOH/EtOAc) to afford tert-butyl )[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (8.33 g, 84%). tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin- 2-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl](methoxymethyl)pyrrolidinecarboxylate tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (8.33 g, 1.049 mmol) was ded in DCM and activated MnO2 (55.0 g, 630 mmol) was added in a single portion. After 13 h, MeOH (200 mL) was added and the slurry was filtered over celite. The filter cake was washed with MeOH (600 mL) and the te was concentrated under reduced pressure. The crude material was purified by silica column chromatography (0% to 45% MeOH/EtOAc) to afford tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (4.85 g, 58%).

Methyl {(2S,3S)[(2S,4S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) xymethyl)pyrrolidinyl]methyloxopentanyl}carbamate tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (179 mg, 0.226 mmol) was ved in DCM (4 mL) and HCl (4.0 M in dioxane, 1 mL) was added. The reaction mixture was stirred for 1 h at RT then concentrated under reduced pressure. The ing residue was treated with (2S,3S)(methoxycarbonylamino)methylpentanoic acid (51 mg, 0.27 mmol), HATU (95 mg, 0.25 mmol), DMF (2 mL) and DIPEA (0.39 mL, 2.3 mmol).

After stirring for 6 min, the reaction was quenched with H2O, filtered and purified by reverse phase HPLC to afford methyl {(2S,3S)[(2S,4S)(5-{2-[(2S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxopentanyl}carbamate (116 mg, 59%). MS (ESI) m/z 864 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.57 (d, J = 14.7 Hz, 1H), 8.45 (s, 1H), 8.20 (d, J = 14.4 Hz, 1H), 8.15 – 7.98 (m, 2H), 7.91 (dd, J = 21.8, 14.1 Hz, 2H), 7.85 – 7.69 (m, 2H), 7.69 – 7.48 (m, 2H), 5.42 – 5.12 (m, 5H), 4.34 (dd, J = 22.3, 13.7 Hz, 1H), 4.30 – 4.10 (m, 2H), 3.87 – 3.73 (m, 1H), 3.73 – 3.63 (m, 7H), 3.62 – 3.48 (m, 2H), 3.48 – 3.38 (m, 4H), 3.35 (s, 3H), 2.95 – 2.70 (m, 1H), 2.70 – 2.55 (m, 2H), 2.55 – 2.20 (m, 2H), 2.20 – 1.91 (m, 3H), 1.77 (d, J = 42.0 Hz, 1H), 1.65 (d, J = 6.6 Hz, 3H), 1.43 (t, J = 24.6 Hz, 1H), 1.28 (d, J = 6.2 Hz, 1H), 1.23 – 1.01 (m, 3H), 0.98 (d, J = 6.6 Hz, 3H), 0.90 (dd, J = 13.1, 5.9 Hz, 10H).

Example OG Methyl {(2S)[(2S,5S)(9-{2-[(2S,4S)[N-(methoxycarbonyl)-L-alloisoleucyl]- 4-(methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate was prepared from tert-butyl (2S,4S)[5-(2-{(2S,5S) [N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate by the same method ed in the synthesis of methyl {(2S,3S)[(2S,4S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)(methoxymethyl)pyrrolidinyl]methyl oxopentanyl}carbamate, replacing )(methoxycarbonylamino)methylpentanoic acid with (2S,3R)(methoxycarbonylamino)methylpentanoic acid. MS (ESI) m/z 864 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.62 – 8.41 (m, 1H), 8.22 (s, 1H), 8.07 (dt, J = 20.1, 10.0 Hz, 1H), 7.89 (dt, J = 35.6, 15.6 Hz, 2H), 7.77 (dd, J = 20.3, 7.0 Hz, 2H), 7.68 – 7.48 (m, 2H), 5.95 (d, J = 5.0 Hz, 1H), 5.42 – 5.13 (m, 4H), 4.47 (t, J = 5.5 Hz, 1H), 4.40 – 4.09 (m, 2H), 3.80 – 3.73 (m, 1H), 3.73 – 3.62 (m, 6H), 3.57 (dt, J = 16.1, 9.7 Hz, 2H), 3.40 (s, 3H), 3.34 (d, J = 7.5 Hz, 1H), 2.81 (dd, J = 18.4, 12.5 Hz, 1H), 2.63 (td, J = 13.3, 6.8 Hz, 2H), 2.55 – 2.18 (m, 2H), 2.16 – 1.77 (m, 4H), 1.65 (d, J = 6.6 Hz, 3H), 1.50 – 1.31 (m, 1H), 1.26 (dd, J = 15.6, 6.7 Hz, 2H), 1.17 – 1.03 (m, 2H), 0.98 (dd, J = 6.7, 4.5 Hz, 5H), 0.89 (dd, J = 15.5, 7.8 Hz, 3H), 0.86 – 0.74 (m, 3H).

Example OH MeO2CHN H H N 1. HCl/dioxane; DCM N N N Boc 2. COMU, DIPEA, DMF N N O NHCO2Me tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1,4,5,11- Ph tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (R) (methoxycarbonylamino) acetic acid MeO2CHN H H N Ph N N N N N MeO2CHN O methyl {(1R)[(2S,4S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)(methoxymethyl)pyrrolidinyl]oxo phenylethyl}carbamate Methyl {(1R)[(2S,4S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (102 mg, 0.128 mmol) was dissolved in DCM (4 mL) and HCl (4.0 M in dioxane, 2.0 mL, 8.0 mmol) was added.

After stirring at RT for 30 min, the solution was concentrated under reduced pressure. The residue was treated with (R)(methoxycarbonylamino)phenylacetic acid (29 mg, 0.141 mmol), COMU (60 mg, 0.141 mmol), DMF (3.0 mL) and DIPEA (0.223 mL, 1.28 mmol).

After stirring at RT for 20 min, the reaction e was diluted with EtOAc. The organic solution was washed with saturated s NaHCO3 and brine, then dried over MgSO4, filtered and trated under reduced pressure. The crude material was purified by reversephase HPLC to afford methyl {(1R)[(2S,4S)(5-{2-[(2S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate as the bis-TFA salt (82.4 mg, 60%). MS (ESI) m/z 866 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 7.94 – 7.67 (m, 4H), 7.59 (d, J = 9.1 Hz, 1H), 7.52 (s, 1H), 7.48 – 7.33 (m, 4H), 7.11 (d, J = 18.7 Hz, 1H), 5.68 (d, J = 6.3 Hz, 1H), 5.48 – 5.33 (m, 1H), 5.23 (dd, J = 24.1, 15.7 Hz, 1H), 5.17 – 5.03 (m, 3H), 4.22 (dd, J = 17.0, 9.6 Hz, 1H), 4.16 – 4.01 (m, 1H), 3.91 (d, J = 24.1 Hz, 1H), 3.83 – 3.68 (m, 1H), 3.68 – 3.59 (m, 3H), 3.59 – 3.49 (m, 3H), 3.38 (ddd, J = 15.9, 9.6, 5.7 Hz, 2H), 3.28 – 3.14 (m, 5H), 3.10 (dd, J = 14.0, 8.2 Hz, 1H), 3.00 (dd, J = 17.8, 9.6 Hz, 1H), 2.92 (dd, J = 14.5, 6.7 Hz, 1H), 2.73 – 2.41 (m, 2H), 2.40 – 2.11 (m, 2H), 2.11 – 1.83 (m, 2H), 1.54 (t, J = 9.7 Hz, 2H), 1.24 (d, J = 6.2 Hz, 1H), 1.06 (t, J = 8.0 Hz, 1H), 0.99 (d, J = 6.8 Hz, 1H), 0.94 (d, J = 6.6 Hz, 2H), 0.85 (d, J = 6.7 Hz, 2H).

Example OI MeO O O O O Boc O Br (2S,4S)(2-(9-bromooxo-8,9,10,11- ydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 4- MeO (methoxymethyl)pyrrolidine-1,2-dicarboxylate H O H BocN N N 1. HCl/dioxane; DCM N OMe N 2. HATU, DIPEA, DMF N O NHCO2Me tert-butyl (2S,4S)(5-{2-[(2S,4S)(tert-butoxycarbonyl) HO (S) (methoxymethyl)pyrrolidinyl]-1,11- (methoxycarbonylamino) dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- methylbutanoic acid imidazolyl)(methoxymethyl)pyrrolidinecarboxylate MeO2CHN H O H N N N N OMe N N MeO2CHN O methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methylbutanoyl}- hoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}- 1H-imidazolyl)(methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate tert-Butyl (2S,4S)(5-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)(methoxymethyl)pyrrolidinecarboxylate was prepared from (2S,4S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) -butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate by the same method employed in the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate, replacing (2S,5S) ((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylic acid with (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid.

Methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate tert-Butyl (2S,4S)(5-{2-[(2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)(methoxymethyl)pyrrolidinecarboxylate (137 mg, 0.179 mmol) was dissolved in DCM (5 mL) and HCl (4.0 M in dioxane, 1 mL) was added. After stirring at RT for 1.5 h, the reaction e was concentrated under reduced pressure. The crude residue was treated with (S)(methoxycarbonylamino)methylbutanoic acid (69 mg, 0.39 mmol), HATU (149 mg, 0.393 mmol), DMF (2.0 mL) and DIPEA (0.31 mL, 1.8 mmol).

After stirring for 15 min at RT, the reaction mixture was quenched with water and purified by HPLC to provide methyl 1-[(2S,4S)(5-{2-[(2S,4S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate (123 mg). MS (ESI) m/z 880 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.48 (s, 1H), 8.05 (t, J = 11.2 Hz, 1H), 7.92 (dd, J = 19.7, 10.1 Hz, 2H), 7.74 (s, 2H), 7.59 – 7.44 (m, 2H), 5.49 (s, 1H), 5.40 (dt, J = 16.3, 8.1 Hz, 1H), 5.31 – 5.15 (m, 3H), 4.47 – 4.10 (m, 4H), 3.86 – 3.44 (m, 12H), 3.39 (dd, J = 13.2, 7.1 Hz, 6H), 2.94 – 2.57 (m, 4H), 2.25 – 1.94 (m, 4H), 1.02 – 0.82 (m, 12H).

Example OJ Methyl S)[(2S,4S)(5-{2-[(2S,4S){(2S,3S) [(methoxycarbonyl)amino]methylpentanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxopentanyl}carbamate was prepared from tert-Butyl (2S,4S)(5-{2-[(2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinecarboxylate using the same method employed in the synthesis of methyl {(2S)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) xymethyl)pyrrolidinyl]methyloxobutanyl}carbamate, replacing with (S) (methoxycarbonylamino)methylbutanoic acid with )(methoxycarbonylamino) methylpentanoic acid. MS (ESI) m/z 908 [M + H]+.

Example OK MeO O O O O Boc O Br (2S,4S)(2-(9-bromooxo-8,9,10,11- tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 4- (methoxymethyl)pyrrolidine-1,2-dicarboxylate MeO2CHN O 1. HCl/dioxane; DCM H O H N N N N 2. COMU, DIPEA, DMF N O NHCO2Me tert-butyl (2S,4S)[5-(2-{(2S)[N- xycarbonyl)-L-valyl]pyrrolidinyl}-1,4,5,11- Ph tetrahydroisochromeno[4',3':6,7]naphtho[1,2- (R) d]imidazolyl)-1H-imidazolyl] (methoxycarbonylamino) (methoxymethyl)pyrrolidinecarboxylate phenylacetic acid MeO2CHN H O H N Ph N N N N N MeO2CHN O methyl {(1R)[(2S,4S)(5-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)(methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate tert-Butyl (2S,4S)[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}- 1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate was synthesized from (2S,4S)(2-(9-bromo oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 4- (methoxymethyl)pyrrolidine-1,2-dicarboxylate using the same methods described for the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] pyrrolidinyl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate, substituting (S)((S)- 2-(methoxycarbonylamino)methylbutanoyl)pyrrolidinecarboxylic acid for (2S,5S) ((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylic acid.

Methyl {(1R)[(2S,4S)(5-{2-[(2S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)(methoxymethyl)pyrrolidinyl]oxo phenylethyl}carbamate was synthesized from tert-butyl )[5-(2-{(2S)[N- (methoxycarbonyl)-L-valyl]pyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate using the same method employed for the synthesis of methyl {(1R)[(2S,4S)(5-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino]- 3-methylbutanoyl}methylpyrrolidinyl]-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate tuting tert-butyl (2S,4S)[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate for tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N- (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 871 [M + H]+. 1H NMR (400 MHz, cd3od) δ 7.87 (ddd, J = 20.5, 15.3, 6.8 Hz, 4H), 7.65 (s, 1H), 7.50 – 7.38 (m, 5H), 7.17 (s, 1H), 5.41 (d, J = 24.5 Hz, 1H), 5.28 (t, J = 8.3 Hz, 1H), 5.20 (d, J = 7.3 Hz, 3H), 4.24 (d, J = 7.2 Hz, 1H), 4.12 (d, J = 10.3 Hz, 1H), 4.03 – 3.94 (m, 1H), 3.89 (dd, J = 15.4, 8.6 Hz, 1H), 3.77 (t, J = 9.6 Hz, 1H), 3.72 – 3.64 (m, 4H), 3.63 – 3.52 (m, 4H), 3.43 (qd, J = 9.5, 5.6 Hz, 3H), 3.30 (s, 3H), 3.24 – 3.08 (m, 2H), 2.97 (dd, J = 11.6, 5.4 Hz, 2H), 2.59 (dt, J = 21.1, 7.8 Hz, 3H), 2.29 (s, 1H), 2.24 – 2.14 (m, 2H), 2.11 – 1.85 (m, 2H), 0.92 (dd, J = 15.8, 6.7 Hz, 6H).

Example OL tert-Butyl (2S,4S)[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}- ihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate was prepared according to the method described for the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate, substituting tert-butyl (2S,4S)- 2-[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate for tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N- xycarbonyl)-L-valyl]methylpyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate.

Methyl {(2S)[(2S)(9-{2-[(2S,4S)[(2R)aminophenylacetyl] (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinyl]methyl oxobutanyl}carbamate was prepared according to the method described for the synthesis of methyl (S)((2S,4S)(2'-((2S,4S)((R)aminophenylacetyl) (methoxymethyl)pyrrolidinyl)-1H,1'H-7,7'-binaphtho[1,2-d]imidazolyl) methylpyrrolidinyl)methyloxobutanylcarbamate, substituting methyl (S) ((2S,4S)(2'-((2S,4S)((R)tert-butoxycarbonylaminophenylacetyl) (methoxymethyl)pyrrolidinyl)-1H,1'H-7,7'-binaphtho[1,2-d]imidazolyl) methylpyrrolidinyl)methyloxobutanylcarbamate with tert-butyl )[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 811 [M + H]+.

Example OM O O 3-(2-bromoacetyl)-10,11-dihydro- 5H-dibenzo[c,g]chromen-8(9H)-one H O H N N N N OMe MnO2 N N DCM MeO2CHN O tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate H O H N N N N OMe 1. HCl/dioxane; DCM N N 2. HATU, DIPEA, DMF N O O NHCO2Me tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)- HO (2S,3R) l]methylpyrrolidinyl}-1H-imidazolyl)-1,11- O methoxy dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]- (methoxycarbonyla hoxymethyl)pyrrolidinecarboxylate mino)butanoic acid MeO2CHN O H O H N N N N OMe N N N O methyl {(2S)[(2S,4S)(5-{2-[(2S,5S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}(methoxymethyl)pyrrolidinyl]- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazolyl)methylpyrrolidinyl]methyloxobutanyl}carbamate tert-Butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate was synthesized from 3-(2-bromoacetyl)-10,11- dihydro-5H-dibenzo[c,g]chromen-8(9H)-one, by the same methods employed in the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin- 2-yl}-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl](methoxymethyl)pyrrolidinecarboxylate, substituting (2S,5S)((S) (methoxycarbonylamino)methylbutanoyl)methylpyrrolidinecarboxylic acid for (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid and (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid for )((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidine carboxylic acid. tert-Butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate was prepared according to the method described for the synthesis of tert-butyl )[5-(2-{(2S,5S)[N- (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate, substituting utyl )[9-(2-{(2S,5S)- 1-[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1H-imidazolyl)-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate for tert-butyl (2S,4S)[5-(2-{(2S,5S)[N- (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] xymethyl)pyrrolidinecarboxylate.

Methyl {(2S)[(2S,4S)(5-{2-[(2S,5S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate was prepared from tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1H- imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate according to the same method described for the synthesis of methyl (S)((2S,4S)(2'-((2S,4S)((2S,3R)methoxycarbonylamino methoxybutanoyl)(methoxymethyl)pyrrolidinyl)-1H,1'H-7,7'-binaphtho[1,2-d]imidazol- 2-yl)methylpyrrolidinyl)methyloxobutanylcarbamate, substituting (2S,4S)-tert- Butyl 2-(2'-((2S,4S)((S)(methoxycarbonylamino)methylbutanoyl) methylpyrrolidinyl)-1H,1'H-7,7'-binaphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinecarboxylate with tert-butyl (2S,4S)[9-(2-{(2S,5S)[N- (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate. MS (ESI) m/z 866 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.44 (d, J = 19.8 Hz, 1H), 8.02 (t, J = 8.6 Hz, 2H), 7.98 – 7.81 (m, 3H), 7.74 (dd, J = 22.2, 13.6 Hz, 2H), 7.63 – 7.41 (m, 2H), 5.79 (d, J = 6.0 Hz, 1H), 5.42 (dt, J = 43.3, 21.5 Hz, 2H), 5.31 – 5.10 (m, 5H), 4.85 – 4.70 (m, 1H), 4.52 (d, J = 3.8 Hz, 1H), 4.31 (t, J = 8.2 Hz, 1H), 4.17 (dd, J = 20.8, 8.8 Hz, 1H), 3.80 (dt, J = 19.0, 7.3 Hz, 2H), 3.73 – 3.63 (m, 7H), 3.63 – 3.49 (m, 3H), 3.39 (d, J = 9.7 Hz, 4H), 3.35 (s, 5H), 3.28 (d, J = 4.4 Hz, 3H), 2.84 (d, J = 8.8 Hz, 1H), 2.72 (dd, J = 12.5, 6.6 Hz, 1H), 2.59 – 2.45 (m, 1H), 2.45 – 2.11 (m, 4H), 2.11 – 1.82 (m, 2H), 1.56 (d, J = 6.6 Hz, 3H), 1.35 – 1.21 (m, 1H), 1.22 – 1.12 (m, 4H), 1.10 – 1.01 (m, 2H), 0.99 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H).

Example ON Methyl {(2S)[(2S,4S)(5-{2-[(2S,5S){(2S,3S)[(methoxycarbonyl)amino]- 3-methylpentanoyl}(methoxymethyl)yl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) pyrrolidinyl]methyloxobutanyl}carbamate was prepared according to the method described for the synthesis of methyl {(2S,3S)[(2S,4S)(5-{2-[(2S,4S) {(2S,3S)[(methoxycarbonyl)amino]methylpentanoyl}(methoxymethyl)pyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxopentanyl}carbamate tuting tertbutyl (2S,4S)[9-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-1H-imidazol- 5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate for tert-Butyl (2S,4S)[5-(2-{(2S,5S)[N- (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 863 [M + H]+. 1H NMR (400 MHz, cd3od) δ 8.43 (d, J = 24.6 Hz, 1H), 8.01 (dt, J = 16.1, 8.0 Hz, 1H), 7.95 – 7.78 (m, 2H), 7.77 – 7.64 (m, 2H), 7.59 – 7.41 (m, 2H), 5.79 (d, J = 5.8 Hz, 1H), 5.39 (dt, J = 46.2, 23.1 Hz, 1H), 5.27 – 5.07 (m, 3H), 4.85 – 4.72 (m, 1H), 4.42 (t, J = 8.6 Hz, 1H), 4.31 (d, J = 7.9 Hz, 1H), 4.17 (dd, J = 19.7, 8.7 Hz, 1H), 3.81 (dd, J = 23.6, 13.3 Hz, 1H), 3.69 (d, J = 10.0 Hz, 5H), 3.60 (dd, J = 14.7, 7.8 Hz, 2H), 3.42 (s, 3H), 3.17 (d, J = 6.1 Hz, 1H), 3.07 (s, 1H), 2.99 – 2.91 (m, 1H), 2.85 (s, 1H), 2.73 (dd, J = 12.5, 6.4 Hz, 1H), 2.62 – 2.48 (m, 1H), 2.45 – 2.14 (m, 3H), 2.10 – 1.91 (m, 2H), 1.83 (s, 1H), 1.57 (d, J = 6.6 Hz, 3H), 1.44 (d, J = 7.4 Hz, 1H), 1.34 – 1.23 (m, 1H), 1.20 – 0.96 (m, 5H), 0.90 (dt, J = 14.8, 6.7 Hz, 9H).

Example OO O 1. HCl/dioxane; DCM H H N N N N OMe 2. COMU, DIPEA, DMF N N O MeO2CHN O NHBoc HO (R)(tertbutoxycarbonylamino ) tert-butyl (2S,4S)[9-(2-{(2S)[N-(methoxycarbonyl)-L- Ph phenylacetic acid valyl]pyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate BocHN H O 1. HCl/dioxane; DCM H N N N N OMe N N MeO2CHN O methyl {(2S)[(2S)(5-{2-[(2S,4S){(2R)[(tertbutoxycarbonyl )amino]phenylacetyl}(methoxymethyl)pyrrolidinyl]- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate H O H N N N N OMe N N MeO2CHN O methyl {(2S)[(2S)(5-{2-[(2S,4S)[(2R)aminophenylacetyl] (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate Methyl {(2S)[(2S)(5-{2-[(2S,4S)[(2R)aminophenylacetyl] (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate was ed according to the method bed for the sis of methyl (S)((2S,4S)(2'-((2S,4S)- 1-((R)aminophenylacetyl)(methoxymethyl)pyrrolidinyl)-1H,1'H-7,7'- binaphtho[1,2-d]imidazolyl)methylpyrrolidinyl)methyloxobutan ylcarbamate, substituting tert-butyl (2S,4S)[9-(2-{(2S)[N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate for )-tert-butyl 2-(2'- ((2S,4S)((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidinyl)- 1H,1'H-7,7'-binaphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidinecarboxylate.

MS (ESI) m/z 811 [M + H]+.

Example OP Boc 1. HCl/dioxane; DCM H O H N N 2. COMU, DIPEA, DMF N N N O O NHCO2Me NHCO2Me utyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)- (R) L-valyl]methylpyrrolidinyl}-1H-imidazolyl)-1,4,5,11- (methoxycarbonylamino) tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol phenylacetic acid yl](methoxymethyl)pyrrolidinecarboxylate MeO2CHN O Ph H O H N N N N N methyl {(1R)[(2S,4S)(9-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino]- 3-methylbutanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate Methyl {(1R)[(2S,4S)(9-{2-[(2S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidin- 1-yl]oxophenylethyl}carbamate was synthesized according to the protocol described for the preparation of methyl {(1R)[(2S,4S)(5-{2-[(2S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate, substituting tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1H- imidazolyl)-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] xymethyl)pyrrolidinecarboxylate for tert-butyl (2S,4S)[5-(2-{(2S)[N- (methoxycarbonyl)-L-valyl]pyrrolidinyl}-1,4,5,11 ydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 886 [M + H]+. 1H NMR (400 MHz, cd3od) δ 8.02 – 7.85 (m, 2H), 7.85 – 7.68 (m, 2H), 7.58 (d, J = 21.5 Hz, 1H), 7.55 – 7.35 (m, 4H), 7.31 (d, J = 13.6 Hz, 1H), 5.43 (d, J = 19.1 Hz, 1H), 5.28 (t, J = 8.3 Hz, 1H), 5.25 – 5.10 (m, 3H), 4.13 (t, J = 9.5 Hz, 1H), 3.93 – 3.54 (m, 7H), 3.42 (qd, J = 9.5, 5.5 Hz, 2H), 3.34 (d, J = 7.9 Hz, 1H), 3.28 (s, 3H), 3.19 (t, J = 7.8 Hz, 2H), 3.00 (t, J = 7.8 Hz, 2H), 2.74 – 2.46 (m, 3H), 2.44 – 2.15 (m, 2H), 2.12 – 1.86 (m, 2H), 1.56 (d, J = 6.7 Hz, 2H), 1.29 (d, J = 6.3 Hz, 1H), 1.15 – 1.01 (m, 1H), 0.98 (d, J = 6.7 Hz, 2H), 0.88 (d, J = 6.8 Hz, 2H). e OQ OEt OEt H H O N Pd(dba)2 N O N N Cl B N (pinB)2 O O N O O HN O O O methyl 1-[(2S,4S)(9-chloro-1,11- methyl [(2S){(2S,4S)ethoxy[9-(4,4,5,5- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) tetramethyl-1,3,2-dioxaborolanyl)-1,11- ethoxypyrrolidinyl]methyloxobutanyl}carbamate dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}methyloxobutanyl]carbamate Pd(PPh3)4 N N N PdCl2(dppf) Boc N N N DME H H O tert-butyl (2S)[5-(2-{(2S,4S)ethoxy[N-(methoxycarbonyl)-L-O valyl]pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]pyrrolidinecarboxylate NH H H 1) HCl O O N N N 2) HATU N N N Moc- Val H O H O methyl {(2S)[(2S)(5-{2-[(2S,4S)ethoxy{(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate (2S,4S)Tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl) 4-ethoxypyrrolidine-1,2-dicarboxylate To a slurry of 9-bromochloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (2.50 g, 6.8 mmol) in MeCN (20 mL) was added (2S,4S)(tert-butoxycarbonyl) ethoxypyrrolidinecarboxylic acid (2.68 g, 10.3 mmol) and DIPEA (1.3 mL, 7.5 mmol).

The reaction was heated with stirring to 50 °C for 18 h. The reaction was then cooled to room temperature and diluted with EtOAc. The solution was washed with HCl (1N) and brine. The aqueous layers were backextracted with EtOAc and the ing organic layers were combined, dried (Na2SO4) and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (15% to 50 % Hexanes) to afford (2S,4S)tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) 4-ethoxypyrrolidine-1,2-dicarboxylate (2.08 g, 56%).

Tert-butyl (2S,4S)(9-chloro-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)ethoxypyrrolidinecarboxylate To a solution of (2S,4S)tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl) 4-ethoxypyrrolidine-1,2-dicarboxylate (2.08 g, 3.8 mmol) in a mixture of toluene (30 mL) and methoxyethanol (4 mL) was added ammonium acetate (2.90 g, 37.7 mmol). The solution was heated with stirring to 80 °C for 18 h. The reaction was then cooled to room temperature and diluted with EtOAc. The solution was washed with brine, and the resulting aqueous layer was backextracted with EtOAc. The ing organic layers were combined, dried (Na2SO4), and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (10% to 75 % EtOAc(w/5% MeOH)/Hexanes) to afford tert-butyl (2S,4S)(9-chloro-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)ethoxypyrrolidine carboxylate (0.99 g, 50%).

Tert-butyl (2S,4S)(9-chloro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)ethoxypyrrolidinecarboxylate To a solution of (2S,4S)(9-chloro-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)ethoxypyrrolidine carboxylate (0.99 g, 1.9 mmol) in CH2Cl2 (18 mL) was added MnO2 (4.52 g, 52.0 mmol).

The resulting slurry was stirred at room temperature for 18 h. The reaction was filtered through , washed with CH2Cl2, and concentrated under reduced pressure. The crude e was purified by silica column chromatography (10% to 75 % EtOAc(w/5% MeOH)/Hexanes) to afford tert-butyl )(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)ethoxypyrrolidine carboxylate (0.71 g, 72%) Methyl {(2S)[(2S,4S)(9-chloro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)ethoxypyrrolidinyl]methyloxobutanyl}carbamate To a solution of tert-butyl (2S,4S)(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)ethoxypyrrolidine carboxylate (0.46 g, 0.9 mmol) in a mixture of CH2Cl2 (9.0 mL) and MeOH (1.5 mL) was added HCl (in dioxanes, 4M, 6.5 mL, 26.0 mmol). The resulting solution was stirred at room temperature for 2 h. The on was trated to dryness under reduced re. To the crude intermediate in CH2Cl2 (10.0 mL) was added (methoxycarbonylamino) methylbutanoic acid (0.17 g, 0.9 mmol), HATU (0.41 g, 1.1 mmol), and DIPEA (0.5 mL, 2.9 mmol). The resulting on was stirred at room temperature for 48 h and diluted with CH2Cl2. The solution was washed with aqueous HCl (1N) and brine. The aqueous layers were backextracted with CH2Cl2 (2x). The resulting organic layers were combined, dried (Na2SO4), and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (20% to 100 % EtOAc(w/5% MeOH)/Hexanes to 80% MeOH/EtOAc) to afford methyl {(2S)[(2S,4S)(9-chloro-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)ethoxypyrrolidinyl] methyloxobutanyl}carbamate (0.46 g, 90%).

Methyl [(2S){(2S,4S)ethoxy[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)- ihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl} methyloxobutanyl]carbamate To a solution of methyl {(2S)[(2S,4S)(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)ethoxypyrrolidinyl] methyloxobutanyl}carbamate (0.46 g, 0.84 mmol) in dioxane (8.5 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.32 g, 1.3 mmol), potassium acetate (0.25 g, 2.5 mmol), bis(dibenzylideneacetone)palladium (0.032 g, 0.035 mmol), and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (Xphos, 0.032 g, 0.067 mmol). The resulting solution was degassed with argon for 5 min and heated, with stirring, to 90 °C for 6 h. The reaction was cooled to room temperature, diluted with EtOAc, and filtered through celite. The crude residue was purified by silica column chromatography (20% to 100 % EtOAc(w/5% MeOH)/Hexanes to 90% MeOH/EtOAc) to afford methyl [(2S){(2S,4S) [9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl}methyl anyl]carbamate (0.41 g, 73%).

Tert-butyl (2S)[5-(2-{(2S,4S)ethoxy[N-(methoxycarbonyl)-L-valyl]pyrrolidin yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]pyrrolidinecarboxylate To a solution of methyl 1-{(2S,4S)ethoxy[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}methyloxobutanyl]carbamate (0.41 g, 0.61 mmol) in a mixture of DME (6.1 mL) and DMF (1.0 mL) was added (S)-tert-butyl 2-(5-bromo-1H-imidazol yl)pyrrolidinecarboxylate (0.39 g, 1.2 mmol), tetrakis(triphenylphosphine)palladium (0.021 g, 0.018 mmol), bis(diphenylphosphino)ferrocene]dichloropalladium (0.030 g, 0.041 mmol), and aqueous ium carbonate (2M, 1.0 mL, 2.0 mmol). The solution was degassed with argon for 5 min and heated, with stirring, to 85 °C for 6 h. The solution was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water and brine. The aqueous layers were backextracted with EtOAc (3x). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The crude e was purified by silica column chromatography (20% to 100 % EtOAc(w/5% MeOH)/Hexanes to 80% MeOH/EtOAc) to afford tert-butyl (2S)[5-(2-{(2S,4S)ethoxy- methoxycarbonyl)-L-valyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate (0.16 g, 33%).

Methyl {(2S)[(2S)(5-{2-[(2S,4S)ethoxy{(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate To a solution of tert-butyl (2S)[5-(2-{(2S,4S)ethoxy[N-(methoxycarbonyl)- L-valyl]pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- dazolyl]pyrrolidinecarboxylate (0.048 g, 0.062 mmol) in a mixture of CH2Cl2 (1.0 mL) and MeOH (0.25 mL) was added HCl (in dioxanes, 4M, 0.47 mL, 1.9 mmol). The solution was stirred at room ature for 3 h, and then concentrated to dryness under reduced pressure. To the crude intermediate suspended in CH2Cl2 (1.5 mL) was added (S) (methoxycarbonylamino)methylbutanoic acid (0.012 g, 0.069 mmol), HATU (0.029 g, 0.076 mmol), and DIPEA (0.050 mL, 0.28 mmol). The resulting solution was stirred at room temperature for 1.5 h. The reaction was diluted with DMF and s LiOH (2.5 M, 4 drops) was added. The solution was concentrated to remove the CH2Cl2 and the crude residue was purified by preparative reverse phase HPLC (10% to 52 % MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under reduced pressure to remove volatile organics. The addition of s sodium bicarbonate with stirring resulted in precipitation of a white solid. The precipitate was filtered through a membrane filter and washed with water. Drying under reduced pressure afforded methyl {(2S)[(2S)- 2-(5-{2-[(2S,4S)ethoxy{(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)pyrrolidinyl]methyloxobutanyl}carbamate (0.008 g, 17%). 1H-NMR: 400 MHz, (MeOD) δ: (Mixture of rs) 8.37 (s, 1H), 7.97 (s, 2H), 7.37-7.76 (m, 5H), 5.38-5.54 (m, 1H), 5.18 (s, 2H), 5.14-5.16 (m, 1H), 4.21-4.31 (m, 4H), 3.87-4.09 (m, 1H), 3.79-3.85 (m, 2H), 3.66 (s, 3H), 3.64 (s, 3H), .55 (m, 2H), 2.30- 2.35 (m, 3H), 2.04-2.06 (m, 3H), 1.11 (m, 2H), 0.95 (d, 3H), 0.88 (d, 3H). MS (ESI) m/z 836.02 [M + H]+.

Example OR 1) HCl N N N N N N 2) COMU H O H O Moc- Phg tert-butyl (2S)[5-(2-{(2S,4S)ethoxy[N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]pyrrolidinecarboxylate NH H H O O N N N N N N H O H O methyl {(1R)[(2S)(5-{2-[(2S,4S)ethoxy{(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazolyl)pyrrolidinyl]oxophenylethyl}carbamate Methyl {(1R)[(2S)(5-{2-[(2S,4S)ethoxy{(2S)[(methoxycarbonyl)amino] butanoyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)pyrrolidinyl]oxophenylethyl}carbamate To a solution of tert-butyl (2S)[5-(2-{(2S,4S)ethoxy[N-(methoxycarbonyl)- l]pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 1H-imidazolyl]pyrrolidinecarboxylate (0.11 g, 0.14 mmol) in a mixture of CH2Cl2 (2.0 mL) and MeOH (0.5 mL) was added HCl (in dioxanes, 4M, 1.0 mL, 4.0 mmol). The solution was stirred at room temperature for 3 h, and then concentrated to dryness under reduced re. To the crude intermediate suspended in CH2Cl2 (1.5 mL) was added (R) (methoxycarbonylamino)phenylacetic acid (0.044 g, 0.21 mmol) and DIPEA (0.075 mL, 0.43 mmol). The resulting solution was cooled to -40 °C and COMU (0.096 g, 0.22 mmol) was added. The on was allowed to slowly warm to 0 °C over 1 h. The reaction was diluted with DMF. The solution was concentrated to remove the CH2Cl2 and the crude residue was purified by preparative reverse phase HPLC (10% to 55% MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under reduced re to remove volatile organics. The addition of aqueous sodium bicarbonate with stirring resulted in precipitation of a white solid. The precipitate was filtered through a membrane filter and washed with water. Drying under reduced pressure afforded methyl 2-[(2S)- 2-(5-{2-[(2S,4S)ethoxy{(2S)[(methoxycarbonyl)amino] butanoyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)pyrrolidinyl]oxophenylethyl}carbamate (0.022 g, 18%). 1H-NMR: 400 MHz, (MeOD) δ: re of rotamers) 8.28 (d, 1H), 7.88 (d, 1H), 7.52-7.70 (m, 3H), 7.28-7.38 (m, 5H), .96 (m, 2H), 5.44-5.47 (m, 1H), 5.31 (s, 1H), 5.12 (s, 2H), 4.16-4.48 (m, 3H), 3.81-3.19 (m, 1H), 3.62-3.76 (m, 2H), 3.58 (s, 3H), 2.56 (s, 3H), 2.42- 2.57 (m, 1H), 2.31 (m, 1H), 1.81-2.41 (m, 5H), 1.04 (t, 3H), 0.87 (d, 3H), 0.81 (d, 3H). MS (ESI) m/z 869.55 [M + H]+. e OS Boc Br 1) HCl NH N N O N H Br H 2) HATU Moc-MeThr N O H (S)-tert-butyl 2-(5-bromo-1H-imidazol yl)pyrrolidinecarboxylate methyl (2S,3R)((S)(5-bromo-1H- imidazolyl)pyrrolidinyl)methoxy- 1-oxobutanylcarbamate Methyl (2S,3R)((S)(5-bromo-1H-imidazolyl)pyrrolidinyl)methoxy oxobutanylcarbamate To a solution of (S)-tert-butyl 2-(5-bromo-1H-imidazolyl)pyrrolidine carboxylate (1.00 g, 3.2 mmol) in a e of CH2Cl2 (30 mL) and MeOH (5 mL) was added HCl (in e, 4 M, 11.5 mL, 46.0 mmol). The solution was stirred at 40 °C for 1h, cooled to room temperature, and concentrated to dryness under reduced pressure. To the crude intermediate suspended in CH2Cl2 (30 mL) was added (2S,3R)methoxy (methoxycarbonylamino)butanoic acid (0.67 g, 3.5 mmol), HATU (1.47 g, 3.8 mmol), and DIPEA (1.00 mL, 6.0 mmol). The resulting solution was stirred at room temperature for 24 h. DMF (2 mL) and aqueous LiOH (2.5 M, 1 mL) were added and the reaction was concentrated to dryness under reduced pressure. The crude material was diluted with EtOAc and washed with H2O and brine. The aqueous layers were backextracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure.

The crude residue was purified by silica column chromatography (20% to 100 % EtOAc(w/5% MeOH)/CH2Cl2) to afford methyl (2S,3R)((S)(5-bromo-1H-imidazol yl)pyrrolidinyl)methoxyoxobutanylcarbamate (1.2g, 100%).

Example OT Tert-butyl (2S,4S)[9-(2-{(2S)[N-(methoxycarbonyl)-O-methyl-L- threonyl]pyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate To a solution of tert-butyl 4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]-naphtho[1,2-d]imidazol yl]pyrrolidinecarboxylate (1.0 g, 3.2 mmol) in a e of DMSO (2.0 mL) and dioxanes (2.0 mL) was added methyl (2S,3R)((S)(5-bromo-1H-imidazolyl)pyrrolidinyl) methoxyoxobutanylcarbamate (0.24 g, 0.62 mmol), tetrakis(triphenylphosphine)palladium (0.050 g, 0.043 mmol), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium (0.030 g, 0.041 mmol), and aqueous potassium ate (2M, 0.65 mL, 1.3 mmol). The solution was degassed with argon for 5 min and heated, with stirring, to 85 °C for 6 h. The solution was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water and brine. The aqueous layers were backextracted with EtOAc (3x). The combined organic layers were dried over Na2SO4 and trated under reduced pressure. The crude residue was ed by silica column chromatography (20% to 100 % EtOAc(w/5% MeOH)/Hexanes to 60% MeOH/EtOAc) to afford tert-butyl (2S,4S)[9-(2-{(2S)[N-(methoxycarbonyl)-O-methyl- L-threonyl]pyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate (0.20 g, 63%).

Methyl {(1R)[(2S,4S)(9-{2-[(2S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate To a solution of tert-butyl (2S,4S)[9-(2-{(2S)[N-(methoxycarbonyl)-O-methyl- L-threonyl]pyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate (0.20 g, 0.26 mmol) in a mixture of CH2Cl2 (3.0 mL) and MeOH (0.5 mL) was added HCl (in dioxanes, 4M, 2.0 mL, 8.0 mmol). The solution was stirred at 40 ºC for 1 h, and then cooled to room temperature and concentrated to dryness under reduced pressure. To the crude ediate suspended in CH2Cl2 (3.0 mL) was added (R) (methoxycarbonylamino)phenylacetic acid (0.081 g, 0.39 mmol) and DIPEA (0.150 mL, 0.86 mmol). The resulting solution was cooled to -40 °C and COMU (0.180 g, 0.42 mmol) was added. The reaction was d to slowly warm to room temperature over 30 min and ined for 1.5 h. The solution was diluted with CH2Cl2 and washed with aqueous bicarbonate. The aqueous layer was backextracted with CH2Cl2. The combined c layers were dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by preparative reverse phase HPLC (10% to 50% MeCN/water with 0.1% TFA).

The desired fractions were combined and concentrated under reduced pressure to remove volatile organics. The addition of aqueous sodium bicarbonate with stirring resulted in itation of a white solid. The precipitate was filtered through a membrane filter and washed with water. Drying under reduced pressure afforded methyl 2-[(2S,4S)(9- {2-[(2S){(2S,3R)methoxy[(methoxycarbonyl)amino]butanoyl}pyrrolidinyl]-1H- imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (0.10 g, 46%). 1H-NMR: 400 MHz, (MeOD) δ: (Mixture of rotamers) 8.34 (s, 1H), 7.92-7.97 (m, 2H), 7.33-7.69 (m, 10H), 5.53 (s, 1H), 5.36-5.39 (m, 1H), 5.15-5.21 (m, 3H), 4.44 (d, 1H), .93 (m, 2H), 3.68-3.75 (m, 2H), 3.66 (s, 3H), 3.65 (s, 3H), 3.46-3.57 (m, 2H), 3.28 (s, 3H), 3.19 (s, 3H), 2.47-2.60 (m, 3H), 2.22-2.36 (m, 4H), 1.99-2.08 (m, 3H), 1.15 (d, 3H). MS (ESI) m/z 886.19 [M + H]+.

Example OU H H 1) HCl O N N B Boc 2) HATU O N Moc-MeThr tert-butyl 4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinecarboxylate Boc I O N N O H O N O O N O O methyl (1-{4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinyl}methoxyoxobutan yl)carbamate H H 1) HCl N N O Boc 2) COMU N N N O Moc- Phg H O tert-butyl (2S)(5-{2-[(2S,4S)[N-(methoxycarbonyl)-O-methyl-L-threonyl] (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- azolyl}-1H-imidazolyl)pyrrolidinecarboxylate NH H H O O N N O N N N H O H O methyl {(1R)[(2S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methoxybutanoyl} (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazolyl)pyrrolidinyl]oxophenylethyl}carbamate Methyl (methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl}methoxy- 1-oxobutanyl)carbamate To a solution of tert-butyl 4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinecarboxylate (0.25 g, 0.41 mmol) in a e of CH2Cl2 (4.0 mL) and MeOH (1.0 mL) was added HCl (in dioxanes, 4M, 3.0 mL, 12.0 mmol). The resulting solution was d at 40 ºC for 45 min. The solution was cooled to room temperature and concentrated to dryness under reduced pressure. To the crude intermediate in CH2Cl2 (4.0 mL) was added (2S,3R)methoxy(methoxycarbonylamino)butanoic acid (0.08 g, 0.42 mmol), HATU (0.17 g, 0.45 mmol), and DIPEA (0.4 mL, 2.3 mmol). The resulting solution was stirred at room temperature for 48 h and diluted with CH2Cl2. The solution was washed with brine.

The aqueous layer was backextracted with CH2Cl2 (2x). The resulting organic layers were combined, dried 4), and concentrated under d pressure. The crude residue was purified by silica column chromatography (30% to 100 % EtOAc(w/5% MeOH)/Hexanes to 80% MeOH/EtOAc) to afford methyl (1-{4-(methoxymethyl)[9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}methoxyoxobutanyl)carbamate (0.24 g, 92%).

Tert-butyl (2S)(5-{2-[(2S,4S)[N-(methoxycarbonyl)-O-methyl-L-threonyl] (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)pyrrolidinecarboxylate To a solution of methyl (1-{4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}methoxyoxobutanyl)carbamate (0.15 g, 0.22 mmol) in a e of DMSO (2.0 mL) and dioxane (2.0 mL) was added (S)-tert-butyl odo-1H-imidazol yl)pyrrolidinecarboxylate (0.15 g, 0.40 mmol), tetrakis(triphenylphosphine)palladium (0.028 g, 0.024 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (0.018 g, 0.025 mmol), and aqueous potassium carbonate (2M, 0.35 mL, 0.70 mmol). The solution was degassed with argon for 5 min and heated, with ng, to 90 °C for 6 h. The solution was cooled to room temperature and d with EtOAc. The organic layer was washed with water and brine. The aqueous layers were tracted with EtOAc (3x). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by preparative reverse phase HPLC (10% to 55% MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under reduced pressure to remove volatile organics. The remaining solution was basified with aqueous bicarbonate and extracted with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to provide tert-butyl (2S)(5-{2-[(2S,4S)[N- (methoxycarbonyl)-O-methyl-L-threonyl](methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidine carboxylate (0.013 g, 7%).

Methyl {(1R)[(2S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methoxybutanoyl}(methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinyl]oxophenylethyl}carbamate To a solution of tert-butyl (2S)(5-{2-[(2S,4S)[N-(methoxycarbonyl)-O-methyl- L-threonyl](methoxymethyl)pyrrolidinyl]-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidine carboxylate (0.013 g, 0.016 mmol) in a mixture of CH2Cl2 (0.5 mL) and MeOH (0.02 mL) was added HCl (in dioxanes, 4M, 0.20 mL, 0.80 mmol). The on was d at room temperature for 1 h, and then concentrated to dryness under reduced pressure. To the crude intermediate ded in CH2Cl2 (0.5 mL) was added (R)(methoxycarbonylamino) acetic acid (0.006 g, 0.029 mmol) and DIPEA (0.05 mL, 0.28 mmol). The resulting solution was cooled to 0 °C and COMU (0.012 g, 0.028 mmol) was added. The reaction was stirred at 0 °C for 30 min. The solution was diluted with DMF and aqueous LiOH (2.5 M, 2 drops) and concentrated under reduced pressure to remove the CH2Cl2. The crude residue was purified by preparative reverse phase HPLC (10% to 55% MeCN/water with 0.1% TFA).

The desired fractions were combined and concentrated under reduced pressure to remove volatile organics. The addition of aqueous sodium bicarbonate with stirring resulted in precipitation of a white solid. The precipitate was filtered through a membrane filter and washed with water. Drying under reduced pressure afforded methyl {(1R)[(2S)(5-{2- S){(2S)[(methoxycarbonyl)amino]methoxybutanoyl} (methoxymethyl)pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)pyrrolidinyl]oxophenylethyl}carbamate (0.008 g, 61%). 1H- NMR: 400 MHz, (MeOD) δ: (Mixture of rotamers) 8.37 (m, 1H), 7.96-7.98 (m, 2H), 7.60- 7.79 (m, 3H), 7.35-7.52 (m, 6H), 6.98-7.03 (m, 1H), 5.52 (s, 1H), 5.26-5.39 (m, 2H), 5.20 (s, 2H), 4.44 (m, 1H), 4.27 (m, 1H), 3.64 (s, 6H), 3.50-3.57 (m, 3H), 3.37 (s, 3H), 3.29-3.44 (m, 3H), 3.20 (s, 3H), 2.68-2.72 (m, 2H), 2.57-2.62 (m, 2H), 1.89-2.15 (m, 6H), 1.18 (d, 3H).

MS (ESI) m/z 885.73 [M + H]+.

Example OV Boc I N N H H (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazolyl) O xymethyl)pyrrolidinecarboxylate N N O N Pd(PPh3)4 O O PdCl2(dppf) DME, DMF methyl [(2S){(2S,4S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]- 2-azabicyclo[3.1.0]hexyl}methyloxobutanyl]carbamate N N N 1) HCl N N N H O O 2) COMU H HN Moc- Phg tert-butyl (2S,4S)[5-(2-{(1S,3S,5S)[N-(methoxycarbonyl)-L-valyl] azabicyclo[3.1.0]hexyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate NH H H O O N N N N N N H O H O methyl {(1R)[(2S,4S)(5-{2-[(1S,3S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}azabicyclo[3.1.0]hexyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)(methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate Methyl [(2S){(2S,4S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]azabicyclo[3.1.0]hex methyloxobutanyl]carbamate Methyl [(2S){(2S,4S)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]azabicyclo[3.1.0]hexyl} methyloxobutanyl]carbamate was prepared following the procedure for methyl [(2S) {(2S,4S)ethoxy[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl}methyl anyl]carbamate by substitution of (1S,3S,5S)(tert-butoxycarbonyl) azabicyclo[3.1.0]hexanecarboxylic acid for (2S,4S)(tert-butoxycarbonyl) ethoxypyrrolidinecarboxylic acid.

Tert-butyl (2S,4S)[5-(2-{(1S,3S,5S)[N-(methoxycarbonyl)-L-valyl] azabicyclo[3.1.0]hexyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate To a solution of methyl 1-{(2S,4S)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] azabicyclo[3.1.0]hexyl}methyloxobutanyl]carbamate (0.19 g, 0.30 mmol) in a mixture of DMSO (2.0 mL) and dioxane (2.0 mL) was added (2S,4S)-tert-butyl 2-(5-iodo- dazolyl)(methoxymethyl)pyrrolidinecarboxylate (0.20 g, 0.55 mmol), tetrakis(triphenylphosphine)palladium (0.035 g, 0.030 mmol), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium (0.025 g, 0.034 mmol), and aqueous potassium carbonate (2M, 0.5 mL, 1.0 mmol). The solution was degassed with argon for 5 min and heated, with stirring, to 90 °C for 6 h. The solution was cooled to room temperature, diluted with EtOAc, and filtered through . The filtrate was trated under reduced pressure and purified by silica column chromatography (2% to 25 % CH2Cl2/MeOH) and preparative reverse phase HPLC (10% to 55% MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under reduced pressure to remove volatile organics. The aqueous layer was ed with aqueous sodium bicarbonate and extracted with CH2Cl2 (3x). The organic layers were combine, dried over Na2SO4, and concentrated under reduced pressure to afford tert-butyl (2S,4S)[5-(2-{(1S,3S,5S)[N- (methoxycarbonyl)-L-valyl]azabicyclo[3.1.0]hexyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate (0.025 g, 11%).

Methyl {(1R)[(2S,4S)(5-{2-[(1S,3S,5S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}azabicyclo[3.1.0]hexyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) xymethyl)pyrrolidinyl]oxophenylethyl}carbamate To a solution of tert-butyl (2S,4S)[5-(2-{(1S,3S,5S)[N-(methoxycarbonyl)-L- valyl]azabicyclo[3.1.0]hexyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (0.025 g, 0.032 mmol) in a mixture of CH2Cl2 (1.0 mL) and MeOH (0.25 mL) was added HCl (in dioxanes, 4M, 0.50 mL, 2.0 mmol). The solution was stirred at room temperature for 12 h, and then trated to dryness under reduced pressure. To the crude intermediate suspended in CH2Cl2 (0.5 mL) was added (R)(methoxycarbonylamino)phenylacetic acid (0.012 g, 0.057 mmol) and DIPEA (0.05 mL, 0.28 mmol). The resulting solution was cooled to 0 °C and COMU (0.023 g, 0.054 mmol) was added. The reaction was stirred at 0 °C for 30 min. The solution was diluted with DMF and aqueous LiOH (2.5 M, 2 drops) and concentrated under reduced pressure to remove the CH2Cl2. The crude residue was purified by preparative reverse phase HPLC (10% to 55% MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under d pressure to remove volatile organics. The addition of aqueous sodium bicarbonate with stirring resulted in precipitation of a white solid. The precipitate was filtered through a membrane filter and washed with water. Drying under reduced pressure ed methyl 2-[(2S,4S)(5-{2- [(1S,3S,5S){(2S)[(methoxycarbonyl)amino]methylbutanoyl} yclo[3.1.0]hexyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}- 1H-imidazolyl)(methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (0.015 g, 55%). 1H-NMR: 400 MHz, (MeOD) δ: (Mixture of rotamers) 8.35 (m, 1H), 7.94- 7.96 (m, 2H), 7.54-7.78 (m, 6H), 6.93-7.00 (m, 1H), 5.72 (m, 1H), 5.46 (s, 1H), 5.19 (s, 2H), .16 (m, 1H), 3.95 (m, 1H), 3.67 (s, 3H), 3.63 (s, 3H), 3.42-3.49 (m, 2H), 3.24 (s, 3H), 2.67-2.78 (m, 2H), 2.41-2.62 (m, 3H), 2.01-2.13 (m, 2H), 1.86-1.99 (m, 3H), 0.99-1.03 (m, 2H), 0.90 (d, 3H). MS (ESI) m/z 882.23 [M + H]+.

Example OW O O N N O methyl (2S,3S)((2S,5S)(5-iodo-1H- imidazolyl)methylpyrrolidinyl) H H oxopentanylcarbamate O N N B Boc Pd(PPh3)4 O N PdCl2(dppf) DME, DMF methyl (1-{4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol rolidinyl}methyloxobutanyl)carbamate O 1) HCl NH H H O O N N N 2) COMU Boc Moc- Phg N N N tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-isoleucyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate NH H H O O N N N N N N H O H O methyl {(1R)[(2S,4S)(9-{2-[(2S,5S){(2S,3S)[(methoxycarbonyl)amino] methylpentanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)(methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate utyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-isoleucyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate To a solution of methyl (1-{4-(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}methyloxobutanyl)carbamate (0.47 g, 0.78 mmol) in a mixture of DMSO (4.0 mL) and dioxane (4.0 mL) was added methyl (2S,3S)((2S,5S)(5-iodo-1H- imidazolyl)methylpyrrolidinyl)methyloxopentanylcarbamate (0.26 g, 0.72 mmol), tetrakis(triphenylphosphine)palladium (0.090 g, 0.078 mmol), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium (0.061g, 0.083 mmol), and aqueous potassium carbonate (2M, 1.2 mL, 2.4 mmol). The solution was degassed with argon for 5 min and heated, with stirring, to 90 °C for 6 h. The on was cooled to room ature, diluted with EtOAc, and filtered through celite. The te was concentrated under reduced pressure and diluted with EtOAc. The organic solution was washed with water and brine and the s layers were backextracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated under reduced re. The crude residue was purified by silica column chromatography (10% to 100% EtOAc (5% MeOH)/CH2Cl2) to afford tertbutyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-isoleucyl]methylpyrrolidin yl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate (0.25 g, 40%).

Methyl {(1R)[(2S,4S)(9-{2-[(2S,5S){(2S,3S)[(methoxycarbonyl)amino] methylpentanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate To a solution of utyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L- cyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate (0.175 g, 0.21 mmol) in a e of CH2Cl2 (2.0 mL) and MeOH (0.5 mL) was added HCl (in dioxanes, 4M, 1.6 mL, 6.4 mmol). The solution was stirred at 40 ºC for 1 h, cooled to room temperature, and then concentrated to dryness under reduced pressure. To the crude intermediate suspended in CH2Cl2 (3.0 mL) was added (R) (methoxycarbonylamino)phenylacetic acid (0.070 g, 0.34 mmol) and DIPEA (0.15 mL, 0.86 mmol). The resulting solution was cooled to -40 °C and COMU (0.15 g, 0.35 mmol) was added. The reaction was warmed to room temperature over 30 min and diluted with CH2Cl2. The solution was washed with saturated aqueous sodium bicarbonate. The aqueous layer was backextracted with CH2Cl2, and the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by preparative reverse phase HPLC (10% to 58% MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under reduced re to remove volatile organics. The addition of s sodium bicarbonate with stirring resulted in precipitation of a white solid. The precipitate was filtered through a membrane filter and washed with water. Drying under reduced pressure afforded methyl {(1R)[(2S,4S)(9-{2-[(2S,5S) {(2S,3S)[(methoxycarbonyl)amino]methylpentanoyl}methylpyrrolidinyl]-1H- imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (0.079 g, 41%). 1H-NMR: 400 MHz, (MeOD) δ: (Mixture of rs) 8.36 (m, 1H), 7.93-7.98 (m, 2H), 7.66-7.84 (m, 3H), .48 (m, 7H), 5.53 (s, 1H), .39 (m, 1H), 5.17 (d, 2H), 5.08 (m, 1H), 4.14- 4.35 (m, 1H), 3.74 (m, 4H), 3.64 (s, 3H), 3.62 (s, 3H), 3.46 (m, 1H), 3.19 (s, 3H), 2.76 (m, 1H), 2.46-2.60 (m, 3H), .35 (m, 1H), 2.08-2.18 (m, 2H), 1.91 (m, 1H), 1.61-1.87 (m, 2H), 1.48 (d, 3H), 1.13-1.21 (m, 3H), 0.80-0.97 (m, 3H). MS (ESI) m/z 898.24 [M + H]+.

Example OX NH H H 1) HCl O O N N N Boc 2) HATU N N N Moc-Val tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L-isoleucyl] pyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate NH H H O O N N N N N N H O H O methyl {(2S)[(2S,4S)(9-{2-[(2S,5S){(2S,3S)[(methoxycarbonyl)amino]methylpentanoyl} methylpyrrolidinyl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)(methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate Methyl {(2S)[(2S,4S)(9-{2-[(2S,5S){(2S,3S)[(methoxycarbonyl)amino] methylpentanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate To a solution of tert-butyl (2S,4S)[9-(2-{(2S,5S)[N-(methoxycarbonyl)-L- isoleucyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate (0.075 g, 0.09 mmol) in a mixture of CH2Cl2 (1.0 mL) and MeOH (0.25 mL) was added HCl (in dioxanes, 4M, 0.7 mL, 2.8 mmol). The solution was stirred at 40 ºC for 1 h, cooled to room temperature, and then concentrated to dryness under reduced pressure. To the crude intermediate suspended in CH2Cl2 (3.0 mL) was added (S)(methoxycarbonylamino)- 3-methylbutanoic acid (0.020 g, 0.14 mmol), HATU (0.043 g, 0.11 mmol) and DIPEA (0.10 mL, 0.57 mmol). The reaction was stirred at room temperature for 2 h. The reaction was diluted with DMF and aqueous LiOH (2.5 M, 3 drops) and the CH2Cl2 was removed under reduced re. The crude e was purified by preparative reverse phase HPLC (10% to 58% MeCN/water with 0.1% TFA). The desired fractions were combined and concentrated under reduced pressure to remove volatile organics. The addition of aqueous sodium bicarbonate with stirring resulted in itation of a white solid. The precipitate was filtered h a membrane filter and washed with water. Drying under reduced pressure afforded methyl {(2S)[(2S,4S)(9-{2-[(2S,5S){(2S,3S) [(methoxycarbonyl)amino]methylpentanoyl}methylpyrrolidinyl]-1H-imidazolyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate (0.031 g, 38%). 1H- NMR: 400 MHz, (MeOD) δ: (Mixture of rotamers) 8.34 (m, 1H), 7.91-9.97 (m, 2H), 7.50- 7.81 (m, 3H), 7.35-7.38 (m, 2H), 5.17-5.26 (m, 3H), 5.08 (m, 1H), 4.14-4.33 (m, 4H), 3.64 (s, 3H), 3.63 (s, 3H), 3.51- 3.59 (m, 3H), 3.37 (s, 3H), 2.71 (m, 1H), 2.55-2.59 (m, 1H), 2.23- 2.33 (m, 1H), 1.92-2.10 (m, 2H), 1.77-1.89 (m, 1H), 1.60 (m, 1H), 1.48 (d, 1H), 1.11-1.22 (m, 2H), 0.81-0.98 (m, 12H). MS (ESI) m/z 864.27 [M + H]+.

Example PF O O N N N H H Moc-Val-OH, HATU, O N B N DIPEA, DMF O N N O Pd(PPh3)4, PdCl2(dppf), H K2CO3, DME/ DMF, 85°C methyl [(2S){(2S,4S)ethoxy[9-(4,4,5,5-tetramethyl-1,3,2- orolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinyl}methyloxobutanyl]carbamate H O O O H N N N N N N O methyl {1-[2-{9-[2-(1-{[(methoxycarbonyl)amino](phenyl)acetyl}methylpyrrolidin- 2-yl)-1H-imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 2-yl}(methoxymethyl)pyrrolidiny l]methyloxobutanyl}carbamate tert-butyl (2S,4S)(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidine carboxylate The title compound was obtained as in example LQ but using (2S,4S)(tertbutoxycarbonyl )(methoxymethyl)pyrrolidinecarboxylic acid in place of (S)(tertbutoxycarbonyl )pyrrolidinecarboxylic acid. methoxymethyl)pyrrolidinyl](4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazole Tert-butyl (2S,4S)(methoxymethyl)[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidine carboxylate ( 310mg, 0.507mmol) was d with 2mL 1.25N HCl in ethanol and d at room temperature for 2h then at 500C for 2h. The reaction mixture was concentrated under d pressure to give a dark yellow solid that was directly in the next step. methyl [(2S){(2S,4S)ethoxy[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl}methyl oxobutanyl]carbamate A mixture of (S)(methoxycarbonylamino)methylbutanoic acid (107mg, 0.608mmol), HATU (231mg, 0.608mmol) and 6mL 10% DIPEA in DMF was pre-activated for 5 minutes, then it was added to the amine salt from the step above and allowed to stir overnight. The reaction mixture was partitioned between ethyl acetate and ted sodium bicarbonate. The organic phase was concentrated and purified by silica gel chromatography. (103mg) tert-butyl 2-[5-(2-{1-[N-(methoxycarbonyl)valyl](methoxymethyl)pyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] methylpyrrolidinecarboxylate The title compound was obtained as in example LQ but using methyl [(2S) S)ethoxy[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl}methyl oxobutanyl]carbamate (103mg, 0.154mmol) in place of tert-butyl 2-[9-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinecarboxylate and methyl (S)((2S,4S)(5-iodo-1H- imidazolyl)methylpyrrolidinyl)methyloxobutanylcarbamate (58mg, 0.154mmol)in place of methyl (S)((S)(5-bromo-1H-imidazolyl)pyrrolidinyl) methyloxobutanylcarbamate. (50.0mg) methyl {1-[4-(methoxymethyl){9-[2-(4-methylpyrrolidinyl)-1H-imidazolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}pyrrolidinyl]methyl oxobutanyl}carbamate tert-butyl 2-[5-(2-{1-[N-(methoxycarbonyl)valyl](methoxymethyl)pyrrolidin yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] methylpyrrolidinecarboxylate (50mg, mol) was treated with 2mL 1.25N HCl in ethanol and heated at 600C for 2h, then it was concentrated under reduced pressure and pumped dry under high vacuum and used directly in the next step. methyl {1-[2-{9-[2-(1-{[(methoxycarbonyl)amino](phenyl)acetyl}methylpyrrolidin -imidazolyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}- 4-(methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate A e of (methoxycarbonylamino)phenylacetic acid (13mg, 0.063mmol), COMU (30mg, 0.069mmol) in 0.500mL DMF and DIPEA (0.033mL, 0.189mmol) was allowed to preactivate for 15 minutes before it was added to the solid crude amine salt from the previous step and stirred overnight. The product was purified by reverse phase HPLC. The product was ted to the free base by dissolution in 2mL 1:1 acetonitrile:methanol and passage through a prepacked cartridge of polymer supported carbonate. Concentration and drying gave an off white powder. g).

MS (ESI) m/z 883.8 [M + H]+ 'H NMR (CD3CN) 8.176 (s, 1H), 7.778 (m, 1H), 7.596-7.521 (m, 4H), 7.455-7.347 (m, 6H), 7.218 (s, 1H), 5.482 (s, 1H), 5.310 (m, 1H), 5.192 (m, 1H), 4.999 (q, 2H, J= 14 Hz), 4.372 (d, 1H, J= 6.4 Hz), 4.279 (m, 1H), 3.800-3.697 (m, 2H), 3.632 (s, 3H) 3.597-3.445 (m, 7H), 3.355 (s, 3H), 2.876 (m, 2H), 2.761 (m, 1H), 2.583 (m, 2H), 2.220 (m, 2H), 1.764 (m, 1H), 1.070 (d, 3H, J = 6.4 Hz), 1.020 (d, 3H, J = 6.4 Hz), 0.898 (d, 3H, J = 6.4 Hz).

Example PG O N N N H H O N B N O N O Pd(PPh3)4, PdCl2(dppf), N O H K2CO3, DME/ DMF, 85°C methyl 3-methyl{(2S,4S)methyl[9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinyl}oxobutanyl]carbamate H O N H O O N N N N N N O methyl {(1R)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]- 3-methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)- 4-methylpyrrolidinyl]oxophenylethyl}carbamate tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin- 2-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]methylpyrrolidinecarboxylate The title compound was obtained as in example LQ but using methyl [(2S)methyl- 1-{(2S,4S)methyl[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl}oxobutan yl]carbamate , mol) in place of tert-butyl 2-[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinecarboxylate and methyl (S)((2S,4S)(5-iodo-1H-imidazolyl) methylpyrrolidinyl)methyloxobutanylcarbamate , 0.481mmol)in place of methyl (S)((S)(5-bromo-1H-imidazolyl)pyrrolidinyl)methyloxobutan ylcarbamate. (200.8mg) methyl {(2S)methyl[(2S,4S)methyl(9-{2-[(2S,4S)methylpyrrolidinyl]- 1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidinyl]oxobutanyl}carbamate Tert-butyl (2S,4S)[5-(2-{(2S,4S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- olyl]methylpyrrolidinecarboxylate (200mg, 0.262mmol) was treated with 2mL 1.25N HCl in ethanol and heated at 600C for 2h, then it was concentrated under reduced pressure and pumped dry under high vacuum and used directly in the next step. methyl {(1R)[(2S,4S)(5-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]oxophenylethyl}carbamate A mixture of (R)(methoxycarbonylamino)phenylacetic acid (13mg, 0.063mmol), COMU (30mg, 0.069mmol) in 1.5mL DMF was allowed to preactivate for 5 minutes before it was added to a solution of the amine from the previous salt in 1.5mL DMF and DIPEA (0.137mL, 0.786mmol) and stirred overnight. The product was purified by reverse phase HPLC. The product was converted to the free base by dissolution in 2mL 1:1 acetonitrile:methanol and e through a prepacked cartridge of polymer supported carbonate. Concentration and drying gave an off white . (25.8mg).

MS (ESI) m/z 853.8 [M + H]+.

'H NMR (CD3CN) 8.164 (s, 1H), 7.781 (m, 1H), 7.609 (m, 2H), 7.535 (m, 2H), 7.433- 7.305 (m, 6H), 7.229 (s, 1H), 5.482 (s, 1H), 5.290 (m, 1H), 5.191 (m, 1H), 4.997 (m, 2H), 4.372 (d, 1H, J= 6.4 Hz), 4.267 (m, 1H), 3.735-3.445 (m, 10H), 2.573 (m, 4H), 2.197 (m, 2H), 2.017 (m, 1H), 1.760 (m, 1H), 1.204 (d, 3H, J= 6.4 Hz), 1.068 (d, 3H, J = 6.4 Hz), 1.010 (d, 3H, J = 6.8 Hz), 0.887 (d, 3H, J = 6.8 Hz).

Example PH tert-butyl (2S,4S)[5-(2-{(2S)[(benzyloxy)carbonyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate The title compound was ed as in example OF (compound tert-butyl (2S,4S) [5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate) but using (S)(benzyloxycarbonyl)pyrrolidine- oxylic acid in place of (2S,5S)((S)(methoxycarbonylamino)methylbutanoyl)- -methylpyrrolidinecarboxylic acid in step 6. tert-butyl )(methoxymethyl)(5-{2-[(2S)-pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinecarboxylate A mixture of tert-butyl )[5-(2-{(2S)[(benzyloxy)carbonyl]pyrrolidin yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate (724mg, ol) and 70mg 10%Pd/C in 20mL l was hydrogenated at 1atm overnight. Additional 10%Pd/C (300mg) and a n of solid NaHCO3 was added and hydrogenation continued for 4 hours. Filtration through celite and concentration of the filtrate under reduced pressure gave the product as a dark brown solid, 454mg. cation by reverse phase HPLC gave 65mg purified product. methyl {(1R)[(2S)(9-{2-[(2S,4S)(methoxymethyl)pyrrolidinyl]-1H-imidazol yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinyl] oxophenylethyl}carbamate A mixture of (R)(methoxycarbonylamino)phenylacetic acid (22mg, 0.105mmol), COMU (45mg, 0.069mmol), and utyl (2S,4S)(methoxymethyl)(5- {2-[(2S)-pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}- 1H-imidazolyl)pyrrolidinecarboxylate (65mg, 0.105mmol) in 1.5mL 10% DIPEA in DMF was stirred for 1.5h. The reaction e was partitioned between ethyl acetate and saturated sodium bicarbonate. The organic phase was dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude intermediate was treated with 8mL 1.25N HCl in ethanol at 500C for 4h. Added saturated sodium bicarbonate and extracted the free base into dichloromethane. (106mg). methyl {(2S)[(2S,4S)(5-{2-[(2S){(2R)[(methoxycarbonyl)amino] phenylacetyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl}-1H-imidazolyl)(methoxymethyl)pyrrolidinyl]methyl oxobutanyl}carbamate A mixture of methyl {(1R)[(2S)(9-{2-[(2S,4S)(methoxymethyl)pyrrolidin yl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidinyl]oxophenylethyl}carbamate (55mg, 0.077mmol), (S) (methoxycarbonylamino)methylbutanoic acid (14mg, 0.077mmol), HATU (32mg, 0.085mmol) and 0.4mL 10% DIPEA in DMF was stirred at room temperature for 1 hour.

The product was purified by reverse phase HPLC. The product was converted to the free base by dissolution in 2mL 1:1 acetonitrile:methanol and passage through a prepacked cartridge of polymer ted carbonate. The eluent was concentrated, the taken up in 1%TFA in 1:1 acetonitrile:water, frozen, and lyophilized to give the product as a trifluoroacetate salt. (30.7mg) MS (ESI) m/z 869.9 [M + H]+. methyl {(1R)[(2S)(9-{2-[(2S,4S)[N-(methoxycarbonyl)-O-methyl-L-threonyl] (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidinyl]oxo phenylethyl}carbamate A mixture of methyl {(1R)[(2S)(9-{2-[(2S,4S)(methoxymethyl)pyrrolidin yl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)pyrrolidinyl]oxophenylethyl}carbamate (51mg, 0.072mmol), (2S,3R) methoxy(methoxycarbonylamino)butanoic acid (14mg, 0.072mmol), HATU (30mg, 0.079mmol) and 0.4mL 10% DIPEA in DMF was stirred at room temperature for 1 hour.

The product was purified by reverse phase HPLC. The product was converted to the free base by dissolution in 2mL 1:1 itrile:methanol and e through a prepacked cartridge of polymer supported carbonate. The eluent was concentrated, the taken up in 1%TFA in 1:1 acetonitrile:water, frozen, and lyophilized to give the product as a trifluoroacetate salt. (24mg) MS (ESI) m/z 885.8 [M + H]+; 'H NMR ) 7.635 (s, 1H), 7.434 (m, 3H), 7.330 (m, 4H), 7.233 (m, 1H), 7.164 (m, 1H), 6.983 (m, 1H), 6.747 (m, 2H), 6.127 (m, 1H), 5.584 (d, 1H, J = 6.4 Hz), 5.431 (m, 1H), 5.145 (m, 1H), 4.729 (s, 2H), 4.442 (m, 1H), 4.029 (m, 2H), 3.838 (m, 1H), 3.662-3.534 (m, 2H), 3.572 (s, 3H) 3.552 (s, 3H), 3.444-3.310 (m, 3H), 3.240 (s, 3H), 3.225 (s, 3H), 2.618 (m, 1H), 2.464 (m, 1H), 2.304 (m, 1H), 2.129 (m, 1H), 2.041 (m, 1H), 1.899 (m, 2H), 1.107 (d, 3H, J = 6.4 Hz).

Example PI O H H N N N 10% Pd/C, H2 Boc N N Boc N N N N N H N N O H H O EtOH tert-butyl (2S,4S)[5-(2-{(2S,5S) [(benzyloxy)carbonyl]methylpyrrolidinyl}-1,11- tert-butyl (2S,4S)(methoxymethyl)(5-{2-[(2S,5S) oisochromeno[4',3':6,7]naphtho[1,2- methylpyrrolidinyl]-1,11- d]imidazolyl)-1H-imidazolyl] dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol (methoxymethyl)pyrrolidinecarboxylate yl}-1H-imidazolyl)pyrrolidinecarboxylate O O (2S,3R) methoxy O OH (methoxycarbonyla mino)butanoic acid O H 1) HATU, DIPEA, DMF N N H N O 2) HCl in Ethanol N N N H O N O methyl {(2S,3R)methoxy[(2S,5S)(9-{2-[(2S,4S) (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- -methylpyrrolidinyl]oxobutanyl}carbamate NH H Moc-Val-OH, HATU, O O N N DIPEA, DMF N O N N N H O N O methyl {(2S)[(2S,4S)(5-{2-[(2S,5S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazol yl)(methoxymethyl)pyrrolidinyl]methyloxobutan yl}carbamate utyl (2S,4S)[5-(2-{(2S,5S)[(benzyloxy)carbonyl]methylpyrrolidinyl}- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate The title compound was obtained as in example OF (compound tert-butyl ) [5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,4,5,11- tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] xymethyl)pyrrolidinecarboxylate) but using (2S,5S)(benzyloxycarbonyl) methylpyrrolidinecarboxylic acid in place of (2S,5S)((S)(methoxycarbonylamino) methylbutanoyl)methylpyrrolidinecarboxylic acid. tert-butyl (2S,4S)(methoxymethyl)(5-{2-[(2S,5S)methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinecarboxylate A mixture of tert-butyl (2S,4S)[5-(2-{(2S,5S)[(benzyloxy)carbonyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (830mg, 1.08mmol) and 100mg %Pd/C in 20mL ethanol was hydrogenated at 1atm overnight. Additional 10%Pd/C (300mg) and a portion of solid NaHCO3 was added and hydrogenation continued for 4 hours.

Filtration h celite and concentration of the te under reduced pressure gave the product as a dark brown solid, 722mg. Purification by reverse phase HPLC gave 100mg purified t. methyl {(2S,3R)methoxy[(2S,5S)(9-{2-[(2S,4S)(methoxymethyl)pyrrolidin yl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- -methylpyrrolidinyl]oxobutanyl}carbamate A mixture of tert-butyl (2S,4S)(methoxymethyl)(5-{2-[(2S,5S) methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H- imidazolyl)pyrrolidinecarboxylate (101mg, 0.159mmol), )methoxy (methoxycarbonylamino)butanoic acid (30mg, 0.159mmol), HATU (61mg, 0.159mmol) and 2mL 10% DIPEA in DMF was stirred at room temperature for 1.5 hours. Saturated sodium onate was added and the t was extracted into dichloromethane, dried over sodium sulphate, ed and concentrated under reduced pressure. This crude product was treated with 5mL 1.25N HCl in ethanol at 500C for 4h and then it was concentrated under reduced pressure. ted sodium bicarbonate was added and the product was extracted into dichloromethane, dried over sodium sulphate, filtered and concentrated under reduced pressure. g) methyl {(2S)[(2S,4S)(5-{2-[(2S,5S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate A mixture of methyl {(2S,3R)methoxy[(2S,5S)(9-{2-[(2S,4S) (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] oxobutanyl}carbamate (74.6mg, 0.105mmol), (S)(methoxycarbonylamino) methylbutanoic acid (18.5mg, 0.105mmol), HATU (44mg, 0.116mmol) and 0.6mL 10% DIPEA in DMF was stirred at room temperature for 1 hour. The product was purified by reverse phase HPLC. (48.1mg) MS (ESI) m/z 866.1 [M + H]+.

Example PJ tert-butyl )(9-{2-[(2S,4S)[N-(methoxycarbonyl)-L-valyl] (trifluoromethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinecarboxylate The title compound was prepared as in example OF for compound tert-butyl (2S,4S)- 2-[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate, by using (2S,4S)((S) (methoxycarbonylamino)methylbutanoyl)(trifluoromethyl)pyrrolidinecarboxylic acid in place of (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid and (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid in place of )((S)(methoxycarbonylamino)methylbutanoyl)methylpyrrolidine- 2-carboxylic acid. methyl {(1R)[(2S,4S)(9-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}(trifluoromethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate tert-butyl (2S,4S)(9-{2-[(2S,4S)[N-(methoxycarbonyl)-L-valyl] (trifluoromethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)(methoxymethyl)pyrrolidine carboxylate (<0.412mmol, crude from us step) was treated with 6mL 4N HCl in dioxane at room temperature overnight and then at 50OC for 1 hour. l ether (20mL) was added and the itate of hydrochloride salt was collected by vacuum tion. (126mg, 0.16mmol). This material was combined with (R)(methoxycarbonylamino) phenylacetic acid (34mg, 0.16mmol), COMU (70mg, 0.16mmol), and 1.6mL of 10% DIPEA in DMF. After 1 hour at room temperature, the mixture was added dropwise into 25mL saturated sodium bicarbonate, with stirring and the resulting precipitate was collected by vacuum filtration and washed with 2mL water. The product was purified, then ified by reverse phase HPLC. (3.5mg).

MS (ESI) m/z 938.1 [M + H]+.

Example PK (2S,4S)-tert-butyl 2-formylmethylpyrrolidinecarboxylate: A mixture of (2S,4S)(tert-butoxycarbonyl)methylpyrrolidinecarboxylic acid (5.2g, 22.7 mmol), O,N-dimethylhydroxylamine hydrochloride (2.4g, 24.9mmol), HATU , 27.2mmol) and DIPEA (9.5mL, 54.5mmol) in 114mL DMF was stirred at room temperature overnight. The mixture was extracted into ethyl acetate and washed with saturated bicarbonate and water, dried over sodium sulphate, filtered, and concentrated. It was then dissolved in diethyl ether (100mL) and washed with water to remove residual DMF, dried, filtered, and concentrated to a pale yellow oil , 19.5mmol) of (2S,4S)-tert-butyl 2-(methoxy(methyl)carbamoyl)methylpyrrolidinecarboxylate. (2S,4S)-tert-butyl 2-(methoxy(methyl)carbamoyl)methylpyrrolidinecarboxylate (5.30g, 19.5mmol) was dissolved in 120mL THF, cooled to -78OC and treated with lithium aluminum hydride (1M in THF, 19.5mL, ol) dropwise via addition funnel. After 1 hour, the mixture was brought to 0OC and kept at that temperature for 2 hours. It was quenched by dropwise addition of a 50mL on of 3.0g KHSO4 in water, removed from the ice bath, and stirred 15 minutes at room temperature. The product was extracted with three 75mL portions of ethyl acetate and washed with brine. The organic phase was dried over sodium sulphate, filtered, and trated to give crude (2S,4S)-tert-butyl 2-formyl methylpyrrolidinecarboxylate. (4.89g) (2S,4S)-tert-butyl 2-(1H-imidazolyl)methylpyrrolidinecarboxylate: To a solution of (2S,4S)-tert-butyl 2-formylmethylpyrrolidinecarboxylate (4.89g, 22.9mmol), ammonium hydroxide (17mL) and water (17mL) was added, se, glyoxal (40% in water, 14.6mL, 128mmol) and the resulting mixture was stirred at room temperature overnight. Saturated sodium bicarbonate ) was added and the e was extracted with four 75mL portions of romethane. The organic phase was washed with water, dried over sodium sulphate, ed and concentrated, and then purified by silica gel chromatography to give a total of 3.76g product. (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazolyl)methylpyrrolidinecarboxylate: A mixture of (2S,4S)-tert-butyl 2-(1H-imidazolyl)methylpyrrolidine carboxylate (1.0g, 3.97mmol), iodine (2.22g, ol) and sodium carbonate (1.3g, 12.31mmol) in 20mL dioxane and 13.25mL water was covered in foil and stirred at room temperature overnight. The mixture was diluted with ethyl acetate and treated with 10% sodium lfate (5mL) and stirred for 10 minutes. The organic phase was washed with brine, and then the aqueous phase was back extracted with ethyl acetate. The combined organic phases were dried over sodium sulphate, filtered and concentrated to provide crude (2S,4S)-tert-butyl 2-(4,5-diiodo-1H-imidazolyl)methylpyrrolidinecarboxylate (2.25g) as a pale yellow solid.

A solution of (2S,4S)-tert-butyl 2-(4,5-diiodo-1H-imidazolyl)methylpyrrolidine- 1-carboxylate (2.25g, 4.4mmol) in 18mL ethanol and 18mL water was treated with sodium sulfite (5.59g, 44.4 mmol) and heated at 90 OC overnight. The mixture was partitioned between ethyl acetate and water. The aqueous phase was extracted with more ethyl acetate and the ed organic phase was washed with brine, dried over sodium sulphate, filtered, concentrated, and purified by silica gel tography to give 766mg )-tert-butyl 2- (5-iodo-1H-imidazolyl)methylpyrrolidinecarboxylate.

Example PL (2S,3aS,6aS)(tert-butoxycarbonyl)octahydrocyclopenta[b]pyrrolecarboxylic acid To a solution of commercially available (2S,3aS,6aS)-benzyl octahydrocyclopenta[b]pyrrolecarboxylate hydrochloride (4.70 g, 16.68 mmol) in methylene chloride (42 mL) was added Di-tert-butyl dicarbonate (7.28 g, 33.36 mmol), N,N- diisopropylethylamine (5.82 mL, 33.36 mmol) and 4-(Dimethylamino)pyridine (0.20 g, 1.67 mmol). The solution was stirred under air for 16 hours. Upon completion, the on was trated in vacuo, diluted in ethyl acetate, and washed with 1N HCl. The aqueous layers were backextracted twice with ethyl acetate and the combined organic layers were dried over sodium sulfate, filtered and concentrated. The resulting e was purified by silica gel chromatography (5-40% ethyl acetate in hexanes) to afford (2S,3aS,6aS)(tert- butoxycarbonyl)octahydrocyclopenta[b]pyrrolecarboxylic acid which was used without further purification. MS (ESI) m/z 368.47 [M + Na]+. (2S,3aS,6aS)(tert-butoxycarbonyl)octahydrocyclopenta[b]pyrrolecarboxylic acid To a 250mL round bottom flask d with a stir bar and (2S,3aS,6aS)benzyl 1- tert-butyl hexahydrocyclopenta[b]pyrrole-1,2(2H)-dicarboxylate (5.76 g, 16.68 mmol) was added 10% Palladium on carbon (1.77g). l was poured over the mixture and the reaction mixture was evacuated and flushed with hydrogen gas three times. The suspension was stirred at room temperature under an atmosphere of hydrogen for 24 hours. Upon completion, the reaction mixture was filtered through celite and concentrated to give (2S,3aS,6aS)(tert-butoxycarbonyl)octahydrocyclopenta[b]pyrrolecarboxylic acid (4.45g, >99%). MS (ESI) m/z 256.21 [M + H]+.

Example PM O H H H 1) HCl N N Cl N Cl N N Boc 2) HATU O HN O MocVal tert-butyl (3aS,6aS)(9-chloro-1,12- methyl {(2S)[(2S,3aS,6aS)(9-chlorodihydrochromeno [4',3':6,7]naphtho[1,2-d]imidazol- 1,11- 2-yl)hexahydrocyclopenta[b]pyrrole-1(2H)- dihydroisochromeno[4',3':6,7]naphtho[1,2- carboxylate d]imidazol yl)hexahydrocyclopenta[b]pyrrol-1(2H)-yl] methyloxobutanyl}carbamate O H H N Boc Br O N N N N Pd2dba3 O N H HN O tert-butyl 2-(5-bromo-1HBis-PinB imidazolyl)pyrrolidine XPhos O methyl {(2S)methyloxo carboxylate [(2S,3aS,6aS)[9-(4,4,5,5-tetramethyl- dioxaborolanyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2- Pd(PPh3)4 d]imidazol PdCl(dppf) yl]hexahydrocyclopenta[b]pyrrol-1(2H)- yl]butanyl}carbamate O H H N N Boc N N N N H O HN O tert-butyl 2-[5-(2-{(2S,3aS,6aS)[N- (methoxycarbonyl)-L- valyl]octahydrocyclopenta[b]pyrrolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate utyl 2-[5-(2-{(2S,3aS,6aS)[N-(methoxycarbonyl)-L- valyl]octahydrocyclopenta[b]pyrrolyl}-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]pyrrolidinecarboxylate This compound was made in an ous manner to tert-butyl (2R)[5-(2-{(2S) [N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate substituting (2S,3aS,6aS)(tert-butoxycarbonyl)octahydrocyclopenta[b]pyrrole- 2-carboxylic acid for the initial alkylation of 9-bromochloro-10,11-dihydro-6H- naphtho[2,3-c]chromen-8(9H)-one. Reactions in the synthesis of tert-butyl 2- {(2S,3aS,6aS)[N-(methoxycarbonyl)-L-valyl]octahydrocyclopenta[b]pyrrolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate gave similar product yields as in the synthesis of tert-butyl (2R)[5-(2-{(2S) [N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate. MS (ESI) m/z 774.1 [M + H]+.

Example PN O H H N N N Boc 1) HCl N N N H O HN O 2) COMU, R-MocPhg tert-butyl 2-[5-(2-{(2S,3aS,6aS)[N- (methoxycarbonyl)-L- valyl]octahydrocyclopenta[b]pyrrolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol -imidazolyl]pyrrolidinecarboxylate HN O H H N N N N N N H O HN O methyl {(1R)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino]- 3-methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol- yrrolidinyl]oxophenylethyl}carbamate methyl {(1R)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinyl]oxophenylethyl}carbamate To a on of tert-butyl 2-[5-(2-{(2S,3aS,6aS)[N-(methoxycarbonyl)-L- valyl]octahydrocyclopenta[b]pyrrolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]pyrrolidinecarboxylate (0.128 g, 0.165 mmol) in a mixture of CH2Cl2 (1.6 mL) and MeOH (0.33 mL) was added HCl (4M in oxane, 1.24 mL, 4.9 mmol). The solution was stirred at room temperature for 1.5 h and concentrated to dryness.

The intermediate was dissolved in CH2Cl2 (1.6 mL). (methoxycarbonylamino)- 2-phenylacetic acid (0.052 g, 0.25 mmol) and DIPEA (0.087 mL, 0.496 mmol) were then added to the solution. The reaction mixture was cooled to -40 °C (external temperature, MeCN/CO2(s) bath). COMU (0.113 g, 0.265 mmol) was then added and solution was allowed to warm to 0 °C over 1.5 h. Upon completion by LCMS, the solution was diluted with DMF and concentrated. The crude product was purified by preparative HPLC (Gemini column, 10-47% MeCN/H2O with 0.1% TFA) and the d fractions were combined. The solution was concentrated until the aqueous layer remained and aqueous bicarbonate (sat.) was slowly added until the solution was basic. The ing slurry was stirred at room temperature for 2h and filtered. The resulting solid was dried in vacuo to provide methyl {(1R)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]oxophenylethyl}carbamate (0.068 g, 48%).

MS (ESI) m/z 865.7 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.44 – 8.30 (m, 1H), 8.02 – 7.82 (m, 2H), 7.81 – 7.58 (m, 4H), 7.50 – 7.11 (m, 6H), 7.09 – 6.83 (m, 2H), 5.72 – .45 (m, 2H), 5.41 (s, 1H), 5.34 – 5.28 (m, 1H), 5.22 (s, 3H), 4.69 – 4.64 (m, 1H), 4.26 – 4.19 (m, 1H), 4.03 – 3.98 (m, 1H), 3.96 – 3.91 (m, 1H), 3.66 (d, 4H), 2.98 – 2.91 (m, 1H), 2.88 – 2.83 (m, 1H), 2.58 – 2.48 (m, 1H), 2.27 – 2.12 (m, 4H), 2.11 – 2.00 (m, 3H), 2.00 – 1.89 (m, 2H), 1.77 – 1.72 (m, 1H), 1.31 – 1.04 (m, 3H), 0.93 (d, 6H).

Example PO O H H N N N 1) HCl N N N H O O 2) HATU, HN S-MocVal tert-butyl 2-{(2S,3aS,6aS)[N- (methoxycarbonyl)-L- octahydrocyclopenta[b]pyrrolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl]pyrrolidinecarboxylate HN O H H N N N N N N H O HN O methyl {(2S)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol- 2-yl)pyrrolidinyl]methyloxobutanyl}carbamate methyl {(2S)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinyl]methyloxobutanyl}carbamate To a solution of tert-butyl 2-{(2S,3aS,6aS)[N-(methoxycarbonyl)-L- valyl]octahydrocyclopenta[b]pyrrolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]pyrrolidinecarboxylate (0.030 g, 0.039 mmol) in a mixture of CH2Cl2 (0.39 mL) and MeOH (0.078 mL) was added HCl (4M in oxane, 0.29 mL, 1.16 mmol). The solution was stirred at room temperature for 1.5 h and concentrated to dryness.

The intermediate was dissolved in CH2Cl2 (0.39 mL). (S)(methoxycarbonylamino)- 3-methylbutanoic acid (0.007 g, 0.043 mmol) and DIPEA (0.020 mL, 0.116 mmol) were then added to the solution. HATU (0.018 g, 0.047 mmol) was added and solution was allowed to stir at room temp. Upon completion, the solution was diluted with DMF and concentrated.

The crude product was purified by preparative HPLC (Gemini column, 10-47% MeCN/H2O with 0.1% TFA) and the desired fractions were combined and lized to provide methyl {(2S)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]methyloxobutanyl}carbamate (0.010g, 31%). MS (ESI) m/z 832.2 [M + H]+. e PP methyl [(1S)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinyl]oxo(tetrahydro-2H-pyranyl)ethyl]carbamate This nd was made in an analogous manner to methyl {(2S)[2-(5-{2- [(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]methyloxobutanyl}carbamate, substituting (S)(methoxycarbonylamino) (tetrahydro-2H-pyranyl)acetic acid for (S)(methoxycarbonylamino)methylbutanoic acid to give methyl [(1S)[2-(5-{2-[(2S,3aS,6aS){(2S)[(methoxycarbonyl)amino] methylbutanoyl}octahydrocyclopenta[b]pyrrolyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl)pyrrolidin yl]oxo(tetrahydro-2H-pyranyl)ethyl]carbamate (0.039 g, 56%). MS (ESI) m/z 874.34 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.58 (s, 2H), 8.26 – 8.08 (m, 2H), 7.96 – 7.75 (m, 4H), 7.65 – 7.54 (m, 5H), 5.36 – 5.11 (m, 4H), 4.34 – 4.04 (m, 4H), 3.97 – 3.79 (m, 4H), 3.65 (s, 4H), 3.53 – 3.44 (m, 2H), 2.68 – 2.47 (m, 4H), 2.32 – 2.02 (m, 7H), 1.95 – 1.82 (m, 3H), 1.77 – 1.54 (m, 4H), 1.49 – 1.24 (m, 5H), 1.10 – 0.99 (m, 3H), 0.92 – 0.85 (m, 4H).

Example PQ O H H F 1) HCl N N N N N N 2) COMU, H O O MocPhg tert-butyl 2-{(2S,4S)[(difluoromethoxy)methyl]- 1-[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl]pyrrolidinecarboxylate O O HN O H H F O N N N N N N H O HN O methyl {(1R)[2-(5-{2-[(2S,4S)[(difluoromethoxy)methyl]{(2S)- 2-[(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imid azolyl)pyrrolidinyl]oxophenylethyl}carbamate tert-butyl 2-[5-(2-{(2S,4S)[(difluoromethoxy)methyl][N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 1H-imidazolyl]pyrrolidinecarboxylate This compound was made in an analogous manner to tert-butyl 2- {(2S,3aS,6aS)[N-(methoxycarbonyl)-L-valyl]octahydrocyclopenta[b]pyrrolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate substituting (2S,4S)(tert-butoxycarbonyl) ((difluoromethoxy)methyl)pyrrolidinecarboxylic acid for the initial alkylation of 9-bromo- 3-chloro-10,11-dihydro-6H-naphtho[2,3-c]chromen-8(9H)-one. Reactions in the synthesis of utyl 2-[5-(2-{(2S,4S)[(difluoromethoxy)methyl][N-(methoxycarbonyl)-L- valyl]pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]pyrrolidinecarboxylate gave similar product yields as in the synthesis of tert-butyl 2-[5-(2-{(2S,3aS,6aS)[N-(methoxycarbonyl)-L- valyl]octahydrocyclopenta[b]pyrrolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl]pyrrolidinecarboxylate. MS (ESI) m/z 815.04 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.58 (s, 1H), 8.18 (d, 1H), 7.96 – 7.85 (m, 3H), 7.70 (s, 1H), 7.60 (d, 1H), 7.50 – 7.38 (m, 4H), 7.10 (s, 1H), 6.46 (t, 1H), 5.51 (s, 1H), 5.39 – 5.36 (m, 1H), 5.31 – 5.28 (m, 2H), 4.43 – 4.36 (m, 1H), 4.24 (d, 1H), 4.13 – 4.02 (m, 3H), 3.75 – 3.62 (m, 7H), 3.51 – 3.47 (m, 1H), 3.18 – 3.11 (m, 2H), 2.93 – 2.83 (m, 2H), 2.75 – 2.69 (m, 1H), 2.47 – 2.36 (m, 2H), 2.23 – 2.09 (m, 3H), 2.01 – 1.94 (m, 2H), 0.87 (dd, 6H).

Example PR HO N O (1R,5R)(tert- O butoxycarbonyl) Cl Cl azabicyclo[3.1.0]hexane O N Br carboxylic acid Boc 9-bromochloro-10,11-dihydro-5H- (1R,5R)tert-butyl 3-(3-chlorooxodibenzo hromen-8(9H)-one 8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl) 2- azabicyclo[3.1.0]hexane-2,3- dicarboxylate O H NH4OAc O H H MnO2 N N N Cl N Cl Boc N Boc tert-butyl (1R,5R)(9-chloro-1,12- tert-butyl (1R,3S,5R)(9-chloro- dihydrochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 11- 2-azabicyclo[3.1.0]hexanecarboxylate tetrahydroisochromeno[4',3':6,7]naphtho[ 1,2-d]imidazolyl) azabicyclo[3.1.0]hexanecarboxylate O H H 1) HCl N Cl N Pd2dba3 2) HATU O HN O Bis-PinB MocVal XPhos methyl {(2S)[(1R,3S,5R)(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) azabicyclo[3.1.0]hexyl]methyloxobutan yl}carbamate tert-butyl (2S,4S)[5-(2-{(1R,3S,5R)[N-(methoxycarbonyl)-L-valyl] azabicyclo[3.1.0]hexyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate This nd was made in an analogous manner to tert-butyl (2R)[5-(2-{(2S) [N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate substituting (1R,5R)(tert-butoxycarbonyl)azabicyclo[3.1.0]hexane carboxylic acid for the l alkylation of 9-bromochloro-10,11-dihydro-5H- dibenzo[c,g]chromen-8(9H)-one, and substituting (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol- 2-yl)(methoxymethyl)pyrrolidinecarboxylate for the Suzuki-Miyara coupling.

Reactions in the synthesis of tert-butyl (2S,4S)[5-(2-{(1R,3S,5R)[N- (methoxycarbonyl)-L-valyl]azabicyclo[3.1.0]hexyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylategave similar t yields as in the synthesis of tert-butyl (2R)[5-(2-{(2S)[N-(methoxycarbonyl)-L-valyl]pyrrolidinyl}-3,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl]pyrrolidine carboxylate. MS (ESI) m/z 791.0 [M + H]+. methyl {(1R)[(2S,4S)(5-{2-[(1R,3S,5R){(2S)[(methoxycarbonyl)amino] methylbutanoyl}azabicyclo[3.1.0]hexyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate To a solution of tert-butyl (2S,4S)[5-(2-{(1R,3S,5R)[N-(methoxycarbonyl)-L- valyl]azabicyclo[3.1.0]hexyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (0.060 g, 0.076 mmol) in a mixture of CH2Cl2 (0.76 mL) and MeOH (0.15 mL) was added HCl (4M in oxane, 0.570 mL, 2.28 mmol). The solution was d at room temperature for 2 h and concentrated to dryness.

The intermediate was dissolved in CH2Cl2 (0.76 mL). (R) (methoxycarbonylamino)phenylacetic acid (0.024 g, 0.114 mmol) and DIPEA (0.040 mL, 0.228 mmol) were then added to the solution. The reaction mixture was cooled to -40 °C (external temperature, MeCN/CO2(s) bath). COMU (0.052 g, 0.122 mmol) was then added and solution was d to warm to 0 °C over 1.5 h. Upon completion by LCMS, the solution was diluted with DMF and concentrated. The crude product was purified by preparative HPLC i column, 10-45% MeCN/H2O with 0.1% TFA) and lyophilized to provide methyl {(1R)[(2S,4S)(5-{2-[(1R,3S,5R){(2S)[(methoxycarbonyl)amino]- 3-methylbutanoyl}azabicyclo[3.1.0]hexyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (0.028 g, 42%). MS (ESI) m/z 881.8 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.45 – 8.33 (m, 1H), 8.02 – 7.94 (m, 1H), 7.91 – 7.75 (m, 2H), 7.72 – 7.67 (m, 1H), 7.61 (s, 1H), 7.59 – 7.34 (m, 6H), 7.09 – 6.91 (m, 2H), 5.62 – 5.38 (m, 2H), 5.29 (t, 1H), 5.24 – 5.09 (m, 3H), 4.61 (d, 1H), 4.37 – 4.26 (m, 1H), 3.83 – 3.73 (m, 1H), 3.69 – 3.56 (m, 6H), 3.50 – 3.40 (m, 1H), 3.20 – 3.11 (m, 1H), 2.99 (s, 1H), 2.83 (d, 1H), 2.63 – 2.50 (m, 2H), 2.47 – 2.34 (m, 2H), 2.29 – 2.13 (m, 2H), 2.10 – 1.95 (m, 2H), 1.37 – 1.23 (m, 3H), 1.19 – 1.10 (m, 1H), 1.03 – 0.78 (m, 7H).

Example PS O H H F 1) HCl/dioxane N N Boc N N N N Boc 2) MocVal, HATU H H DIPEA, DMF tert-butyl (2S,4S)(9-{2-[(2S,5S)(tertbutoxycarbonyl )methylpyrrolidinyl]-1H- imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)[(difluoromethoxy)methyl]pyrroli dinecarboxylate O O HN O H H O N N N N N N H H O O NH methyl {(2S)[(2S,5S)(5-{2-[(2S,4S) [(difluoromethoxy)methyl]{(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl} idazolyl)methylpyrrolidinyl]methyloxobutan- 2-yl}carbamate utyl (2S,4S)(9-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidinyl]-1H- imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) uoromethoxy)methyl]pyrrolidinecarboxylate This nd was made in an analogous manner to tert-butyl (2S,4S)[5-(2- {(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] xymethyl)pyrrolidinecarboxylate substituting (2S,5S)(tert-butoxycarbonyl) methylpyrrolidinecarboxylic acid for the initial alkylation of 3-(2-bromoacetyl)-10,11- dihydro-5H-dibenzo[c,g]chromen-8(9H)-one, and substituting (2S,4S)(tertbutoxycarbonyl )((difluoromethoxy)methyl)pyrrolidinecarboxylic acid for the other alkylation in the sequence. Reactions in the synthesis of tert-butyl (2S,4S)(9-{2-[(2S,5S)- 1-(tert-butoxycarbonyl)methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) [(difluoromethoxy)methyl]pyrrolidinecarboxylategave similar product yields as in the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 772.03 [M + H]+. methyl {(2S)[(2S,5S)(5-{2-[(2S,4S)[(difluoromethoxy)methyl]{(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate To a solution of tert-butyl (2S,4S)(9-{2-[(2S,5S)(tert-butoxycarbonyl) methylpyrrolidinyl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)[(difluoromethoxy)methyl]pyrrolidinecarboxylate (0.081 g, 0.105 mmol) in a mixture of CH2Cl2 (1.05 mL) and MeOH (0.210 mL) was added HCl (4M in 1,4- dioxane, 0.788 mL, 3.15 mmol). The solution was stirred at room temperature for 2 h and concentrated to dryness.

The intermediate was ved in CH2Cl2 (1.05 mL). (S)(methoxycarbonylamino)- 3-methylbutanoic acid (0.040 g, 0.231 mmol) and DIPEA (0.055 mL, 0.315 mmol) were then added to the solution. HATU (0.176 g, 0.462 mmol) was added and solution was allowed to stir at room temp. Upon completion, the solution was diluted with DMF and concentrated.

The crude product was purified by ative HPLC (Gemini column, 10-45% 2O with 0.1% TFA) and the desired fractions were combined. The solution was concentrated until the aqueous layer ed and aqueous bicarbonate (sat.) was slowly added until the solution was basic. The ing slurry was stirred at room temperature for 2h and filtered.

The resulting solid was dried in vacuo to provide methyl {(2S)[(2S,5S)(5-{2-[(2S,4S)- 4-[(difluoromethoxy)methyl]{(2S)[(methoxycarbonyl)amino] methylbutanoyl}pyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 9-yl}-1H-imidazolyl)methylpyrrolidinyl]methyloxobutanyl}carbamate (0.025 g, 27%). MS (ESI) m/z 886.1 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.49 – 8.25 (m, 2H), 8.08 – 7.82 (m, 2H), 7.79 – 7.27 (m, 5H), 6.45 (t, 1H), 5.36 – 5.26 (m, 1H), 5.22 – .07 (m, 3H), 4.78 – 4.49 (m, 2H), 4.45 – 4.19 (m, 3H), 4.16 – 4.05 (m, 2H), 3.99 – 3.92 (m, 1H), 3.85 – 3.71 (m, 2H), 3.66 (s, 3H), 2.88 – 2.70 (m, 2H), 2.69 – 2.49 (m, 2H), 2.42 – 2.26 (m, 2H), 2.23 – 2.10 (m, 2H), 2.07 – 1.87 (m, 3H), 1.51 (d, 2H), 1.34 – 1.20 (m, 2H), 1.17 – 0.76 (m, 12H).

Example PT O H H N N Boc N 1) HCl/dioxane N N N Boc F H H F 2) , HATU O DIPEA, DMF tert-butyl (2S,4S)(5-{2-[(2S,5S)(tert-butoxycarbonyl)- ylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}- 1H-imidazolyl)[(difluoromethoxy)methyl]pyrroli dinecarboxylate HN O H H O N N N N N N F H H O O NH O O methyl {(2S)[(2S,4S)[(difluoromethoxy)methyl](5-{2-[(2S,5S) {(2S)[(methoxycarbonyl)amino]methylbutanoyl} methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imida zolyl}-1H-imidazolyl)pyrrolidinyl]methyloxobutan yl}carbamate methyl {(2S)[(2S,4S)[(difluoromethoxy)methyl](5-{2-[(2S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol rolidinyl]methyloxobutanyl}carbamate This compound was made in an analogous manner to tert-butyl (2S,4S)[5-(2- {(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate substituting (2S,4S)(tert-butoxycarbonyl) ((difluoromethoxy)methyl)pyrrolidinecarboxylic acid for the initial alkylation of 3-(2- bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one, and substituting (2S,5S) (tert-butoxycarbonyl)methylpyrrolidinecarboxylic acid for the other alkylation in the sequence. Reactions in the synthesis of tert-butyl (2S,4S)(5-{2-[(2S,5S)(tert- butoxycarbonyl)methylpyrrolidinyl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- azolyl}-1H-imidazolyl)[(difluoromethoxy)methyl]pyrrolidine ylategave similar product yields as in the synthesis of tert-butyl (2S,4S)[5-(2- {(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 772.31 [M + H]+. methyl {(2S)[(2S,4S)[(difluoromethoxy)methyl](5-{2-[(2S,5S){(2S) [(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol rolidinyl]methyloxobutanyl}carbamate To tert-butyl (2S,4S)(5-{2-[(2S,5S)(tert-butoxycarbonyl)methylpyrrolidin yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) uoromethoxy)methyl]pyrrolidinecarboxylate (0.057 g, 0.074 mmol) in a mixture of CH2Cl2 (0.739 mL) and MeOH (0.148 mL) was added HCl (4M in 1,4-dioxane, 0.555 mL, 2.218 mmol). The solution was stirred at room temperature for 2 h and concentrated to dryness.

The ediate was dissolved in CH2Cl2 (0.739 mL). (S) (methoxycarbonylamino)methylbutanoic acid (0.028 g, 0.163 mmol) and DIPEA (0.039 mL, 0.222 mmol) were then added to the solution. HATU (0.124 g, 0.325 mmol) was added and solution was allowed to stir at room temp. Upon completion, the solution was diluted with DMF and concentrated. The crude product was purified by ative HPLC (Gemini column, 10-46% MeCN/H2O with 0.1% TFA) and the desired fractions were combined and lyophilized to provide methyl {(2S)[(2S,4S)[(difluoromethoxy)methyl](5-{2- [(2S,5S){(2S)[(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazol yl)pyrrolidinyl]methyloxobutanyl}carbamate (0.011 g, 17%). MS (ESI) m/z 886.1 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.67 – 8.51 (m, 1H), 8.26 – 8.11 (m, 1H), 8.04 – 7.75 (m, 3H), 7.69 – 7.58 (m, 2H), 6.43 (t, 1H), 5.41 – 5.15 (m, 4H), 4.48 – 3.90 (m, 6H), 3.82 (s, 1H), 3.71 – 3.57 (m, 5H), 3.53 – 3.43 (m, 1H), 3.20 – 3.01 (m, 2H), 2.92 – 2.63 (m, 3H), 2.60 – 2.25 (m, 4H), 2.15 – 1.86 (m, 4H), 1.57 (d, 3H), 1.24 (d, 2H), 1.07 (dd, 2H), 0.98 – 0.77 (m, 9H).

Example PU utyl (2S,4S)[5-(2-{(2S,4S)(tert-butoxycarbonyl) [(difluoromethoxy)methyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate This compound was made in an analogous manner to utyl (2S,4S)[5-(2- {(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate substituting (2S,4S)(tert-butoxycarbonyl) (methoxymethyl)pyrrolidinecarboxylic acid for the initial alkylation of 3-(2-bromoacetyl)- ,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one, and substituting (2S,4S)(tertbutoxycarbonyl )((difluoromethoxy)methyl)pyrrolidinecarboxylic acid for the other tion in the sequence. Reactions in the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,4S)- 1-(tert-butoxycarbonyl)[(difluoromethoxy)methyl]pyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate gave similar product yields as in the synthesis of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] (methoxymethyl)pyrrolidinecarboxylate. MS (ESI) m/z 801.1 [M + H]+. methyl {(2S)[(2S,4S)(5-{2-[(2S,4S)[(difluoromethoxy)methyl]{(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) xymethyl)pyrrolidinyl]methyloxobutanyl}carbamate To tert-butyl (2S,4S)[5-(2-{(2S,4S)(tert-butoxycarbonyl) [(difluoromethoxy)methyl]pyrrolidinyl}-1,11 dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)-1H-imidazolyl](methoxymethyl)pyrrolidinecarboxylate (0.092 g, 0.115 mmol) in a mixture of CH2Cl2 (1.15 mL) and MeOH (0.230 mL) was added HCl (4M in 1,4-dioxane, 0.862 mL, 3.446 mmol). The solution was stirred at room temperature for 2 h and concentrated to s.

The intermediate was dissolved in CH2Cl2 (1.149 mL). (S) (methoxycarbonylamino)methylbutanoic acid (0.044 g, 0.253 mmol) and DIPEA (0.060 mL, 0.345 mmol) were then added to the solution. HATU (0.192 g, 0.505 mmol) was added and solution was d to stir at room temp. Upon completion, the solution was diluted with DMF and concentrated. The crude product was purified by preparative HPLC (Gemini column, 10-45% MeCN/H2O with 0.1% TFA) and the desired fractions were combined. The solution was concentrated until the s layer remained and s bicarbonate (sat.) was slowly added until the solution was basic. The resulting slurry was stirred at room temperature for 2h and filtered. The resulting solid was dried in vacuo to provide methyl {(2S)[(2S,4S)(5-{2-[(2S,4S)[(difluoromethoxy)methyl]{(2S) [(methoxycarbonyl)amino]methylbutanoyl}pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate (0.042 g, 40%). MS (ESI) m/z 916.30 [M + H]+. 1H NMR (400 MHz, cd 3od) δ 8.55 – 8.25 (m, 1H), 8.15 – 7.85 (m, 2H), 7.83 – 7.26 (m, 5H), 6.44 (t, 1H), 5.37 – 5.02 (m, 4H), 4.47 – 4.35 (m, 1H), 4.33 – 4.18 (m, 3H), 4.15 – 3.90 (m, 3H), 3.81 – 3.45 (m, 11H), 3.39 (s, 3H), 2.90 – 2.27 (m, 5H), 2.22 – 1.92 (m, 4H), 1.12 – 0.73 (m, 13H).

Example PX (2S,4S)tert-butyl 2-methyl 4-((difluoromethoxy)methyl)pyrrolidine-1,2-dicarboxylate A 100 mL bottom flask was d with (2S,4S)tert-butyl 2-methyl 4- (hydroxymethyl)pyrrolidine-1,2-dicarboxylate (3.33 g, 12.84 mmol), CuI (0.489 g, 2.56 mmol), and anhydrous acetonitrile (57.1 mL). The reaction was heated to 45 °C (ext. oil bath). 2,2-difluoro(fluorosulfonyl)acetic acid (2.655 mL, 25.68 mmol) was added at 45 °C over 30 minutes via syringe pump. The reaction was heated for 30 minutes. Upon completion as monitored by TLC, the on mixture was cooled to room temperature and concentrated in vacuo. The crude residue was diluted in EtOAc and washed with sodium bicarbonate (aq). The bicarbonate layer was back extracted with ethyl e twice.

Combined organic layers were washed with brine, dried over sodium sulphate, filtered and concentrated. The resulting residue was further purified via silica gel tography (10 to 40 % EtOAc/Hexanes) to afford (2S,4S)tert-butyl 2-methyl 4- ((difluoromethoxy)methyl)pyrrolidine-1,2-dicarboxylate (2.41 g, 61%). MS (ESI) m/z 210.21 [M + H - Boc]+. (2S,4S)(tert-butoxycarbonyl)((difluoromethoxy)methyl)pyrrolidinecarboxylic acid To a solution of (2S,4S)tert-butyl 2-methyl 4- ((difluoromethoxy)methyl)pyrrolidine-1,2-dicarboxylate (2.41 g, 7.79 mmol) in a mixture of THF (39 mL) and MeOH (15.6 mL) was added LiOH (2.5 M aqueous, 15.6 mL, 38.9 mmol).

The resulting on was stirred at room temperature for 1h. Upon completion by TLC the reaction mixture was acidified with aqueous HCl (1N). The desired product was extracted with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and trated to provide (2S,4S)(tert-butoxycarbonyl)((difluoromethoxy)methyl)pyrrolidine carboxylic acid (2.4 g, 99%). MS (ESI) m/z 294.96 [M - H]-. 1H-NMR: 400 MHz, (acetoned6 ) δ (mixture of rotamers): 6.50 (t, 1H), 4.36-4.17 (m, 1H), 3.93 (d, 2H), 3.77-3.67 (m, 1H), 3.63-3.59 (m, 1H), 3.26-3.12 (m, 1H), 2.72-2.41 (m, 2H), 1.89-1.73 (m, 2H), 1.41 (s, 9H).

Example PY Methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}(methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate A on of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (150 mg, 0.19 mmol) in 1.25 N HCl in EtOH (3 mL) was stirred ght then heated to 50 °C for 3h. The reaction was concentrated and the crude material dissolved in DMF (2 mL). To this solution was added a solution of (R)(methoxycarbonylamino)phenylacetic acid (52 mg, 0.25 mmol) and COMU (90 mg, 0.21 mmol). To the resulting solution was added diisopropylethylamine (0.099 mL, 0.57 mmol). After ng for 2h at room temperature, the reaction was quenched with 1N HCl (0.200 mL) and purified by HPLC. After lyophilizati on, the TFA salt was dissolved in EtOAc and washed with ted NaHCO3. The organic phase was dried over Na2SO4 and concentrated. The free base was then dissolved in MeCN/H2O and lyophilized to afford methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}(methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate (65 mg, 39%). SI+: calculated for C49H54N8O8: 882.4; observed : 884.1. Diagnostic peaks in NMR 'H NMR (CD3OD): 8.28 (s, 1H), 8.21 (s, 1H), 8.04 (s, 1H), .01 (m, 10H), 3.62 (s, 3H), 3.34 (s, 3H), 3.23 (s, 3H), 1.56 (d, 3H), 1.03 (d, 3H), 0.94 (d, 3H).

Example PY-1 9-bromo(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one To 3-(2-bromohydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (20.3g, 54.4 mmol) in DCM (365 mL) was added MeOH (22 mL) and pyridinium tribromide (18.24 g, 57.0 mmol). After 2h, water was added (100mL) and after briefly ing the layers split and the bottom organic layer was collected. The organic layer was then washed with 1M HCl (100 mL) and the bottom organic layer containing 9-bromo(2-bromo hydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one was collected. 400 MHz 1H NMR (CDCl 3) 7.75 (d, J = 8.1 Hz, 1H), 7.68 (s, 1H), 7.61 (s, 1H), 7.42 (d, J = 7.5 Hz, 1H), 7.24 (s, 1H), 5.13 (s, 2H), 4.99-4.96 (m, 1H), 4.73 (dd, J = 4.1, 4.1 Hz, 1H), 3.69-3.66 (m, 1H), 3.58-3.53 (m, 1H), 3.35-3.27 (m, 1H), 2.96-2.90 (m, 1H), 2.58-2.44 (m, 2H), C-OH not observed.

To 9-bromo(2-bromohydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen- 8(9H)-one (approx. 54.4 mmol) in DCM (365mL) was added sodium bicarbonate (5.45 g), sodium bromide (6.14 g), TEMPO (16.55 mg) and water (60 mL). The solution was cooled between 0-5 °C and 6% bleach (91.5 mL) was added. After 1h isopropyl alcohol (20 mL) was added and the reaction mixture was warmed to room temperature. Agitation was stopped, the layers separated and the lower organic layer was collected and concentrated removing approximately 345 g of solvent. The slurry was filtered and the cake washed with 50 mL water and then 50 mL DCM (pre-cooled to 5 °C). The solids were collected and dried under vacuum to obtain 9-bromo(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen- 8(9H)-one (18.6 g, 76% yield). 400 MHz 1H NMR (CDCl 3) δ 8.03-8.01 (m, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.82 (s, 1H), 7.71 (s, 1H), 7.67 (s, 1H), 5.19 (s, 2H), 4.74 (dd, J = 4.1, 4.1 Hz, 1H), 4.45 (s, 2H), 3.37-3.29 (m, 1H), .92 (m,1H), 2.59-2.46 (m, 2H); 100 MHz 13C NMR (CDCl3) δ 190.4, 189.6, 154.2, 136.6, 134.1, 133.9, 132.9, 131.8, 129.3, 127.2, 125.6, 124.2, 123.3, 117.0, 68.1, 49.9, 31.8, 30.4, 25.5.

Example PY-2 o(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one A mixture of 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (2.58 g, 6.95 mmol), pyridinium tribromide (2.56 g, 8.0 mmol), dichloromethane (22mL) and methanol (2.5mL) was stirred at about 20°C for 3 hours to obtain a . The precipitated product was filtered , washed with dichloromethane (10mL) and dried in a vacuum oven at 40°C to give 9-bromo(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (2.62 g, 84% . 400 MHz 1H NMR (CDCl 3) δ 8.03-8.01 (m, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.82 (s, 1H), 7.71 (s, 1H), 7.67 (s, 1H), 5.19 (s, 2H), 4.74 (dd, J = 4.1, 4.1 Hz, 1H), 4.45 (s, 2H), 3.37-3.29 (m, 1H), 2.99-2.92 (m,1H), 2.59-2.46 (m, 2H).

Example PY-3 O O O TMS H O TFA, H2O Cl TMS PdCl2(MeCN)2, X-Phos 65 °C K3PO4, MeCN, 65 °C 3-chloro-10,11-dihydro- 3-((trimethylsilyl)ethynyl)- 5H- 10,11-dihydro-5H- dibenzo[c,g]chromen- dibenzo[c,g]chromen-8(9H)- 8(9H)-one one O O O O PyHBr3 O O Me DCM, MeOH Br Br °C 3-acetyl-10,11-dihydro- 9-bromo(2-bromoacetyl)-10,11- 5H- dihydro-5H-dibenzo[c,g]chromendibenzo [c,g]chromen- 8(9H)-one 8(9H)-one 3-((trimethylsilyl)ethynyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one A 300 mL flask equipped with an overhead stirrer and a reflux condenser under an atmosphere of nitrogen was charged with ro-10,11-dihydro-5H-dibenzo[c,g]chromen- 8(9H)-one (10.0g, 35.12 mmol), powdered anhydrous tripotassium ate (22.4 g, 105.4 mmol), XPhos (1.34 g, 2.81 mmol), and PdCl2(MeCN)2 (364 mg, 1.40 mmol). Acetonitrile (140 mL) was added followed by tylene (18 mL, 141 mmol). The e was heated to 65 °C. After 6h, the reaction was judged complete, and the mixture was cooled to 20 °C. The mixture was filtered through a fritted , and the filtercake was washed with acetonitrile. The filtrate was concentrated to about 150 mL under reduced pressure and extracted with heptane (50 mL, 3×100 mL). N-Acetyl cysteine (15 g) was added to the acetonitrile phase, and the mixture was agitated for 5 h at 45 °C. The e was cooled to ambient temperature, filtered through a fritted funnel, and the filtercake was washed with acetonitrile. The filtrate was concentrated to about 120 mL under reduced pressure. Water (120 mL) was added and the mixture was agitated for 40 minutes at 45 °C and then cooled to ambient temperature. After 30 minutes the mixture was ed through a d funnel to provide 3-((trimethylsilyl)ethynyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (4.07 g, 33.4% yield ) as a yellow solid: 400 MHz 1H NMR (CDCl 3) δ 7.65 (d, J = 8.1 Hz, 1H), 7.60 (s, 1H), 7.55 (s, 1H), 7.47 (dd, J = 8.1, 1.4 Hz, 1H), 7.27 (s, 1H), 5.06 (s, 2H), 2.95 (t, J = 6.1 Hz, 2H), 2.67 – 2.59 (m, 2H), 2.18 – 2.08 (m, 2H), 0.26 (s, 9H). 3-acetyl-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one A 20 mL vial with stir bar was charged with 3-((trimethylsilyl)ethynyl)-10,11- dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (850 mg, 2.44 mmol) and TFA (9.8 mL). The on was heated to 65 °C. After 3 h, the reaction was judged complete. The mixture was concentrated under reduced pressure; the resulting residue was taken up in CH2Cl2 and loaded onto a prepacked 25g silica gel dge. The product was purified by chromatography on a ked 80g silica gel column eluting with a solvent gradient from 5% to 85% EtOAc/hexanes. The product containing fractions were combined and concentrated to provide 3-acetyl-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (616 mg, 86%): 400 MHz 1H NMR (CDCl 3) δ 8.00 – 7.94 (m, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.77 (s, 1H), 7.64 (s, 2H), 5.16 (s, 2H), 2.98 (t, J = 6.1 Hz, 2H), 2.69 – 2.64 (m, 2H), 2.63 (s, 3H), 2.21 – 2.09 (m, 2H). 9-bromo(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one A 20 mL vial with a stir bar was charged with 3-acetyl-10,11-dihydro-5H- dibenzo[c,g]chromen-8(9H)-one (100 mg, 0.366 mmol), 9:1 CH2Cl2/MeOH (3.4 mL) and nium tribromide (246 mg, 0.769 mmol). The solution was heated to 35 °C. After 30 minutes, the reaction was judged complete. The mixture was cooled to ambient temperature, diluted with EtOAc (50 mL) and tially washed with saturated aqueous Na2S2O3 (20 mL), 2% aqueous NaHCO3 (20 mL), water (20 mL), and brine (10 mL). The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure resulting in 9- bromo(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (68 mg, 41%): 400 MHz 1H NMR (CDCl 3) δ 8.03 - 8.01 (m, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.82 (s, 1H), 7.71 (s, 1H), 7.67 (s, 1H), 5.19 (s, 2H), 4.74 (dd, J = 4.1, 4.1 Hz, 1H), 4.45 (s, 2H), 3.37-3.29 (m, 1H), 2.99 - 2.92 (m,1H), 2.59 - 2.46 (m, 2H).

Example PY-4 (2S, 5S)(2-(9-bromooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate o(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (1.43 g, 3.17 mmol) was treated with a solution of (2S,5S)(tert-butoxycarbonyl) methylpyrrolidinecarboxylic acid (800 mg, 3.49 mmol) in dichloromethane (14 mL) and K2CO3 (658 mg, 1.18 mmol). The stirred reaction mixture was stirred at RT and d with CH2Cl2 and extracted 3X. The organic phase was washed with brine, then dried over MgSO4, filtered and concentrated under reduced pressure to afford ((2S,5S)(2-(9-bromooxo- 8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl)oxoethyl) 1-tert-butyl 5- methylpyrrolidine-1,2-dicarboxylate (1.61 g, 84%).

This synthesis may be used to make a variety of compounds described herein, ing the compound exemplified in PY.

Example PZ Methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}(methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate Tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (100 mg, 0.13 mmol) in 1.25 N HCl in EtOH (3 mL) was heated to 50 °C for 3h and then concentrated under reduced pressure. The crude residue was treated with (S)(methoxycarbonylamino) methylbutanoic acid (34 mg, 0.20 mmol), HATU (54 mg, 0.14 mmol) and DMF (1.3 mL), then ylmorpholine (0.043 mL, 0.39 mmol) was added dropwise. After 3h, the e was quenched with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(2S) [(2S,5S)(9-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methylbutanoyl} (methoxymethyl)pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate ( 91 mg, 82%).

LCMS-ESI+: calculated for C46H56N8O8: 848.4; observed [M+1]+: 850.2.

Example QA 1. HCl O H 2. HATU, NMM, DMF Boc N N N N N N O O O H HO N N O O H O H tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] (2S,3R)methoxy methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- (methoxycarbonylamino) azolyl)-1H-imidazolyl](methoxymethyl)pyrrolidine ic acid carboxylate O N O H N N N O N N N O N H O methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S,3S)methoxy [(methoxycarbonyl)amino]butanoyl}(methoxymethyl)pyrrolidin yl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate Methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S,3S)methoxy [(methoxycarbonyl)amino]butanoyl}(methoxymethyl)pyrrolidinyl]-1H-imidazol 11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidin- 1-yl]methyloxobutanyl}carbamate Tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl](methoxymethyl)pyrrolidinecarboxylate (119 mg, 0.15 mmol) in 1.25 N HCl in EtOH (3 mL) was heated to 50 °C for 3h and then concentrated under reduced pressure. The crude residue was treated with (2S,3R)methoxy (methoxycarbonylamino)butanoic acid (43 mg, 0.23 mmol), HATU (63 mg, 0.17 mmol) and DMF (2 mL), then N-methylmorpholine (0.050 mL, 0.45 mmol) was added dropwise. After 3 hr, the mixture was ed with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S,3S)methoxy [(methoxycarbonyl)amino]butanoyl}(methoxymethyl)pyrrolidinyl]-1H-imidazolyl}- ihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate ( 76 mg, 59%).

LCMS-ESI+: calculated for C46H56N8O9: 864.4; observed [M+1]+: 866.1.

Example QB 1. HCl Boc N 2. HATU, DIPEA N Br O H HO N O (2S,4S)-tert-butyl 2-(5-bromo-1H- ) imidazolyl)methylpyrrolidine (methoxycarbonylamino) carboxylate methylpentanoic acid O NH O H O O N N N N + N O N Br Boc (2S,4S)-tert-butyl 4-(methoxymethyl)(9-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)- 1,11- methyl (2S,3S)((2S,4S)(5-bromo-1H- dihydroisochromeno[4',3':6,7]naphtho[1,2- imidazolyl)methylpyrrolidinyl) d]imidazolyl)pyrrolidinecarboxylate methyloxopentanylcarbamate Methyl (2S,3S)((2S,4S)(5-bromo-1H-imidazolyl)methylpyrrolidinyl) methyloxopentanylcarbamate (2S,4S)-tert-butyl 2-(5-bromo-1H-imidazolyl)methylpyrrolidinecarboxylate (100 mg, 0.13 mmol) in 1.25 N HCl in EtOH (15 mL) was heated to 50 °C for 3h and then concentrated under reduced pressure. The crude e was treated with (2S,3S) (methoxycarbonylamino)methylpentanoic acid (625 mg, 3.30 mmol), HATU (1.05 g, 2.77 mmol) and DMF (10 mL), then DIPEA (1.33 mL, 7.62 mmol) was added dropwise. After 2h, the mixture was poured into ted aqueous NaHCO3 and then extracted with EtOAc. The c phase was washed successively with 5% aqueous LiCl and Brine. The organics were dried over Na2SO4, ed and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (30 to 90% of 10%MeOH/EtoAc to Hexanes) afforded methyl (2S,3S)((2S,4S)(5-bromo-1H-imidazolyl)methylpyrrolidinyl)- 3-methyloxopentanylcarbamate ( 932 mg, 81%).

Tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-alloisoleucyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (methoxymethyl)pyrrolidinecarboxylate )-Tert-butyl 4-(methoxymethyl)(9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)pyrrolidine carboxylate (856 mg, 1.4 mmol), methyl (2S,3S)((2S,4S)(5-bromo-1H-imidazolyl)- 4-methylpyrrolidinyl)methyloxopentanylcarbamate (932 mg, 2.1 mmol), Pd(PPh3)4 (162 mg, 0.14 mmol), PdCl2(dppf)2 (102 mg, 0.14 mmol), and K2CO3 (2M in H2O, 2.31 mL, 4.62 mmol) were combined in DMSO (8 mL) and dioxanes (8 mL). The mixture was degassed with bubbling Argon for 10 min then heated to 95 ˚C for 1h. After cooling, the reaction mixture was diluted with EtOAc, and washed successively with saturated aqueous NaHCO3 and brine. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was ed by silica column chromatography (1% to % MeOH/EtOAc) to afford tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)- L-alloisoleucyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate (701 mg, 62%).

Methyl {(1R)[(2S,4S)(9-{2-[(2S,4S){(2S,3R)[(methoxycarbonyl)amino] pentanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate A solution of tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L- alloisoleucyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl](methoxymethyl)pyrrolidine carboxylate (218 mg, 0.27 mmol) in 1.25 N HCl in EtOH (3 mL) was heated to 50 °C for 3h.

The reaction was concentrated and the crude material dissolved in DMF (3 mL). To this solution was added a solution of (R)(methoxycarbonylamino)phenylacetic acid (73 mg, 0.35 mmol) and COMU (127 mg, 0.30 mmol). To the resulting solution was added diisopropylethylamine (0.141 mL, 0.81 mmol). After stirring for 2h at room temperature, the reaction was quenched with 1N HCl (0.200 mL) and purified by HPLC. After lization, the TFA salt was dissolved in EtOAc and washed with ted NaHCO3. The organic phase was dried over Na2SO4 and concentrated. The free base was then dissolved in 2O and lyophilized to afford methyl {(1R)[(2S,4S)(9-{2-[(2S,4S){(2S,3R)- 2-[(methoxycarbonyl)amino]methylpentanoyl}methylpyrrolidinyl]-1H-imidazol yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]oxophenylethyl}carbamate (121 mg, 50%). LCMS-ESI+: calculated for C50H56N8O8: 896.4; observed [M+1]+: 897.5.

Example QC H O O N O H O N N 1. HCl N N 2. HATU, NMM N Boc H O N O tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L- O alloisoleucyl]methylpyrrolidinyl}-1H-imidazolyl)-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl] (S) (methoxymethyl)pyrrolidinecarboxylate (methoxycarbonylamino) butanoic acid H O O N O H N N N N N N H O methyl {(2S)[(2S,4S)(9-{2-[(2S,4S){(2S,3R) [(methoxycarbonyl)amino]methylpentanoyl}methylpyrrolidinyl]- 1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)(methoxymethyl)pyrrolidinyl]methyl oxobutanyl}carbamate Methyl {(2S)[(2S,4S)(9-{2-[(2S,4S){(2S,3R)[(methoxycarbonyl)amino] methylpentanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-alloisoleucyl] pyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate (105 mg, 0.13 mmol) in 1.25 N HCl in EtOH (3 mL) was heated to 50 °C for 3h and then trated under reduced pressure. The crude residue was treated with (S)(methoxycarbonylamino) methylbutanoic acid (32 mg, 0.18 mmol), HATU (59 mg, 0.16 mmol) and DMF (1.3 mL), then N-methylmorpholine (0.043 mL, 0.39 mmol) was added dropwise. After 3h, the mixture was quenched with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(2S) [(2S,4S)(9-{2-[(2S,4S){(2S,3R)[(methoxycarbonyl)amino]methylpentanoyl} methylpyrrolidinyl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)(methoxymethyl)pyrrolidinyl]methyloxobutanyl}carbamate ( 80 mg, 71%).

LCMS-ESI+: calculated for C47H58N8O8: 862.4; observed [M+1]+: 864.2.

Example QD Methyl {(2S,3R)[(2S,4S)(5-{2-[(2S,4S)[N-(methoxycarbonyl)-O-methyl-L- allothreonyl](methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxopentanyl}carbamate tert-butyl (2S,4S)[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-alloisoleucyl] methylpyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate (105 mg, 0.13 mmol) in 1.25 N HCl in EtOH (3 mL) was heated to 50 °C for 3h and then concentrated under reduced pressure. The crude residue was treated with (2S,3R)methoxy xycarbonylamino)butanoic acid (35 mg, 0.18 mmol), HATU (59 mg, 0.16 mmol) and DMF (1.3 mL), then ylmorpholine (0.043 mL, 0.39 mmol) was added dropwise. After 3 hr, the mixture was quenched with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(2S,3R)[(2S,4S)(5-{2-[(2S,4S)[N-(methoxycarbonyl)-O-methyl-L- allothreonyl](methoxymethyl)pyrrolidinyl]-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl}-1H-imidazolyl) methylpyrrolidinyl]methyloxopentanyl}carbamate ( 92 mg, 81%).

LCMS-ESI+: calculated for C47H58N8O9: 878.4; observed [M+1]+: 879.3. e QE Methyl {(3R)[(2S,4S)(9-{2-[(2S,4S){(2S,3R)[(methoxycarbonyl)amino] methylpentanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) (methoxymethyl)pyrrolidinyl]methyloxopentanyl}carbamate tert-butyl )[9-(2-{(2S,4S)[N-(methoxycarbonyl)-L-alloisoleucyl] pyrrolidinyl}-1H-imidazolyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl](methoxymethyl)pyrrolidinecarboxylate (105 mg, 0.13 mmol) in 1.25 N HCl in EtOH (3 mL) was heated to 50 °C for 3h and then concentrated under reduced pressure. The crude residue was treated with (2S,3S)(methoxycarbonylamino) methylpentanoic acid (34 mg, 0.18 mmol), HATU (59 mg, 0.16 mmol) and DMF (1.3 mL), then N-methylmorpholine (0.043 mL, 0.39 mmol) was added dropwise. After 3h, the mixture was quenched with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(3R) [(2S,4S)(9-{2-[(2S,4S){(2S,3R)[(methoxycarbonyl)amino]methylpentanoyl} methylpyrrolidinyl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)(methoxymethyl)pyrrolidinyl]methyloxopentanyl}carbamate ( 98 mg, 86%).

LCMS-ESI+: calculated for N8O8: 876.5; observed [M+1]+: 878.2.

Example QF O H Pd(PPh3)4, O N N O O Pd(dppf)2Cl2, K2CO3 B N O N N Br DME O + N 85 °C H N O O (2S,4S)-tert-butyl 2-(5-bromo-1H- methyl [(2S)methyl{(2S,5S)methyl[9- imidazolyl)methylpyrrolidine ,5-tetramethyl-1,3,2-dioxaborolanyl)- carboxylate 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl]pyrrolidinyl}oxobutan yl]carbamate O N O H N N N N N N H N O methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2R) [(methoxycarbonyl)amino]phenylacetyl} methylpyrrolidinyl]-1H-imidazolyl}-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- -methylpyrrolidinyl]methyloxobutan yl}carbamate (2S,5S)tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen yl) ylpyrrolidine-1,2-dicarboxylate To a solution of ochloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)- one (1.41 g, 3.88 mmol) in MeCN (17 mL) was added (2S,5S)(tert-butoxycarbonyl) methylpyrrolidinecarboxylic acid (980 mg, 4.27 mmol) and DIPEA (1.49 mL, 8.54 mmol).

After stirring for 18 h at 50 °C, the solution was diluted with EtOAc and washed successively with 1N HCl, saturated aqueous NaHCO3 and brine. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column tography (10% to 30% EtOAc/hexanes) to afford (2S,5S)tert-butyl 2-(3- chlorooxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromenyl) 5-methylpyrrolidine-1,2- dicarboxylate (1.63 g, 81%). (2S,5S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H-naphtho[c,g]chromeno[8,9-d]imidazol yl)(methyl)pyrrolidinecarboxylate (2S,5S)tert-butyl 2-(3-chlorooxo-8,9,10,11-tetrahydro-5H- dibenzo[c,g]chromenyl) 5-methylpyrrolidine-1,2-dicarboxylate (1.63 g, 3.18 mmol) was added toluene (30 mL), 2-methoxyethanol (3 mL), and ammonium acetate (3.68 g, 77.1 mmol) and the solution was heated to reflux overnight. The following morning, the solution was cooled to rt and was diluted with EtOAc and washed successively with water, saturated aqueous NaHCO3 and brine. The organics were dried over Na2SO4, ed and concentrated under reduced pressure. The crude residue was ed by silica column chromatography (40% to 80 % EtOAc/hexanes) to afford (2S,5S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)methylpyrrolidinecarboxylate (1.13 g, 72%). ((2S,5S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl) methylpyrrolidinecarboxylate To a solution of (2S,5S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H- naphtho[c,g]chromeno[8,9-d]imidazolyl)(methyl)pyrrolidinecarboxylate (1.13 g, 2.3 mmol) in CH2Cl2 (25 mL) was added MnO2 (9.98 g, 115 mmol). The reaction mixture was stirred overnight then filtered over celite. The filter cake was washed with copious CH2Cl2 and MeOH, and the filtrate was concentrated under reduced pressure to afford the crude product (2S,5S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl) methylpyrrolidinecarboxylate (931 mg, 83%).

Methyl {(2S)[(2S,5S)(9-chloro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)methylpyrrolidinyl]methyloxobutanyl}carbamate (2S,5S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazolyl) pyrrolidinecarboxylate (931 mg, 1.9 mmol) in 1.25 N HCl in EtOH (8 mL) was heated to 50 °C for 3h and then trated under reduced re. The crude residue was treated with (S)(methoxycarbonylamino)methylbutanoic acid (499 mg, 2.9 mmol), HATU (795 mg, 2.1 mmol) and DMF (10 mL), then N-methylmorpholine (0.627 mL, 5.7 mmol) was added dropwise. After stirring for 1 h, the reaction was diluted with EtOAc and washed successively with saturated s NaHCO3, 5% LiCl, and brine. The organics were dried over Na2SO4, filtered and trated under reduced pressure. The crude residue was purified by silica column chromatography (50% to 100% EtOAc/hexanes) to afford methyl {(2S)[(2S,5S)(9-chloro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol methylpyrrolidinyl]methyloxobutanyl}carbamate (950 mg, 91%).

Methyl [(2S)methyl{(2S,5S)methyl[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl]pyrrolidinyl} oxobutanyl]carbamate To methyl {(2S)[(2S,5S)(9-chloro-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate (950 mg, 1.74 mmol) in dioxane (17 mL) was added bis(pinacolato)diboron (662 mg, 2.61 mmol), KOAc (512 mg, 5.22 mmol), X-Phos (25 mg, 0.05 mmol), and Pd2dba3 (80 mg, 0.08 mmol). The on was degassed with N2 for 10 min, then heated to 90 °C for 16 h. The on was cooled to rt, diluted with EtOAc, washed with ted aqueous , brine, dried with Na2SO4, and trated.

Purification by silica gel chromatography (30% to 75 % gradient using 5%MeOH/EtOAc to Hexanes) to afford methyl [(2S)methyl{(2S,5S)methyl[9-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}oxobutanyl]carbamate (800 mg, 72%). tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidin- 2-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazol yl]methylpyrrolidinecarboxylate To a solution of [(2S)methyl{(2S,5S)methyl[9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolanyl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl]pyrrolidinyl}oxobutanyl]carbamate (269 mg, 0.42 mmol), (2S,4S)-tert-butyl 2-(5- bromo-1H-imidazolyl)methylpyrrolidinecarboxylate (206 mg, 0.54 mmol), tetrakis(triphenylphosphine) palladium(0) (49 mg, 0.042 mmol) and dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(II) (31 mg, 0.042 mmol) in DMSO (3 mL) and dioxanes (3 mL) was added a solution of potassium ate (2M in water, 0.69 mL, 1.39 mmol). The resulting mixture was degassed and then heated to 95 °C for 2h. After cooling to room temperature, the reaction was diluted with ethyl acetate. The organics were washed with saturated sodium bicarbonate and brine, dried over Na2SO4 and concentrated. The crude residue was purified by flash chromatography (1 to 20% MeOH/EtOAc) to yield tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H-imidazolyl] methylpyrrolidinecarboxylate (202 mg, 63%).

Methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate A solution of tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] pyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]methylpyrrolidinecarboxylate (80 mg, 0.11 mmol) in 1.25 N HCl in EtOH (2 mL) was heated to 50 °C for 3h. The reaction was concentrated and the crude material ved in DMF (1.5 mL). To this solution was added a solution of (R) (methoxycarbonylamino)phenylacetic acid (29 mg, 0.14 mmol) and COMU (52 mg, 0.12 mmol). To the resulting solution was added diisopropylethylamine (0.057 mL, 0.33 mmol).

After stirring for 2h at room temperature, the reaction was ed with 1N HCl (0.200 mL) and purified by HPLC. After lyophilization, the TFA salt was dissolved in EtOAc and washed with saturated NaHCO3. The organic phase was dried over Na2SO4 and concentrated. The free base was then dissolved in MeCN/H2O and lyophilized to afford methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2R)[(methoxycarbonyl)amino] phenylacetyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- oisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate: (42 mg, 45%). LCMS-ESI+: calculated for C48H52N8O7: 852.4; observed [M+1]+: 854.2. e QG O H Boc 1. HCl N N N N N N 2. HATU, O NMM H O H N O HO N O O O H (S) tert-butyl (2S,4S)[5-(2-{(2S,5S)[N- (methoxycarbonylamino) (methoxycarbonyl)-L-valyl]methylpyrrolidinyl}-1,11- methylbutanoic acid dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)- 1H-imidazolyl]methylpyrrolidinecarboxylate O N O H N N N N N N H N O methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S) [(methoxycarbonyl)amino]methylbutanoyl} methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol yl)methylpyrrolidinyl]methyloxobutan yl}carbamate Methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino] methylbutanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate tert-butyl )[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]methylpyrrolidinecarboxylate (60 mg, 0.079 mmol) in 1.25 N HCl in EtOH (2 mL) was heated to 50 °C for 3h and then concentrated under reduced pressure. The crude residue was treated with (S)(methoxycarbonylamino)methylbutanoic acid (21 mg, 0.12 mmol), HATU (36 mg, 0.095 mmol) and DMF (1.5 mL), then N-methylmorpholine (0.027 mL, 0.24 mmol) was added dropwise. After 3h, the mixture was quenched with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(2S)[(2S,5S)(9-{2- [(2S,4S){(2S)[(methoxycarbonyl)amino]methylbutanoyl}methylpyrrolidinyl]- dazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) pyrrolidinyl]methyloxobutanyl}carbamate ( 33 mg, 51%).

LCMS-ESI+: calculated for C45H54N8O7: 818.4; observed [M+1]+: 820.2.

Example QH O H 1. HCl BocN N N 2. HATU, NMM, DMF N N N (2S,3R)methoxy H (methoxycarbonylamino)butanoic acid H O tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L- valyl]methylpyrrolidinyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- olyl]methylpyrrolidinecarboxylate O N O H N N N O N N N H O methyl {(2S)[(2S,5S)(9-{2-[(2S,4S){(2S,3R) methoxy[(methoxycarbonyl)amino]butanoyl} pyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl) methylpyrrolidinyl]methyloxobutanyl}carbamate Methyl 1-[(2S,5S)(9-{2-[(2S,4S){(2S,3R)methoxy [(methoxycarbonyl)amino]butanoyl}methylpyrrolidinyl]-1H-imidazolyl}-1,11- dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)methylpyrrolidinyl] methyloxobutanyl}carbamate tert-butyl (2S,4S)[5-(2-{(2S,5S)[N-(methoxycarbonyl)-L-valyl] methylpyrrolidinyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazolyl)-1H- imidazolyl]methylpyrrolidinecarboxylate (20 mg, 0.079 mmol) in 1.25 N HCl in EtOH (2 mL) was heated to 50 °C for 3h and then concentrated under d pressure. The crude residue was treated with (2S,3R)methoxy(methoxycarbonylamino)butanoic acid (8 mg, 0.04 mmol), HATU (12 mg, 0.03 mmol) and DMF (0.5 mL), then N- methylmorpholine (0.009 mL, 0.078 mmol) was added dropwise. After 3h, the mixture was quenched with 1N HCl (0.100 mL) and then purified by HPLC to afford methyl {(2S) [(2S,5S)(9-{2-[(2S,4S){(2S)[(methoxycarbonyl)amino]methylbutanoyl} methylpyrrolidinyl]-1H-imidazolyl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- d]imidazolyl)methylpyrrolidinyl]methyloxobutanyl}carbamate ( 7.5 mg, %).

LCMS-ESI+: calculated for C45H54N8O8: 834.4; observed [M+1]+: 835.7.

Compounds 478-647 Using procedures similar to those described herein, the following compounds of the disclosure were ed.

# Compound LCMS (observed (M+H)+) 478 879.4 493 838.2 494 837.3 495 835.73 498 835.34 499 823.35 503 837.35 507 865.32 510 880.0 516 836.04 518 803.2 526 806.11 536 838.29 588 842.10 602 847.99 603 822.02 617 854.19 626 885.80 643 878.15 O H O H H 646 N O N N O N O 881.66 N N O O H O BIOLOGICAL ASSAYS Effect of serum proteins on replicon potency: on assays are conducted in normal cell culture medium (DMEM + 10%FBS) supplemented with logic concentrations of human serum n (40 mg/mL) or α-acid glycoprotein (1 mg/mL).

EC50s in the presence of human serum proteins are compared to the EC50 in normal medium to determine the fold shift in potency.

MT-4 Cell Cytotoxicity: MT4 cells are treated with serial dilutions of compounds for a five day period. Cell viability is measured at the end of the treatment period using the Promega CellTiter-Glo assay and non-linear regression is performed to calculate CC50.

Compound Concentration ated with Cells at EC50: Huh-luc cultures are incubated with compound at concentrations equal to EC50. At multiple time points (0 – 72 , cells are washed 2X with cold medium and extracted with 85% acetonitrile; a sample of the media at each time-point will also be extracted. Cell and media ts are analyzed by LC/MS/MS to determine the Molar concentration of compounds in each on.

Representative compounds of the disclosure have shown ty.

Solubility and Stability: Solubility is determined by taking an aliquot of 10 mM DMSO stock solution and preparing the compound at a final concentration of 100 µM in the test media solutions (PBS, pH 7.4 and 0.1 N HCl, pH 1.5) with a total DMSO concentration of 1%. The test media solutions are incubated at room temperature with shaking for 1 hr.

The solutions will then be centrifuged and the recovered supernatants are assayed on the HPLC/UV. Solubility will be calculated by comparing the amount of compound detected in the defined test on ed to the amount detected in DMSO at the same concentration. Stability of compounds after an 1 hour incubation with PBS at 37°C will also be determined.

Stability in eserved Human, Dog, and Rat Hepatocytes: Each compound is incubated for up to 1 hour in hepatocyte suspensions (100 µl, 80,000°Cells per well) at 37°C. Cryopreserved hepatocytes are reconstituted in the serum-free incubation medium.

The suspension is transferred into 96-well plates (50 µL/well). The compounds are diluted to 2 µM in incubation medium and then are added to hepatocyte suspensions to start the incubation. Samples are taken at 0, 10, 30 and 60 minutes after the start of incubation and on will be quenched with a mixture consisting of 0.3% formic acid in 90% acetonitrile/10% water. The concentration of the compound in each sample is analyzed using LC/MS/MS. The disappearance half-life of the nd in hepatocyte suspension is determined by fitting the concentration-time data with a monophasic exponential equation.

The data will also be scaled up to represent intrinsic hepatic clearance and/or total hepatic clearance.

Stability in Hepatic S9 Fraction from Human, Dog, and Rat: Each compound is incubated for up to 1 hour in S9 suspension (500 µl, 3 mg protein/mL) at 37°C (n = 3). The compounds are added to the S9 suspension to start the incubation. Samples are taken at 0, 10, , and 60 minutes after the start of incubation. The concentration of the compound in each sample is analyzed using MS. The disappearance half-life of the compound in S9 suspension is determined by fitting the concentration-time data with a monophasic ntial equation.

Caco-2 Permeability: Compounds are assayed via a contract service (Absorption Systems, Exton, PA). nds are provided to the contractor in a blinded manner. Both forward (A-to-B) and reverse A) permeability will be measured. Caco-2 monolayers are grown to ence on collagen-coated, microporous, polycarbonate membranes in 12- well Costar TRANSWELL® plates. The compounds are dosed on the apical side for forward permeability B), and are dosed on the basolateral side for reverse permeability (B-to- A). The cells are ted at 37°C with 5% CO2 in a humidified incubator. At the beginning of incubation and at 1 hr and 2 hr after incubation, a 200-µL aliquot is taken from the receiver chamber and replaced with fresh assay buffer. The concentration of the nd in each sample is determined with LC/MS/MS. The apparent permeability, Papp, is calculated.

Plasma Protein Binding: Plasma protein binding is measured by equilibrium dialysis. Each compound is spiked into blank plasma at a final concentration of 2 µM. The spiked plasma and phosphate buffer is placed into opposite sides of the assembled dialysis cells, which will then be d slowly in a 37°C water bath. At the end of the incubation, the concentration of the compound in plasma and phosphate buffer is determined. The percent unbound is calculated using the following equation:  C  % Unbound = 100  f  Cb  C Where Cf and Cb are free and bound concentrations determined as the post-dialysis buffer and plasma concentrations, respectively.

CYP450 Profiling: Each nd is incubated with each of 5 recombinant human CYP450 enzymes, ing CYP1A2, CYP2C9, CYP3A4, CYP2D6 and CYP2C19 in the presence and absence of NADPH. Serial samples will be taken from the incubation mixture at the beginning of the incubation and at 5, 15, 30, 45 and 60 minutes after the start of the tion. The concentration of the compound in the incubation mixture is determined by LC/MS/MS. The percentage of the compound ing after incubation at each time point is calculated by comparing with the sampling at the start of incubation.

Stability in Rat, Dog, Monkey and Human Plasma: Compounds will be ted for up to 2 hours in plasma (rat, dog, , or human) at 37°C. Compounds are added to the plasma at final concentrations of 1 and 10 µg/mL. Aliquots are taken at 0, 5, 15, 30, 60, and 120 s after adding the compound. Concentration of compounds and major metabolites at each time point are measured by LC/MS/MS.

Evaluation of ased anti-HCV activity: Antiviral potency (EC50) was determined using a Renilla rase -based HCV replicon reporter assay. To perform the assay for pe 1 and 2a JFH-1, stable HCV 1a RLuc replicon cells (harboring a dicistronic genotype 1a H77 replicon that encodes a RLuc reporter), stable HCV 1b RLuc replicon cells (harboring a dicistronic genotype 1b Con1 on that encodes a RLuc reporter), or stable HCV 2a JFH-1 Rluc replicon cells (harboring a dicistronic genotype 2a JFH-1 replicon that encodes a RLuc reporter; with L31 present in NS5A) were dispensed into 384-well plates for EC50 assays. To perform the assay for genotype 2a (with M31 present in NS5A) or 2b, NS5A chimeric genotype 2a JFH-1 replicons that encodes a RLuc-Neo reporter and either genotype 2a J6 strain NS5A gene or genotype 2b MD2b-1 strain NS5A gene (both with M31 present) respectively, were either transiently transfected (t) into Huh- Lunet cells or were established as stably replicating replicon cells (s) is provided. Either cells were dispensed into 384-well plates for EC50 assays. To perform the assay for genotype 3 and 4, NS5A chimeric genotype 1b Con1 replicons that encodes a Pi-RLuc reporter and either genotype 3a S52 strain NS5A gene or genotype 4a ED43 strain NS5A gene respectively, were ently transfected (t) into Huh-Lunet cells, which were uently dispensed into 384-well plates. Compounds were dissolved in DMSO at a concentration of 10 mM and diluted in DMSO either manually or using an automated pipeting instrument. Serially 3-fold diluted compounds were either manually mixed with cell culture media and added to the seeded cells or directly added to the cells using an automated instrument. DMSO was used as a negative (solvent; no inhibition) control, and the protease inhibitor ITMN-191 was included at a concentration > 100 x EC50 as a positive control. 72 hours later, cells were lysed and a luciferase activity quantified as recommended by the manufacturer (Promega- Madison, WI). near regression was performed to calculate EC50 values.

To determine the ral potency (EC50) against resistance mutants, resistance mutations, ing M28T, Q30R, Q30H, L31M, and Y93C in genotype 1a NS5A and Y93H in pe 1b NS5A, were introduced individually into either 1a Pi-Rluc or 1b Pi- Rluc replicons by site directed mutagenesis. Replicon RNA of each resistant mutant was transiently transfected into Huhderived 51 cells and antiviral y was determined on these transfected cells as described above.

The EC50 ranges for genotype 1a, 1a Q30R, and 2a JFH are as follows: A ≥ 44 nM, B = 1 nM to 43.99 nM, C < 1 nM. The EC50 ranges for genotype 2a J6, 2b, 3a, and 4a are as follows: A ≥ 5 nM, B = 1 nM to 4.99 nM, C < 1 nM. The EC50 ranges for genotype 2a J6, 2b, and 4a correspond to the assay of transiently transfected cells (t). If this data is unavailable, the EC50 range for the stably replicating cells (s) is provided.

IV and PO Single Dose Pharmacokinetic Studies in SD Rats: The cokinetics of selected compounds was terized in male Sprague-Dawley (SD) rats (250-300g). In this study, two groups of naïve purebred SD rats (N=3 per group, fasted over night) received the selected compound either as an enous (IV) infusion (1 mg/kg over 30 minutes) via the jugular vein or by oral gavage (2 mg/kg). The intravenous (IV) dosing vehicle was 5% ethanol, 35% polyethylene glycol 400 (PEG 400) and 60% water pH 2.0. The oral dosing vehicle was 5% ethanol, 55% PEG 400 and 40% citrate buffer pH 2.2.

Serial blood samples (approximately 0.3 mL each) were collected from jugular vein or other suitable vein at specified time points. For the IV infusion group, the blood samples were collected predose and at 0.25, 0.48, 0.58, 0.75, 1.5, 3, 6, 8, 12 and 24 hours after the start of infusion. For the oral group, the blood samples were collected predose and at 0.25, 0.50, 1, 2, 4, 6, 8, 12 and 24 hours after dosing. The blood samples were collected into iner tubes containing EDTA-K3 as the anti-coagulant and were centrifuged at approximately 4ºC to obtain plasma. The plasma samples were stored at -20ºC until analysis by LC/MS/MS.

A bioanalytical method utilizing high performance liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS) was developed for analysis of the selected nd in rat plasma. Detection was performed using selected reaction monitoring (SRM); Ions representing the precursor (M+H)+ species was selected in quadrupole 1 (Q1) and collided with argon gas in the collision cell (Q2) to generate specific product ion, which was subsequently monitored by quadrupole 3 (Q3). Standard curve and quality l samples were prepared in male rat plasma and processed in the same way as the test samples to te quantitative data.

Pharmacokinetic parameters were ted using non-compartmental pharmacokinetic analysis (Phoenix WinNonlin, version 6.3). Values below the lower limit of quantification (LLOQ) were assigned a value of zero if predose and treated as missing thereafter. Area under the curve (AUC) was calculated using the linear oidal rule. The oral bioavailability (%F) was determined by comparison of the area under the curve (AUC) of the compound and/or a metabolite generated in plasma following oral stration to that generated ing intravenous administration. # e 1b 1a 1a 2a 2a 2b 3a 4a 1a 1a 2a 2a J6 2a J6 2b (t) 2b (s) 3a 4a (t) 4a (s) Rat %F No. (nM) Q30R JFH J6 (nM) Q30R JFH (t) (s) (nM) (nM) (nM) (nM) (nM) (nM) (nM) (nM) (nM) 422 MC 0.017 C C C B C C C 0.016 0.990 0.004 1.155 3.523 0.162 0.375 0.004 0.008 0.028 423 LQ 0.020 C C C C C C C 0.022 0.135 0.004 0.134 0.543 0.012 0.035 0.005 0.008 0.02 426 MD 0.033 C C C C C C C 0.035 0.192 0.006 0.073 0.439 0.016 0.038 0.006 0.011 0.035 427 ME 0.049 C B C B C C C 0.033 2.514 0.012 3.428 16.075 0.198 0.701 0.015 0.016 0.029 434 MG 0.055 C C C C C C C 0.054 0.663 0.012 0.337 2.288 0.070 0.010 0.024 0.08 435 MF 0.058 C C C C C C C 0.059 0.768 0.012 0.476 2.136 0.083 0.011 0.025 478 478 0.048 C C B C C C 0.045 0.011 3.654 0.820 0.065 0.023 0.019 493 493 0.030 C C A C C C 0.036 0.008 5.036 0.650 0.050 0.013 0.018 494 494 0.021 C C C C C C C 0.037 0.118 0.005 0.098 0.017 0.005 0.017 0.031 495 495 0.026 C C C C C C C 0.021 0.201 0.008 0.280 1.016 0.135 0.541 0.024 0.014 0.014 498 498 0.016 C C C C C C C 0.030 0.040 0.004 0.012 0.039 0.010 0.013 0.005 0.011 0.004 499 499 0.032 C C C C C C 0.057 0.008 0.206 0.040 0.010 0.021 0.005 503 503 0.041 C C C C C C 0.062 0.012 0.155 0.037 0.016 0.028 0.025 507 507 1.503 B C A B C C 3.698 0.297 20.096 1.561 0.382 0.594 0.025 510 510 0.050 C C C C C C 0.021 0.009 0.007 0.018 0.017 0.020 0.008 0.016 0.072 516 516 0.024 C C C C C C 0.015 0.009 0.043 0.013 0.005 0.010 0.025 518 518 0.010 C C B C C C 0.005 0.006 2.493 0.643 0.005 0.004 0.011 526 526 0.018 C C C C C C C 0.011 0.095 0.007 0.443 1.639 0.132 0.404 0.018 0.011 0.011 536 536 0.013 C C C C C C C 0.008 0.048 0.004 0.040 0.154 0.011 0.037 0.009 0.005 0.01 538 LR-1 0.016 C C C C C C C 0.011 0.015 0.005 0.018 0.048 0.010 0.024 0.013 0.010 0.012 539 LT 0.016 C C C C C C C 0.009 0.010 0.004 0.010 0.047 0.009 0.039 0.012 0.015 0.009 543 MY 0.015 C C C C C C C 0.016 0.024 0.005 0.047 0.165 0.016 0.047 0.010 0.008 0.02 544 MM 0.026 C C C C C C C 0.022 0.044 0.007 0.018 0.064 0.015 0.042 0.020 0.017 0.016 551 OQ 0.018 C C C C C C C 0.015 0.102 0.007 0.378 1.492 0.265 0.982 0.048 0.020 0.016 552 OR 0.033 C C C C C C C 0.030 0.059 0.011 0.068 0.160 0.037 0.109 0.031 0.036 0.006 555 MN 0.021 C C C C C C C 0.014 0.018 0.008 0.017 0.071 0.013 0.040 0.034 0.024 0.007 1.5 556 MS 0.008 C C A A C 0.008 0.005 15.564 9.562 0.014 0.02 558 PQ 0.014 C C C C C C 0.014 0.106 0.005 0.025 0.155 0.032 0.057 0.015 0.017 561 MP 0.010 C C C C C C C 0.006 0.031 0.004 0.039 0.336 0.032 0.184 0.015 0.015 0.013 24.2 562 MO 0.019 C C C C C C C 0.013 0.052 0.007 0.089 0.471 0.137 0.427 0.051 0.022 0.018 7.46 563 MT 0.007 C C A A B C 0.003 0.021 44.444 44.444 1.092 0.015 0.025 565 NB 0.017 C C C C C C C 0.010 0.034 0.004 0.020 0.138 0.007 0.039 0.011 0.023 0.025 566 NC 0.009 C C C C C C C 0.007 0.060 0.005 0.089 0.762 0.068 0.191 0.014 0.011 0.026 569 ND 0.024 C C C C C C C 0.020 0.057 0.014 0.314 2.338 0.270 1.319 0.035 0.031 0.044 571 OO 0.114 C C C C C C C 0.072 0.139 0.015 0.028 0.259 0.020 0.076 0.028 0.086 0.018 572 PF 0.044 C C C C C C C 0.032 0.034 0.014 0.025 0.127 0.023 0.117 0.072 0.050 0.018 4.3 573 PG 0.030 C C C C C C C 0.033 0.043 0.018 0.045 0.335 0.027 0.119 0.050 0.063 0.008 574 PN 0.016 C C C C C C C 0.015 0.030 0.009 0.027 0.277 0.014 0.035 0.016 0.014 0.02 575 PP 0.029 C C C C C C C 0.014 0.043 0.011 0.061 0.403 0.038 0.110 0.019 0.027 0.011 576 PO 0.014 C C B C C C 0.013 0.011 3.135 0.470 0.012 0.013 0.013 579 OI 0.034 C C C C C C C 0.024 0.086 0.010 0.061 0.326 0.178 0.629 0.206 0.036 0.007 580 OJ 0.017 C C C C C C 0.018 0.013 0.502 0.813 0.259 0.026 0.017 582 NF 0.010 C C C C C C C 0.011 0.017 0.006 0.031 0.218 0.018 0.064 0.017 0.009 0.012 585 NG 0.009 C C C C C C C 0.006 0.243 0.010 0.370 1.672 0.063 0.135 0.020 0.008 587 MR 0.041 C C C C C C C 0.028 0.128 0.017 0.079 0.176 0.039 0.053 0.078 0.045 588 588 0.017 C C C C C C C 0.012 0.087 0.004 0.038 0.140 0.012 0.017 0.027 0.019 589 MQ 0.011 C C C C C C C 0.008 0.023 0.004 0.017 0.095 0.009 0.023 0.016 0.011 590 MU 0.014 C C C C C C C 0.008 0.023 0.004 0.013 0.046 0.009 0.025 0.017 0.011 592 NI 0.015 C C C C C C C 0.015 0.059 0.007 0.026 0.169 0.019 0.054 0.022 0.020 24.1 594 NP 0.013 C C C C C C C 0.014 0.032 0.007 0.010 0.096 0.011 0.043 0.020 0.028 26.1 597 NJ 0.005 C C C C C C C 0.007 0.025 0.007 0.099 0.939 0.094 0.416 0.019 0.017 599 PY 0.009 C C C C C C C 0.012 0.013 0.006 0.009 0.098 0.007 0.030 0.017 0.018 27.7 600 PZ 0.007 C C C C C C 0.009 0.057 0.005 0.175 1.712 0.071 0.386 0.025 601 MV 0.014 C C C C C C C 0.010 0.012 0.004 0.047 0.034 0.041 0.011 0.011 602 602 0.025 C C C C C 0.025 0.010 0.053 0.036 0.036 0.013 603 603 0.015 C C C C C C C 0.009 0.146 0.007 0.194 0.067 0.088 0.015 0.022 604 NR 0.020 C C C C C 0.026 0.006 0.118 0.017 0.017 0.007 605 NQ 0.015 C C C C C C 0.017 0.039 0.006 0.064 0.013 0.012 0.013 606 OK 0.034 C C C C C C 0.026 0.039 0.011 0.076 0.036 0.045 0.028 607 OL 0.067 C C C C 0.047 0.012 0.070 0.052 0.052 608 OH 0.017 C C C C C C 0.016 0.031 0.007 0.054 0.023 0.022 0.026 22.7 609 QF 0.005 C C C C C C 0.008 0.032 0.004 0.053 0.015 0.011 0.020 610 QA 0.013 C C C C C C 0.012 0.045 0.007 0.094 0.052 0.040 0.038 7.46 612 QH 0.005 C C C C C C 0.007 0.051 0.005 0.182 0.051 0.049 0.020 613 QG 0.005 C C C C C C 0.005 0.071 0.004 0.551 0.065 0.043 0.016 614 OP 0.013 C C C C C C 0.013 0.026 0.008 0.018 0.011 0.007 0.027 15.1 615 OM 0.019 C C C C C C 0.014 0.035 0.009 0.045 0.053 0.054 0.035 12.2 617 617 0.005 C C C C C C 0.009 0.024 0.004 0.032 0.013 0.011 0.019 14.4 618 OT 0.020 C C C C C C 0.011 0.041 0.005 0.013 0.012 0.024 619 OF 0.007 C C C C 0.010 0.008 0.445 0.196 620 NK 0.081 C C C C 0.049 0.018 0.056 0.154 621 NL 0.013 C C C C 0.011 0.007 0.043 0.034 622 NM 0.016 C C C C C C 0.011 0.028 0.006 0.012 0.013 0.024 6.93 623 ON 0.006 C C C C 0.005 0.004 0.068 0.086 625 PH 0.031 C C C C C C 0.024 0.051 0.014 0.055 0.042 0.029 626 626 0.030 C C C C C C 0.021 0.041 0.009 0.021 0.021 0.027 627 PI 0.039 C C C C C C 0.031 0.094 0.020 0.129 0.090 0.065 8.7 628 OG 0.009 C C C C 0.009 0.008 0.601 0.437 631 PS 0.006 C C C C A 0.005 0.004 0.077 0.113 44.444 632 PT 0.008 C C C C 0.007 0.007 0.383 0.182 633 PR 0.020 C C C C C C 0.013 0.045 0.007 0.022 0.028 0.018 634 PU 0.015 C C C C 0.012 0.006 0.068 0.442 635 OU 0.041 C C C C 0.047 0.016 0.040 0.035 636 OV 0.011 C C C C C C 0.010 0.031 0.007 0.113 0.046 0.013 637 OW 0.009 C C C C C C 0.009 0.019 0.006 0.009 0.008 0.013 13.3 638 OX 0.009 C C C C 0.007 0.006 0.113 0.107 639 QB 0.011 C C C C C C 0.011 0.029 0.008 0.021 0.022 0.028 9.56 640 QE 0.015 C C C C 0.013 0.011 0.291 0.563 641 QD 0.030 C C C C 0.025 0.013 0.103 0.193 642 QC 0.014 C C C C 0.012 0.008 0.157 0.317 643 643 0.015 C C C C 0.015 0.013 0.206 0.607 644 MW 0.026 C C C C C 0.012 0.012 0.020 0.043 0.123 0.011 645 MX 0.076 C C C C C 0.036 0.024 0.035 0.070 0.139 0.033 646 646 0.109 C C C C C 0.058 0.030 0.042 0.112 0.262 0.034 648 PJ 0.088 C C C C C 0.068 0.058 0.136 0.335 0.854 0.056 1001946297

Claims (16)

Claims

1. A nd of formula: 6297 6297 6297 6297 6297 6297 6297 or a pharmaceutically acceptable salt thereof.

2. A compound of formula: 6297 6297 6297 6297 6297 6297 1001946297

3. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 and at least one pharmaceutically acceptable r.

4. The pharmaceutical ition according to claim 3, r comprising a nucleoside or 5 nucleotide inhibitor of NS5B rase.

5. Use of a nd or pharmaceutically acceptable salt thereof according to claim 1 in the manufacture of a medicament for the treatment of hepatitis C.

6. Use of a compound or pharmaceutically acceptable salt thereof according to claim 5, wherein the medicament is combined with a nucleoside or nucleotide inhibitor of HCV NS5B 10 polymerase.

7. A pharmaceutical composition comprising a compound according to claim 2 and at least one pharmaceutically acceptable carrier.

8. A pharmaceutical composition according to claim 7, further sing a nucleoside or nucleotide inhibitor of NS5B polymerase. 15

9. Use of a compound according to claim 2 in the manufacture of a medicament for the treatment of hepatitis C.

10. Use of a compound according to claim 9, wherein the medicament is combined with a nucleoside or nucleotide inhibitor of HCV NS5B polymerase. 1001946297

11. Use of a pharmaceutical composition according to claim 3 or claim 4, in the manufacture of a medicament for the treatment of hepatitis C.

12. Use of a pharmaceutical composition according to claim 7 or claim 8, in the manufacture of a medicament for the ent of hepatitis C. 5

13. A compound according to claim 1, substantially as herein described.

14. A compound according to claim 2, substantially as herein described.

15. A pharmaceutical composition according to claim 3 or 7, substantially as herein described.

16. Use ing to claim 5 or 9, ntially as herein described.